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Nanotechnology has become a field of intense interest due to its applications in medicine, 
cosmetics, energy, and fabrics. The field has evolved to include nanodimensional self-
assembling cage proteins which are multisubunit proteins surrounding a hollow cavity. Cage 
proteins can be engineered with precision, by either chemical, enzymatic or recombinant DNA 
methods, to accommodate non-native guest molecules both internally or externally.  The inside 
cavity could be engineered to encapsulate inorganic nanoparticles or drugs, enzymes, or to serve 
as a size constraint reaction vessel for nanoparticle synthesis. However, exterior modification of 
these proteins has not been extensively explored. The most common initial studies have included 
the attachment of antibodies for targeting. We show that: (1) The N-termini of the subunits of 
Escherichia coli bacterioferritin (Bfr) can be modified by recombinant DNA methodologies to 
produce peptide fusions, which are termed “QTag-Bfr” tags, and which can be modified by 
bacterial transglutaminase to link substituted amines to the exterior surface of Bfr. These 
modifiable tags may be employed in the future for affinity chromatography applications, as 
precursors to nanoparticle superlattices and as anticancer drug/imaging agent delivery vehicles. 
The exact sequence of these tags was found to also control the final quaternary structure of Bfr. 
(2) The interior surface can be modified with affinity tags to allow for controllable encapsulation 
of functionalized guest molecules, and we extend previous research by elaborating on the 
incorporation of green fluorescent protein, gold nanoparticles, and micelles with Bfr and the 
“QTag-Bfr” constructs. (3) Similar strategies were extended to a recently discovered 
thermophilic Archaeoglobus fulgidus ferritin (AfFtn), and various engineered AfFtn were studied 
with respect to the encapsulation of a range of guest molecules, yet also provide a more open 
cavity capable of novel investigations on guest entrapment. (4) An extensive computational 
docking study was undertaken on the Bfr heme cofactor binding site which led to the 
identification of potential non-heme replacements which were tested for control of the quaternary 
structure of E. coli Bfr. These studies provide several versatile nanodimensional capsule protein 
frameworks which could be utilized in the future for the production of new biomaterials, as 
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 CHAPTER 1: INTRODUCTION 
 
1.0. Overview 
Recent advances in bionanotechnology have included biological materials (biological 
nanostructures) with relevant nanometer dimensions. Biological nanostructures have defined 
subunits with a high degree of structural organization. This arrangement allows for the precise 
modifications of their addressable surfaces; exterior, interior, and the interfaces between the 
subunits.1 The applications of these molecules include but are not limited to: materials 
engineering,2,3 health 4and energy production.5-7   
Here we show how two nanodimensional multisubuit proteins, Archaeoglubus fulgidus 
ferritin (AfFtn) and Escherichia coli Bacterioferritin (Bfr) (seen in Figure 1) have been 
engineered to encapsulate or display functional guest molecules. We also elaborate on the 
modification strategies as well as their applications in various fields of science. Both AfFtn and 
Bfr proteins are roughly spherical with 8 nm and 12 nm interior and exterior diameters, 
respectively. Their spherical shapes are assembled from 24 identical subunits. The subunits self-
associate with their C-termini oriented towards the interior surface and the N-termini towards the 










Figure 1. Crystal structures of Bfr and Aftn. (a) Bfr (1Bfr) capsule with 12 heme cofactors 
(within dimer interfaces). (b) The 12 nm AfFtn (1SQ3) capsule with a 4.5 nm triangular pore. The 
Figures were generated with Maestro software (Schrödinger, LLC). 
 
The well-defined Bfr exterior surface was genetically fused with peptide sequences that 
were used for enzymatic modification on the Bfr surface whereas the internal C-termini were 
genetically fused hexahistidine (H6) tags for nickel (II) mediated affinity interaction with 
nitriloacetic acid (NTA)-containing guest molecules. AfFtn was similarly engineered with C-
terminal H6 tags for nickel mediated affinity purification and guest encapsulations. AfFtn 
containing a cysteine mutation was also studied as to its ability to be modified for the fabrication 
of a new internal affinity site within the cavity. 
Lastly, computational modeling was used to identify heme analogs that might be capable of 
binding the Bfr heme pocket and hence replacing heme as the Bfr cofactor. Some of the docked 
ligands, from the library, were subsequently obtained from commercial sources and encapsulated 
into the Bfr protein and their effects on the Bfr quaternary structure were studied. This chapter 
introduces multisubunit architectures and their applications, followed by a detailed description of 







1.1. Multisubunit Assemblies  
Many proteins are composed of an arrangement of protein subunits. The cage protein 
family is comprised of several types of proteins with the architectures that assemble from 
homologous protein chains or a combination of different protein chains.10 Their shapes are mostly 
spherical with a few other geometries possible such as: tubes (tobacco mosaic virus, TMV11), 
knots (Ketol-acid reductoisomerase, KARI),12,13 catenane (Bacteriophage HK97 gp6 capsid),14 
icosahedral virus capsids (Cowpea chlorotic mottle virus)15 and other intricate structures of well-
defined exterior and interior surfaces. Spherical cages are found in ferritins,16 DNA binding 
proteins from Starved cells (Dps),17 certain heat shock proteins,18 hepatitis B virus,19 and many 
others (Figure 1.1). The spherical folding pattern physically separates the exterior surface from 
the interior surface, making them useful for guest encapsulation applications.20 
Additionally, DNA assemblies have emerged as building blocks for nanodimensional 
structures. The advances in DNA nanodevices are due to their ease of production as well as the 
ability to build complex yet predictable and controllable two-dimensional21 and three-dimensional 
22 structures from only four base pairs (adenine A, guanine G, cytosine C, and thymine T). These 
advances have inspired the engineering of DNA-based synthetic cage-like assemblies to extend 
their applications.  
 
1.1.1. Natural and Synthetic Assemblies 
Unlike synthetic polymeric materials, natural polymeric assemblies have ease of synthesis, 
assembly, great structural, and functional properties. Even though the properties of natural 
polymeric materials make them versatile, they may not entirely replace their synthetic partners. 
For example, the tensile strength of the toughest natural fiber, spider dragline silk (1.1 GPa), is 
close to that of steel (1.3 GPa),23 but nowhere close to the tensile strength of carbon nanotubes 
which is over 100-fold24 stronger, coupled with its remarkable electrical properties that are not 
found in natural polymeric materials. The properties of non-natural and natural polymeric 
materials have inspired the production of artificial capsid-like cage proteins. These capsids are 
computationally designed from component protein molecules and further assemble in vitro into 
structures that have desirable properties and promising applications in drug delivery.25 Another 
form of biomaterial involves the removal of genetic material from viral capsids to produce non-




VLPs can be recombinantly produced and capable of self -associating into their native forms 
without their genetic material, but having similar antigenicity to the infectious form. VLPs mimic 
their parent virus structures (without the genetic material) and activate the immune system 
through pattern-recognition receptors on immune cells to induce a potent immune response.26 For 
example, the commercial HPV (human papillomavirus) vaccine, Gardasil® (Merck and Co., Inc) 
is a VLP-based vaccine that is capable of producing antibodies against HPV related infections. 
Additionally, the hollow interior of VLP can be used to encapsulate large quantities of non-
native materials. Tauze and Coursagate reported the application of VLP in gene therapy. The 
interior of recombinant HPV16L1 virus-like particles was loaded with GFP genes that were 




Figure 1.1. Crystal structures of multisubunit biological assemblies. (a) Vault shell 
(PDB:2QZV) (b) The icosahedral Cowpea Chlorotic mottle virus, CCMV (PDB:3JVO) (c) the 
Bacteriophage HK97 gp6 capsid catenane (PDB:2IMV) (d) The top and side view of tobacco 
mosaic virus, TMV (PDB:5A7A) (e) Human H-type ferritin (PDB:2FHA). All images were 




 1.2 Structure-function Relationship of Multisubunit Assemblies 
Recent developments in biology and chemistry have shown that the association of multiple 
protein subunits into rings, tubes, spheres, and vaults is required for the proper biological function 
of some biomolecules. For instance, the ferritin cage has been reported to store up to 4500 atoms 
of iron in vivo,28 even though the Fe (II) oxidation occurs within the subunit, the oxidized Fe (III) 
is stored in the interior cavity. Similarly, the process of GroEL-mediated denatured protein 
folding occurs inside a barrel-shaped multisubunit structure. The repaired protein remains in the 
barrel until an ATP-induced conformation occurs to release it.  These and many more structure-
related applications of multisubunit assemblies make them interesting platforms to explore for 
materials fabrication. 
A particular cage protein presents three interfaces for biotemplating: (1) The interior 
surface, (2) Exterior Surface, and (3) the interfaces between the subunits. The physical separation 
of these surfaces enables cage proteins to undergo simultaneous modifications. For example, the 
interior of a cage protein can be loaded with a guest molecule which can be successfully delivered 
to the desired location via exterior surface targeting. Futhermore, the multiple copies of subunits 
present multiple copies of amino acid functional groups for modification.3 This feature allows 
loading large quantities of cargo molecules on the multisubunit host assembly. 
Moreover, the accessibility of the exterior surface facilitates the biotemplating of these 
assemblies, as illustrated by the engineering of heterogeneous crystals from the electrostatic 
interaction between a negatively charged cowpea chlorotic mottle virus (CCMV, pI 3.8) and 
positively charged (pI ~10.5) avidin molecule.2 Further applications of multisubunit protein 
assemblies will be discussed under four main subheadings: (1) Synthesis of metallic 
nanoparticles, (2) Drug delivery and theranosis (3) Energy production and water purification and 
(4) Materials synthesis 
 
1.2.1 Synthesis of Inorganic Nanoparticles 
Ferritins were one of the first cage proteins used in inorganic nanoparticle synthesis. This 
could be due to the ease of production and its major structural feature, the restricted interior space 
which helps to constrain the size of the synthesized nanoparticle, and the commercial availability 
of some ferritins. Cage proteins can template the size of the formed inorganic nanoparticle due to 




synthesized nanoparticles useful in drug delivery due to their controlled size which can enhance 
their permeability and retention (EPR) within tumour tissue.29 Another advantage of an 
encapsulated nanoparticle is its decreased toxicity since the protein shell prevents direct contact 
with cells.29 
Metallic nanoparticle synthesis can be achieved through either delivering metal ions to the 
cage interior and allowing them to nucleate (or chemically be reduced to their zero-oxidation 
state) or by clustering biomolecule subunits around the preformed inorganic nanoparticle which 
are within the dimensions of the cage interior. The first method has been widely used to 
synthesize ZnSe nanoparticles where Zn2+ ions were permitted to diffuse into the interior cavity of 
horse spleen apoferritin via its iron transport channels and made to react with Se (as selenourea) 
slowly. The formation of a ZnSe compound led to autonucleation and growth of the ZnSe core 
within the apoferritin cavity. Polycrystals of ZnSe were formed with 3 nm diameters which were 
anaerobically heated at 500 ° C for 1 hour to form 7 nm, single cubic ZnSe crystals (Figure 1.2). 
The synthesized ZnSe quantum dots could be used subsequently as biological labels due to their 











Figure 1.2. Production of ZnSe nanoparticle via ion delivery. (a) The electrostatic localization 
of Zn2+ ions to the HosFtn cavity through the ion channels (upon incubation). (b) subsequent 
interaction with Se2- ions from selenourea degradation. (c) The reaction between Zn2+ and Se2- 
leads to the formation of  3 nm ZnSe polycrystals in the cavity. (d) Subsequent heating of the 3 
nm polycrytals ( at 500 ° C for 1 h) resulted in a  7 nm core crystal.This figure was redrawn from 




In addition to the production of monodispersed metallic nanoparticles, the cage architecture 
mediates or enforces metal crystallization. Douglas and Young have shown that CCMV can 
mediate crystallization of 15 nm paratungstate (H2W12O42
10-). A control reaction in the absence of 
the CCMV templates did not result in the formation of the paratungstate crystals.31 Furthermore, 
the encapsulation of preformed nanoparticles was reported by Zheng and co-workers where 
recombinant apoferritin was used to deliver gold nanoparticles (AuNP) to SiO surfaces. The C- 
and N-termini of the ferritin subunits were modified with gold-binding peptides and inorganic 
(Ti/SiO2/Ag) binding peptides, respectively. The AuNP was encapsulated by the affinity 
interaction between the C-terminal peptide and the AuNP surface which resulted in the packing of 
the ferritin subunits around the gold nanoparticle, and encapsulating the AuNP (Figure 1.2.1).  
The packing of subunits can be applied to various AuNP sizes provided there is the right 
kind of affinity interaction occurring between the AuNP and the inner surface of the ferritin 
subunit. This approach serves as an important strategy for the fabrication of materials with surface 
plasmon resonance properties.32 Lastly, virus capsids can be utilized to encapsulate quantum dots 
by modifying the surface of the quantum dot (QD) with the base sequence required for capsid 
assembly. Self-assembly of the viral coat proteins resulted in encapsulation of the quantum dot.33 
Alternatively, the viral capsids can also be dissociated by changing the pH and ionic strength of 
the buffer and then utilized to encapsulate non-native guest molecules. This approach involved 
removal of the genetic material of Cowpea Chlorotic Mottle Virus, and the resulting VLP was 
used to encapsulate heterogenous CdSe/ZnS quantum dots which were efficiently internalized by 
HeLa cells and RAW 246.7 macrophages without any toxic effect.34 These systems can be useful 








Figure 1.2.1. A representation of gold nanoparticle (GNP) encapsulation via subunit 
packing. The C-termini of ferritin subunits were modified with gold binding peptide (GBP) 
which interacted with the GNP surface as demonstrated by Zheng and co-workers.32 This Figure 
was generated with Maestro (Schrödinger, LLC) and Microsoft PowerPoint. 
 
 
1.2.2. Theragnosis and Drug Delivery 
Biological assemblies containing therapeutic agents have promising applications in 
medicine. Some formulations are currently employed in medicine while others are being 
investigated in clinical trials.25b, 29 The continuous exploitation of proteins for medicinal 
applications despite the existing liposomal delivery vehicles is due to their numerous advantages, 
not limited to: biocompatibility and ease of metabolism; non-toxic; well-defined size that 
enhances permeability; ease of modification and production; as well as the availability of 
structural and functional information for many proteins.35,36 Clinical applications of caged 
proteins arise due to their generally high stability, biocompatibility and their ability to dissociate 
and associate and encapsulate therapeutic molecules. The hollowed interior serves as a useful 
space for drug and imaging cargo and their surfaces could be used for targeting. Examples of 
these are not limited to the in vivo targeting of arteriosclerosis-associated macrophages with 
tumor targeting LyP-1 peptide on the surface of heat shock protein which was loaded with 
fluorescent dyes. This arrangement allowed for site-specific imaging and diagnosis of 




nanoparticles in the drug delivery area, wherein the surface of human ferritin was modified with 
melanoma targeting antibodies, and the interior was loaded with the anticancer agent cisplatin. 
The Ep1 monoclonal antibody specifically targetted the CSPG4 melanoma antigen to deliver the 
cisplatin to C30 melanoma cell lines. A proper stoichiometry between antibody, ferritin, and 
cisplatin generated a drug with remarkable anti-tumor effects.4b Lastly, the iron core in ferritin has 
been used as an MRI agent due to its intrinsic quantum mechanical properties.38 The mineral core 
is capable of accelerating transverse relaxation of water protons that leads to black or dark 
contrast in tissues.36a The super magnetic ferric oxide mineral was used as a reporter for delivery 
of replicative-effective adenovirus (Adv) vector to mouse brain. The presence of this vector 
resulted in the expression of ferritin subunits, which were used to sequester cellular Fe (II) in the 
brain tissue and stored as the Fe (III) oxide   MRI contrasting agent.39 The medical applications of 
multisubunit biological assemblies are diverse with untapped applications. Their structural 
properties could enable the fabrication of multifunctional theranostic molecules beyond the 
double duties illustrated here. There is the potential for building an all-in-one theranostic 
molecule with integrated diagnosis, drug monitoring, targeted delivery, and controlled drug 
release.36a  
 
1.2.3. Energy Production and Water Purification 
1.2.3.1. Energy Production 
Hydrogen gas production is another application of metallic nanoparticle synthesis. Two 
groups of researchers have reported the conversion of atomic hydrogen to molecular hydrogen 
employing cage proteins.  In 2005, Varpness et al. mimicked the hydrogenase enzyme with a 
small heat shock protein (Hsp), the interior of Hsp was loaded with up to 1000 platinum atoms. 
Hydrogen gas was produced by photoreduction of methyl viologen by Ru(bpy)3
2+ which then 
transferred electrons to the Pt mineral surface and caused proton reduction. They observed a 
comparable rate of proton reduction to that produced by an active hydrogenase enzyme.5 Recently 
Clark and co-workers presented another route for hydrogen gas production using the 
bacterioferritin heme cofactor. The native heme was replaced with a zinc analog, zinc-
protoporphyrin IX, and platinum was encapsulated within the bacterioferritin cavity. The light 
activation of triethanolamine resulted in electron release which was mediated by methyl viologen 






1.2.3.2. Water Purification 
There is an increased release of phosphorus in municipal wastewater since most synthetic 
detergents are phosphorous-based. Most of the phosphorus is converted to phosphate in 
wastewater, which has detrimental effects on aquatic life and increased water purification cost. 
The primary method of phosphate removal is chemical precipitation. Chemical precipitation uses 
coagulants to precipitate the phosphate ions, lowering phosphate levels, but does not reach the 
0.01 mg/L ecological level. Also, this process is expensive, requiring a higher concentration of 
coagulants and leads to increased sludge volume.40  
An alternative approach to phosphate removal is the biological phosphate removal which 
uses organisms capable of soaking up these ions. The idea that ferritin cages can be used in water 
purification stems from the presence of phosphate ion in the Fe (III) mineral core. Aitken et al. 
observed up to a 1:1 ratio of Fe (III) to phosphate in the bacterioferritin mineral core. Phosphate 
ions serve as counter-ions for maintaining the positive charge on Fe3+ and also are believed to 
enhance the rate of core formation (by 5-fold) by an unknown mechanism.41 Ferritin-mediated 
phosphate absorption was illustrated by the thermophilic Pyrococcus furiosus ferritin, PfFtn. The 
PfFtn mineral core completely removed phosphate ions in solution with a gram of PfFtn removing 
up to 11 mg of phosphate from solution, unlike the chemical precipitation method. Another 
advantage of this approach is that the PfFtn cage could be regenerated to save on the purification 
cost. 42 A commercial example is the “intelligent enzyme solution” from EUCODIS Bioscience 
and BiAqua limited, who launched a pilot-scale Pyrococcus furiosus ferritin water treatment 
system on September 30, 2013. The company has stated that they have produced 1 m3 of the 
protein of this particular ferritin for this purpose. http://www.eucodis.com/ 
 
1.2.4. Materials Synthesis 
There are increasing demands for flexible electronics for health monitoring and other 
materials applications. This demand has led to the successful fabrication of inorganic materials 
with unique electrical, optical, and plasmonic properties. However, these materials suffer from 
sustainability and biocompatibility issues. Hence biomolecules have emerged as naturally 




applications in bendable materials such as paper-like displays, photovoltaic cells, light-emitting 
diodes, and theranostic devices.43-45  
  The self-assembling property of multisubunit proteins allows them to exist in different 
shapes and sizes for one, two, and three-dimensional materials. For example, the cylindrical 
shaped virus particles have been employed in the fabrication of thin and flexible electronic 
devices. Genetically programmed self-assembly was used to immobilize BaTiO3 nanocrystals on 
the filamentous bacteriophage M13 coat proteins and resulted in a high electrical output (up to 
300 nA and 6 V) energy harvesting device.7 
Alternatively, spherical assemblies can be immobilized onto two-dimensional electrodes as 
seen in the construction of a ferritin-based indium oxide electrode. The electrode was 
functionalized with horse spleen ferritin through a poly (L-lysine) and poly(L-arginine) linker on 
the indium oxide surface and interactions resulted in the formation of a monolayer of ferritin- 
coated electrode having 9-13 x1011 ferritin molecules per cm-2 of the electrode. This ferritin-
coated electrode has potential application for in situ voltammetric measurements.46 Moreover, a 
one-dimensional array was reported by Biswas et al., wherein they fabricated up to 2.5-micron 
long tubes from the GroEL chaperonin without affecting its native functionality, that of a protein 
folding chaperone. The rim of the GroEL barrel (Figure 1.2.2) was modified with cysteine 
residues which interacted with spiropyran (SP), in the presence of Mg2+ and light, to 
spontaneously form the merocyanine isomer. The merocyanine (MC) induced self-association of 
the micrometer long GroELSP/MC fibers. These fibers were capable of aiding in the refolding of 
denatured ɑ-lactalbumin,47 showing that biological multi-assemblies are very robust and can 






Figure 1.2.2. Formation of one-dimensional tubular assembly from GroEL-merocyanine 
conjugate. The assembled complex possesses chaperonin activity. Figure was generated with 
Chemdraw and Microsoft PowerPoint based on the report by Biswas et al.47 
 
 
1.2.6. Catalytic Confinement 
The process of encapsulating active enzymes within capsule proteins might be a useful 
mimic of the crowded intracellular cellular conditions found within cells. It has been suggested 
that the encapsulated enzyme may have an increased rate of catalysis due to an increased collision 
between the confined enzyme and the substrate to form the enzyme-substrate complex.48,25b For 
example, key enzymes (methylglyoxal synthase, glycerol dehydrogenase, and alcohol 
dehydrogenase) involved in the biosynthesis of the compound R-1,2-propanediol had a higher 
catalytic turnover for the compartmentalized enzymes which were confined to a specific sub-
volume while all other metabolites could freely diffuse. The compartmentalization resulted in a 
higher catalytic turnover being measured compared to the non-compartmentalized pathway.49 
Conversely, excessive enzyme loading in the cavity may prevent substrate turnover due to 
the constrained interior space of the host protein, and this may lead to decreased turnover.50 




controlled entrapment of enzymes/catalysts in a caged assembly enables the investigation of the 
rates of diffusion of reactants and products. When a single horseradish peroxidase (HRP) enzyme 
was encapsulated within the CCMV capsid, the pores of CCMV allowed diffusion of the 
dihydrorhodamine 6G substrate into the core. The observed diffusion times of fluorescent 
products from entrapped HRP were different from those detected for free HRP due to pH-




1.3. Cage Proteins 
Cage proteins can be defined as three-dimensional (3D) assemblies of protein subunits that 
form an internal cavity when these subunits self-associate. These topologies are diverse in terms 
of dimensions (9 -750 nm),17,52 structure, overall fold, stability, and electrostatics.10,13 Despite the 
structural variations, their subunits assemble into structures that have hollow interior cavities 
which can be useful for the encapsulation of a range of guest molecules, targeted guest delivery, 
constrained reaction vessels, imaging, and diagnostics.53,29-30,36a,54 The encapsulated guests are 
protected from the external environment, similar to how viral capsids protect their genetic 
material. These shells are capable of withstanding very harsh conditions, yet dynamic enough to 
release their encapsulated cargos. Their dynamic nature is mediated by protein-protein 
interactions between the subunits. The exterior motifs are useful in targeting whereas the interior 
motifs accommodate the guest molecules.  
Interesting cage structures and their possible applications have been reported (Figure 1), 
but this work focuses on the ferritin family. The ferritin superfamily and their structure-function 
relations will be described. Lastly, two types of ferritins, Archaeoglobus fulgidus ferritin and E. 











 1.3.2. The Ferritin Superfamily and Classes 
The ferritin cages are subdivided into: the classical and universal ferritins (maxi ferritins) 
of Prokarya and Eukarya16; the prokaryotic Dps ferritins (mini ferritins)17 and the heme-
containing bacterioferritins in bacteria.55 Maxi ferritins are assembled from 24 subunits with 
interior and exterior diameters of 8 and 12 nm, respectively, whereas the mini ferritins have 12 
subunits with 8 nm and 6 nm exterior and interior diameters (Figure1.1), respectively.56 The cages 
are also referred to as iron storage containers due to their ability to store essential Fe3+ in a stable, 
bioavailable form. A maxi ferritin cage can store up to 4500 atoms of iron.28 The bioavailability 
of natural iron in most habitats makes it useful for catalytic reactions in many organisms, 
requiring organisms to regulate the cellular levels of iron. Fe3+ precipitates under physiological 
conditions due its limited solubility57 so ferritins have evolved to store this ion in its Fe3+ 
oxidation state in biocompatible and bioavailable forms to prevent issues associated with iron 
toxicity. Ferritin nomenclature is mostly derived from the organism whose ferritin is being 
studied, such as human ferritin,16 horse spleen ferritin,58 E. coli ferritins,59 Arhaeoglobus fulgidus 
ferritin,8 Pyrococcus furiosus ferritin,60 Pseudomonas aeruginosa bacterioferritin,61 bullfrog M-
type ferritin,62 and many more.  
 
 
Figure 1.3.  Composition, structure, and size comparison of the ferritin family members. 
The four alpha-helical bundle that makes up individual subunits (a, b). The Dsp mini ferritin 
(2IY4), E. coli bacterioferritin with its heme cofactors in spheres (1BFR) and the human H-type 
ferritin (2FHA), (c-e) respectively.The images were generated with Maestro (Schrodinger, LLC) 





1.3.3. Structural Features of Ferritin 
Even though ferritins are approximately spherical in overall shape, they have very low 
sequence similarity (20%) among their family members 9,16-17,59,61,63. There are various types of 
intersubunit associations that contribute to the overall 24-mer or 12-mer quaternary structures. 
The individual subunits from the 24-mer and 12-mer ferritins are all α-helical, similar to that of 
methane monooxygenase, ribonucleotide reductase, archaeoferritin, bacterioferritin, DNA binding 
protein from starved cells (Dps), and many others from the four ɑ- helix bundle structure family.56 
Each subunit has four (A-D) tightly packed left-handed alpha helices. Successive helices are 
connected by a series of short loop sequences except that the A-B pair of helices are connected to 
the C-D helices via a long loop sequence (that connects helix B to C). Inaddition, a fifth helix, the 
E helix, which is the shortest helix of the subunit, is located at an angle relative to the 
arrangement of the C-terminal sequence of the D helix(Figure 1.3). The individual helices interact 
via hydrogen bonding.  
Also, there are 3-fold and 4-fold axes of symmetry in the overall ferritin three-dimensional 
structure where the apices of the rhombic dodecahedron touch in the 432-point group symmetry 
(Figure 1.3.1a). The 3- and 4-fold subunit arrangements result in the formation of 0.3-0.5 nm 
diameter channels that penetrate the shell (Figure 1.3.1b). These channels are useful for iron and 
small molecule transport, and the close packing of subunits gate them from unwanted reducing 
agents.58 The arrangement of subunits results in the formation of a hollow interior that is used for 
iron storage. The amount of stored iron is dependent on cellular availability. Hence the cage may 








Figure 1.3.1. The surface of a Bfr (1Bfr) showing the symmetry-related axes. (a) The 3 and 4-
fold channels are used for Fe2+ and small molecule transport. pyMOL image (b) The electrostatic 
potential on the exterior surface of Bfr with pores at 4-fold axes (red pores) for transport in and 
out of the cage (Source: J. Honek).  
 
 
Some members of the classical ferritins are homopolymeric while others are 
heteropolymeric.64 A particular ferritin cage could be composed of a mixture of heavy, light and 
middle weight chains having masses of 22.8 kDa, 20 kDa, and 21 kDa, respectively.64 The 24-mer 
assembly of eukaryotic ferritins is usually a combination of these homologous chains. An 
example is ferritin from horse spleen (HoSF) which is self-assembled from variable amounts of H 
and L-type chains. Alternatively, homopolymeric eukaryotic ferritins have been genetically 
engineered to possess only one type of these chains such as the human H-type ferritin (HuHF) and 
the bullfrog M-type ferritin.64 
On the other hand, the mini ferritins have tetrahedral (23-point group) symmetry and form 
a hollow assembly of 12 identical subunits. The interior and exterior dimensions of the mini 
ferritin cage are roughly 4.6 nm and 9 nm, respectively. The subunit composition is similar to 




that they lack the short C-terminal E helix. This E helix is involved in symmetry related 
interactions to generate the four-fold channels in ferritins. As a result, there are no 4-fold channels 
in mini ferritins, but the C-termini of the D helices engage other 3-fold interactions with lower 
symmetry that results in a more compact cage architecture, capable of withstanding the highly 
negative charge distribution and a cluster of acidic residues on the interior surface and 3-fold 
axes, respectively.17,65 Figure 1.3 shows the size comparison of the three classes. 
 
1.3.4. Ferritin Self-assembly 
 Five interacting subunits surround each ferritin subunit. The flexible loop regions of two 
separate subunits give rise to a two-fold symmetry arrangement known as dimers. Other 
oligomeric forms of subunit association such as trimers, tetramers, as well as octamers have been 
reported,66,58 but the exact intermediates involved in the native 24-mer arrangement has not been 
established. Thus, it is necessary to investigate the species involved in the self-assembly process, 
from monomers to intact 24-mers. Analysis of sedimentation velocity and circular dichroism 
analyses of pH-dependent reassembly showed that self-assembly of horse spleen ferritin (HoSF) 
proceeds from a dimer through to tetramers and octamers.66 However, dimers and trimers could 
efficiently produce 80 % of the 24-mers in solution while tetramers alone did not form intact 24-
mers.58 This appears to suggest an alternative route for 24-mer assembly. In order to identify the 
quaternary structures that lead to 24-mers, Yang and coworkers used “virtual alanine scanning” to 
identify key residues at the 2-fold, 3-fold and 4-fold axes of E. coli bacterioferritin. Nine residues 
at the 2,3 and 4-fold axis were designed and further analyzed via size exclusion, temperature 
dependent CD, dynamic light scattering, and native PAGE for 24-mer formation. Their results 
showed that mutation of two 3-fold residues (R61A and Y114 A) and one 2 -fold residue (R30A) 
completely abolished the formation of intact 24-mers leading to the formation of only dimers in 
solution.67  Recently, Huard et al. used Cu(II)-induced self-assembly to study the mechanism of 
24-mer formation (for human H-ferritin) where they induced dimer formation from monomeric 
subunits in response to  Cu(II) via the reverse metal-templated interface redesign (rMeTIR) 
strategy and found Y39E, N74E, and P88A mutants form monomers that were converted to 
dimers upon addition of Cu(II) and ultimately 24-mer shells.68 The Cu(II) mediated 24-mer 
formation, and other research suggests that dimers are the most stable intermediates that 




connect the A-B helix to C-D play a vital role in the assembly process. The mutation of aspartic 
acid residue to lysine in the loop (Asp80K in the middle) that connects the dimers in bullfrog M-
type ferritin (BfMFtn) is reported to decrease the rate of dimer formation and its stability by 
abolishing the salt bridge between Asp80 and Lys82.  Thus, electrostatic interactions within the 
dimer interface play a crucial role in the 24-mer assembly process.64 
Thermally stable ferritins from hyperthermophilic organisms (optimum growth ≥ 80 oC), 
such as Pyrococcus furiosus ferritin (PfFtn) and Archaeoglubus fulgidus ferritin (AfFtn), are 
classical ferritins. The PfFtn molecule exhibits the characteristic 432-point group symmetry of 
classical ferritins and bacterioferritins.60  Both AfFtn and PfFtn have roughly spherical shapes 
with a hollow internal cavity, but AfFtn has been reported to exhibit 23 symmetry with four large 
pores (approximately 4.5 nm) that penetrate the shell (Figure 1).8  Archaeoglobus fulgidus ferritin 
subunits are monomeric in solution and self-assemble in the presence of salt. The spontaneous 
assembly is mediated by high salt concentrations (> 150 mM). A 432 symmetry was observed 





Figure 1.3.2. AfFtn pore closure. The conversion of tetrahedral AfFtn (1S3Q) to octahedral 
AfFtn (3KX9) upon mutation of R151 and KI50 in the E-helix. The Figure was made with 





1.3.5. Ferritin Iron Homeostasis 
Iron is one of the most abundant elements in the earth’s crust, and its ability to exist in 
different oxidation states makes it important in biological systems. Iron has a variety of functions 
which include its presence in metalloenzymes involved in metabolism,70 yet it can be toxic.71 
Despite it being an essential biological factor, a few organisms have evolved that do not require 
iron, yet flourish in little or no iron environments. An example is Lactobacilli, one of the common 
bacteria in infant gut.72  Also, the  Borrelia burgdorferi pathogen can cause Lyme disease at 
cellular iron concentrations since it possesses iron-independent pathogenesis unlike the vast 
majority of pathogens which require iron depletion before infecting their host.73 The spontaneous 
aerobic conversion of Fe(II) to the highly insoluble Fe(III) at neutral pH (10-18, pH 7)8 in 
biological systems leads to Fe(II) deficiency. Iron depletion/ deficiency has been implicated in 
early embryonic death in mice74 as well as in Parkinson’s disease where the unusual distribution 
of iron in patients’ brain was attributed to iron-mediated oxidative stress.75 
Even though iron is essential for life, it is necessary to regulate cellular iron concentrations 
due to its limited solubility and toxicity. 36b Hence, many organisms have developed types of 
machinery such as iron transporters and iron storage compartments for effective iron regulation. 
Ferritins are forms of iron storage compartments in archaea, bacteria, and eukaryotes. They store 
iron in a bioavailable ferric oxyhydroxide form to prevent reactive oxygen formation (superoxide, 
hydrogen peroxide, hydroxyl radical). A Fenton reaction involving Fe (II) with hydrogen 
peroxide (H2O2) generates hydroxyl radicals while the superoxide and peroxide species can 
undergo a Heber-Weiss reaction to generate additional reactive hydroxyl radicals (equation 1). 
Excess amounts of free radicals could lead to a self-propagating chain reaction that destroys lipid 
membranes (lipid peroxidation) and hinders other processes such as cell viability, enzymatic 
activity, and antioxidant defense mechanisms.76 Another enzymatic regulatory system is the DNA 
binding protein from starved cells (Dsp). Dsp has a ferritin-like fold of 12 identical subunits with 
a hollow interior for storing iron. Dsp has a DNA binding motif and an iron sequestration 











1.3.6.  The Acquisition and Release of Iron from a Ferritin Cage 
1.3.6.1. The Ferroxidase Center 
The conversion of ferrous iron to ferric iron in ferritin occurs in the catalytic ferroxidase 
center (FC) which is located in the middle of the four ɑ-helical domains of each subunit 
(illustrated in Figure 1.3.3a). The FC of heteropolymeric ferritins (for example, horse spleen 
ferritin, HoSF) is located in the heavy chain (H subunit) while the light chain has been reported to 
show pH-dependent iron uptake with non-detectable Fe (II) oxidation. Also, the rate of Fe (II) 
oxidation is similar to background oxidation of Fe (II) by molecular oxygen, suggesting that the 
light chain has no ferroxidase center.77 The catalytic center has two iron binding sites (A and B) 
that form the dinuclear iron-binding site in most ferritins,78 but a third site C has been observed 
close to A and B towards the interior surface of some ferritins (Figure 1.3.3 b and c) 
Due to the variations found in the structure of the ferroxidase centers, these centers are 
classified into the H-chain-type ferroxidase centers, bacterial ferroxidase centers, and the 
bacterioferritin ferroxidase centers. The FC of eukaryotic ferritins, for example, BfMF, shows site 
A and B iron atoms pentavalently coordinated with the site A iron atom coordinated by three 
oxygens (bidentate Glu 23 and monodentate Glu 58), one water molecule and one nitrogen from 
His61 whereas the B site iron is coordinated by four oxygens (Glu103, Asp140, Gln137, and 
Glu58) and one water molecule. The Glu58 residue bridges site A and B. Eukaryotic FC binds the 
Fe3+ + O2 Fe2+ + O2
Fe2+ + H2O2 Fe3+ +  OH +  OH






native Fe (III) and other metals such as Tb (III), Mg (II), Zn (II) and Cu (II). These metal ions 
affect the coordinating ligands at the C site as well as its conformation relative to the sites A and 
B. Lawson et al. observed that Tb(III) at site C of HuHF is coordinated by Glu61 and Glu64,16 
His57 replaces the Glu 64 residue in the presence of Zn(II) (human H-type apoferritin)79 and  
Glu140 for Mg(II) bound in soybean ferritin.80 Mutation of the residues that coordinate a Mg(II) 
ion at site C resulted in a decreased rate of Fe(II) oxidation indicating that site C is an essential 
component of the ferroxidase center.80 
Bacterial ferritin FC closely resembles the H-chain ferroxidase center, for example, the site 
A in Chlorobium tepidum ferritin (CtFtn) is coordinated by Glu17, His53, and Glu50 that bridges 
to the B site. The B site iron atom is additionally coordinated by Glu94 and second bridging 
glutamine (Glu30) from site B to C which is further coordinated by Glu49, Glu126, and Glu129.81 
This type of coordination is highly conserved in the hyperthermophilic ferritins, such as that the 
Archaeoglobus fulgidus ferritin and the Pyrococcus furiosus ferritin.8,60 The  Fe-Fe distance of 
AfFtn is 3.18 Å  for site A and B whereas site C is situated 6.3Å from this center(Figure 1.3.3 
c).82 The levels of metal bound at sites A, B and C could be affected by the crystallization 
conditions such as the pH of the crystallization solutions which would affect the 
protonation/deprotonation state of the coordinating functional groups. 
Unlike the two FC sites described above, bacterioferritins have a symmetrical ferroxidase 
site similar to that observed in the methane monooxygenases and ribonucleotide reductases 
(Figure 1.3.3 b).83The symmetrical ferroxidase center of Bfr contains a dinuclear iron and a site C 
(not observed in the PDB:1Bfr crystals in Figure 1.3.3 b).84 Unlike the other ferroxidase centers 
there are two bridging glutamates (Glu51 and Glu127) between sites A and B. The A site iron 
atom is coordinated by Glu18/His54 pair and the B site iron atom is coordinated by 
Glu94/His130.78 The dinuclear sites are 3.6 Å apart,85 more extended than the observed 
prokaryotic ferritins and Archaeoglubus ferritin above, but similar to other heme-containing 









Figure 1.3.3. Ferritin Fe (II) oxidation. (a) A schematic representation of ferritin iron 
homeostasis. (b) The ferroxidases center, located within Bfr (PDB:1BFR) subunit (cyan,in red 
box) with 2 Mn2+ bound expanded  (c) The ABC type ferroxidase site observed in AfFtn crystals 
(PDB:1SQ3), all 3 Fe binding sites are occupied by Fe2+ ions. The expanded subunit(in brown) 
illustrates the arragements of the 3 Fe atoms at the ferroxidase sites. Figure generated with 





1.3.6.2. The Pathway of Fe (II) to and from the Ferroxidase Center 
Small molecules and charged ions are believed to enter the cage interior via a diffusion 
gradient. This gradient exists due to the sequence of amino acids lining the pores that are different 
from the inner cavity and are believed to aid in propelling these molecules and ions. For instance, 
Fe2+ can diffuse in and out of the cavity during Fe homeostasis through the 3- and the 4-fold axis 
of symmetry. However, these axes of symmetry are not aligned with the ferroxidase center, 
located in the 2-fold axis of symmetry of a subunit. So, it has become necessary to find the exact 
route of Fe (II)/Fe (III) to and from the cavity. This has led to the proposal of three possible 
mechanisms for Fe(II) delivery to the ferroxidase center: (1) The existence of a ferroxidase 
channel, a 1-fold axis of symmetry, that was proposed by molecular dynamics to show a direct 
connection of the catalytic center to the outside environment.87 (2) A Fe(II) chaperone which 
induces a conformational change in the ferritin that results in local conformational changes in 
response to Fe(II). This conformational change may lead to ferritin channels that could be used 
for translocation. The conformational change is similar to the process of methane and molecular 
oxygen transfer in methane monooxygenase (MMO). (3) Human poly(rC)-binding protein 
(PCBP1) may act as a chaperone for Fe(II) delivery to ferritin based on the increased levels of 
Fe(III) mineral from the interaction between human PCBP1 and ferritin in yeast expression 
systems, but this interaction is absent in human cell lines.88 Alternatively, channels within the 
cage architecture could be the main route for Fe(II) acquisition. Analysis of molecular dynamics 
simulations undertaken on human ferritin iron uptake indicate that the ferroxidase site directly 
connects to the exterior via the ferroxidase channel. Also, Fe(II) reaches the FC by interacting 
with two strong (Asp131 and Glu 134) and two weak binding sites ( His111 and Cys130) found in 
the 3-fold channel.87 Moreover, chemical modification of Cys126 located at the 3-fold channel in 
horse spleen ferritin resulted in decreased Fe(II) oxidation66 and the crystal structure of iron-
loaded bullfrog M-type ferritin (BfMF) revealed Fe(II)/Fe(III) in both 3 and 4-fold channels.89 
The  B-pore channel at the junction of three bacterioferritin subunits is also involved in Fe(II) 
entry.88 Even though the exact mechanism of Fe(II) entry remains unclear, Fe(II) may 
simultaneously reach the ferritin core through several channels and subsequently to the C site 
where it later diffuses to the remaining sites in the ferroxidase center. The involvement of this site 




binding in Archaeoglobus fulgidus ferritin (AfFtn) and the diminishing rate of Fe (II) oxidation in 
Pyrococcus furiosus ferritin upon mutating the coordinating ligands.8  
To answer the question as to how the Fe (III) is stored at the ferroxidase center, Ebrahimi et 
al. proposed the  Fe(III)-Fe(II) displacement mechanism for ferritins.90 This mechanism suggests 
that Fe(III) remains in a metastable state at the oxidation site until an incoming Fe(II) displaces it. 
This differs from the accepted substrate model which states that Fe (III) spontaneously leaves the 
oxidation site and proceeds towards the nucleation site after oxidation. This mechanism is evident 
in the observation of Fe (III) in the ferroxidase center of eukaryotic (BfMF)89 and bacterial 
ferritin, Chlorobium tepidum ferritin (CtFtn).81 
The exciting structure and function of the ferritin cage provide an extremely interesting 
structural model system for biotemplating. The subsequent sections are based on two ferritins 
from microorganisms, E. coli bacterioferritin (Bfr) and the thermophilic ferritin from the archaea 
Archaeoglobus fulgidis (AfFtn). Their structural properties and potential biotemplating strategies 





















1.4. Detail Description of the Ferritins AfFtn and Bfr 
1.4.1. E. coli Bacterioferritin (Bfr) 
E. coli bacterioferritin (Bfr) is the iron storage protein in E. coli. It is a maxi ferritin 
composed of 24 identical subunits. A heme cofactor is sandwiched between two neighboring 
subunits (Figure 1.4), making up a total of 12 heme cofactors per intact bacterioferritin. The 
association of identical subunits results in a relatively large protein (~ 450 kDa). Additionally, 
each subunit interacts with five adjacent subunits to form a 432-symmetry structure (Figure 
1.4).63a Also, the interaction of subunits generates 3-fold and 4-fold axes of symmetry that are 
used for Fe (II) transport.  
The Bfr subunit consists of 158 amino acids having a molecular mass of 18,945 Da with 
low proline content and a resultant 80 % alpha-helical content.59 The Bfr structure closely 
resembles the ferritins from animals and plants (Horse spleen ferritin, HoSF, human ferritin, 
HuFtn). However, only 20 % of the amino acids of Bfr are similar to these ferritins.   
The roughly spherical Bfr structure has an interior diameter of 8 nm and an exterior 
diameter of 12 nm. The association of homopolymeric Bfr subunits results in the N-termini of 
each subunit on the exterior surface and C-termini exposed on the interior surface. Similarly, the 
self-assembly of subunits generates 2, 3, and 4- fold axes of symmetry that connects the interior 
to the exterior surface of the Bfr cage. In addition to these channels, a B-pore is formed which is 
found only in Bfr. The B-pore in combination with the 3- and 4- fold channels are proposed for 
iron and small molecule entry/exit in and out of the cage.88 
The 24-mer capsid in ferritin is a copolymer of two chains, heavy and light chains, but Bfr 
is a homomeric assembly of 24 heavy chains. However, The ferritin from  Pseudomonas 
aeruginosa is the only bacterioferritin that contains two different chains (ɑ and β).61 The 
significant difference between Bfr and other ferritin members is the presence of the twelve 
protoporphyrin IX Fe (II) (heme) per intact capsule. These heme molecules are intercalated 
between every two subunits, and they are coordinated by two methionines from each of these two 
subunits. Moreover, the heme is not accessible to the exterior environment due to a cluster of four 
water molecules above the heme cofactor, and two extended loops at the dimer interface.91 The 
heme chromophore is responsible for the characteristic absorbances at 417, 530 and 560 nm that 
is not observed for ferritins, but similar to the reduction spectrum of cytochrome b1 hence it was 




been observed for other bacterioferritin family members such as bacterioferritins from 
Rhodobacter capsulatus (Rc) Bfr63b, Azotobacter vinelandii, and Pseudomonas aeruginosa.59 
Finally, bacterioferritin contains iron at three different locations: (1) the ferroxidase center, (2) the 
heme cofactor, and (3) at the interior cavity where iron is mineralized. In contrast, the classical 
ferritins and mini ferritins have iron in the ferroxidase center and interior cavity.   
Bfr’s oxidation/reduction chemistry occurs at the ferroxidase site92 that is located in the 
four-ɑ-helix bundle of the subunits (Figure 1.3.3b). The oxidation/ reduction processes protect the 
organism against Reactive Oxygen Species (ROS). This process occurs at the ferroxidase site as 
previously described. However, the exact mechanisms of iron acquisition, oxidation, and 
subsequent nucleation are unknown. The in vivo core demineralization in bacterioferritin has been 
described and a bacterioferritin-associated ferredoxin (Bfd) binds to the 2-fold channel on top of 
the heme molecule in ferritin. This brings the Bfd’s iron-sulfur cluster, [ 2Fe-2S],  close to the 
heme group, allowing for the transfer of electrons from [ 2Fe-2S] to the heme molecule. The 
electrons are then transferred to the inside of the Bfr cavity, close to the iron mineral and 
subsequent reduction of the mineral core.93,94 This then reduces the Fe3+ to the soluble Fe2+ form, 
which is believed to diffuse out through the protein pores. 
 
Figure 1.4. Structural features of Bfr. The surface diagram shows the exterior 12 nm 
dimensions, and the interior dimension is shown in the cartoon. The positions of the N- and C-
termini are on the exterior and interior, respectively. All images were generated the 1Bfr crystal 





1.4.2.  Archaeoglobus Fulgidus Ferritin (AfFtn) 
The ferritin from the sulfate-reducing marine archaeon, Archaeoglobus fulgidus, is a 
nonheme-containing ferritin with 24 identical subunits. Monomeric Archaeoglobus ferritin is 
composed of 160 amino acids (approximately 20 kDa) and has a predominantly alpha helical 
secondary structure which folds into the typical four alpha-helix bundle structure, similar to other 
maxi ferritins. Despite the structural similarity, AfFtn shares only 31 % sequence identity with 
human H ferritin and 38 % with E. coli bacterioferritin. The AfFtn subunit and overall fold are 
structurally identical to bacterioferritins and eukaryotic ferritins except it forms a tetrahedral 23-
point group symmetry arrangement instead of the 432 octahedral symmetry. Other interesting 
characteristics of AfFtn is its hyperthermostability, and its assembly/disassembly process which is 
mediated by variation of salt concentration.8 
The roughly spherical AfFtn has four large triangular pores which are due to the presence 
of Lys150 in the E helix, compared to glutamate and leucine in human and E. coli ferritins (Figure 
1.4.1). The Lys150 residue associates with neighboring residues at the four-fold interface. 
However, the presence of  the positively charged residues Lys150 and Arg151 abolishes the four-
fold interface and forms four large triangular pores in AfFtn.8 Also, The AfFtn E-helix is longer 
than the Bfr E-helix as seen in Figure 1.6, while the loop sequences connecting the subunits are 
shorter in AfFtn than Bfr except for the 19-residue B-C loop. The shorter loop sequences further 
compact the AfFtn structure and enhance its thermostability. Another thermostabilizing feature of 
the thermophilic enzyme is reducing solvent accessibility.95 This phenomenon occurs by the 
formation of higher oligomers, hexamers, in maxi ferritins. Hexamer formation in AfFtn brings 
the amine side chain of Lys 150 close to hydrogen bond with the carbonyl oxygen in Met111 and 
further stabilizes the tetrahedral symmetry.8 The mutation of Lys150 has been found to collapse 
the triangular pores and results in the formation of an octahedral (432) symmetry cage identical in 
overall shape to the Bfr and HuHF ferritins as seen in figure.69 
Iron oxidation/reduction in AfFtn is proposed to take place at its ferroxidase center. The 
AfFtn catalytic center is capable of binding three iron atoms similar to bacterioferritins with sites 
A and B situated 3.18 Å apart, and site C is 5.96 Å from the site B iron atom, towards the cage 
interior (Figure 1.3.3c). The A and B site iron atoms have Bfr-type coordination from glutamates 




ferritins,55 has been proposed to direct incoming Fe2+ through the triangular pore as well as other 




Figure 1.4.1. Structural features of Archaeoglobus ferritin (AfFtn, PDB ID 1SQ3). (a) AfFtn 
subunit (brown) is similar to a Bfr subunit (green) except for the longer E-helix of AfFtn 
(brown,in red circle) and the length of B-C loop. (b) Cartoon image of AfFtn showing the 12 nm 
exterior diameter. (c) The surface of AfFtn highlighting the 4.5 nm triangular pore. This Figure 















1.5. Biotemplating Strategies 
1.5.1. Dissociation and Association of Subunits 
Multisubunit assemblies may exist in different structural forms in response to different 
conditions such as pH, temperature, chaotropes, and ionic strength. For example, the Cowpea 
Chlorotic Mottle Virus (CCMV) undergoes pH and metal ion-dependent structural changes. The 
native capsid transitions to the swollen form when the pH is raised from 5.5 to 6.5 (in low ionic 
strength, I< 0.1 M) and further dissociates into dimers and releases its viral RNA at pH 7.5 and 
higher ionic strength (I > 1 M). The dimeric CCMV can be reassembled in the presence of novel 
guest molecules to repurpose the capsid.96 Similarly, the thermophilic Archeaeoglobus fulgidus 
ferritin exists as intact 24-mers with 23 point symmetry, with a triangular pore, in high ionic 
strength buffer (I ≥ 150 mM) and dissociates into monomers in low ionic strength buffers (I ≤ 20 
mM).8 On the other hand, the icosahedral bacteriophage, P22, transforms from the empty 58 nm 
capsid to the mature 60 nm capsid upon incubation at 65 °C for 10 minutes and increasing the 
temperature to 75 °C  results in the loss of several subunits and converts into a so-called “whiffle-
ball” (WB) capsid form.97,25b Both P22 WB shape and triangular pore AfFtn can be used for 
molecular exchange in and out of the capsids. 
Similarly, bacterioferritin subunits can dissociate from the capsule protein under 
declustering conditions such as decreased pH, higher temperatures, and with the addition of 
chaotropes (Figure 1.5); removal of the declustering agent causes re-association of the subunits 
into an intact 24-mer cage. This property makes Bfr an exciting and useful platform for 
bionanotechnology,89 and advanced studies in biocatalysis, and materials science.5 Small 
molecules can be entrapped into the ferritin cage through the iron channels, but in order to entrap 
larger, non-native guest molecules it becomes necessary to use these declustering techniques to 
separate the subunits and later assemble the subunits around the guest molecule as illustrated in 







Figure 1.5. The Bfr declustering strategy. Large non-native molecules can be entrapped by 
dissociation of Bfr subunits under the three conditions to allow the guest to interact with a C-
terminal affinity tag. The removal of declustering agents causes the subunits to re-associate 











1.4.1.2 Guest Stabilization  
The guest molecules could enter the cage interior and be stabilized inside the interior 
surface by a concentration-dependent approach or mediated by affinity interactions. Most metal 
ion mineralization employs a concentration-dependent approach wherein a high concentration of 
the guest metal outside the capsule protein is incubated with the intact ferritin and allowed to 
passively diffuse into the interior through the small pores in the shell after which they are 
precipitated inside the cavity.98,30 The limitation of this method is that there could be nonspecific 
interactions between guest and host ferritin, which could result in a weakly trapped guest 
molecule and may require excess guest molecules to establish a diffusion gradient. Despite the 
limitations, this method has been successfully used to entrap intact enzyme, HRP, into the CCMV 
capsid.51  
 The second method stabilizes the guest by some interaction, either metal coordination or 
non-covalent interaction. Similar to IMAC protein purification, the insides of a cage can be 
engineeried with polyhistidine tags that interact with an NTA guest, in the presence of Ni2+ or 
Co2+ or vice versa as seen in Figure 1.7. This approach will be used to encapsulate commercial 
NTA-functionalized gold nanoparticles (5 nm) into both Bfr and AfFtn. Also, a metal-mediated 
non-covalent interaction was employed in the fabrication of a quantum dot fluorescent mCherry 
protein complex by the interaction between dihydrolipoic acid on the quantum dot (QD) surface, 
and a poly-histidine mCherry protein, containing a caspase 3 cleaving site.99 The arrangement 
resulted in Förster resonance energy transfer being detected between the QD and the mCherry 
fluorescent protein, which was abolished upon caspase 3 cleavage to allow for protein sensing.   
Alternatively, the host-guest interaction could be mediated by a covalent interaction. A 
cage protein containing a cysteine mutation was covalently modified with a fluorescent 
maleimide reagent which resulted in the encapsulation of a fluorescent dye within the cavity of a 
heat shock protein.37 The abilities of both AfFtn and Bfr to decluster and recluster paves the way 
for the use of strategies to controllably encapsulate a diverse set of guest molecules such as 
inorganic nanoparticles, quantum dots, dyes, proteins, and magnetic resonance imaging (MRI) 
agents. As described above, efficient guest encapsulation can be aided by specific groups on the 





1.5.1.3. Modification of the Heme Cofactor in Bacterioferritin 
The heme cofactor in bacterioferritin is ligated to the neighboring subunits via bis-thioether 
axial coordination to a methionine from each of these subunits. This arrangement exposes the 
heme molecule to the interior of the cage, but it is occluded from the surface by the subunit 
protein coat. Hence the propionate groups from all the 12 heme cofactors point towards the 
interior of the cage where Fe (III) mineralization occurs. Despite the presence of multiple copies 
of heme cofactors within the Bfr molecule, its exact role is not completely understood. In 1995, 
Andrew and coworkers demonstrated that the heme cofactor is neither required for 24-mer 
assembly nor Fe(III) mineralization since the removal of the methionine 52 (Meth  52) that ligates 
the heme molecule does not significantly affect these processes.100 However, recent studies, 
including work in the Honek laboratory, have shown that the heme molecule is involved in the 
stability of the intact 24-mer quaternary structure (Figure 1.6).101 Moreover, the heme molecule 
has been implicated in Fe(III) core demineralization. Yasmin et al. demonstrated that the release 
of iron from the core is independent of the catalytic activity of the ferroxidase center wheras the 
process of Fe (II) uptake is the rate-determining step for Fe (III) release. The iron release is 
mediated by the heme cofactor which aids the transfer of electrons from a reductase protein to the 
bacterioferritin mineral core, hence the addition of small amounts of heme significantly enhanced 
the rate of Fe(III) reduction and Fe(II) release.102 The heme cofactor in Bfr can also be used for 
other applications. The ability to modify and reinsert the heme cofactor into the dimer interface 
has been explored for H2 production.
6 Alternatively, the Honek laboratory has demonstrated that 
other protoporphyrin analogs could be inserted in the Bfr dimer interface and used for 
modification of the Bfr interior cavity (Figure 1.6.1).120 The heme can be labeled by first 
activating the propionate groups, followed by a nucleophilic attack on the activating group by a 
desired primary amine. This allows for modification of the heme with a range of functional 





Figure 1.6. Heme-mediated Bfr 24-mer association. Monomeric Bfr subunits spontaneously 







Figure 1.6.1. Bfr heme-mediated guest encapsulation. The heme cofactor has been used in the 
Honek laboratory to encapsulate guest molecules by synthesizing heme analogs attached to the 
guest molecule (through His-Ni2+-NTA interaction) and reinserting these modified hemes into the 
dimer interface to eventually encapsulate the guest. As well as the subunits could be engineered 




            
1.5.2. Surface Modification 
One of the most interesting characteristics of both AfFtn and Bfr is the physical separation 
between the N-termini and C-termini that are located on the exterior and interior surfaces, 
respectively. A potential application of ferritin is for targeted guest delivery, where the surface 
contains the targeting moiety that guides the internalized cargo to the desired cell. The targeting 
moiety could improve the therapeutic success of a drug and minimize the associated side effects 
of treatment. The exterior surfaces of these proteins could be modified via genetic methods to 
express cell-specific peptide sequences,37 to bioconjugate antibodies to the surface via Cys 
conjugation4b and introduce peptide tags that serve as enzyme substrates for post-translational 
modification.32,103 The E. coli bacterioferritin in this research will be genetically engineered to 
display surface tags that are amenable to further modifications employing the enzyme 
transglutaminase. These peptide fusions could be attached to the N-terminal methionine and be 
useful as long as they do not affect the overall quaternary structure of the ferritin cage. The 
technique of phage display has been used to identify peptide sequences that have affinity to a host 
of molecules, cells and surfaces, and their fusion to the external surface of a ferritin could 
provided additional targeting capabilities to the capsule protein.104 Recombinant techniques can 
be used to engineer the ferritins into specific enzyme substrates. This will allow different enzyme 
manipulations on the ferritin surface provided the required sequences are sufficiently exposed. 
Another way to introduce surface tags is through chemoenzymatic post-translational modification. 
This approach labels purified protein with enzyme-substrate acceptor tags which are then 
irreversibly modified with desired guest molecules in the presence of the specific enzyme. 
Examples are the acceptor tag for biotin ligase, the LETPG peptide for sortase mediated 
modification, the 12-mer acceptor peptide for phosphopantetheine transferase (PPTase) and the 
glutamine tag sequence for transglutaminase-catalyzed reactions.105,106 
Certain amino acids can be chemically modified by a variety of reagents, provided that the 
protein has the desired amino acid residue and in the appropriate position. A typical example of 
this is cysteine modification which has been used extensively for chemical modification, but 
many proteins including bacterioferritin and the Archaeoglobus ferritin lack this residue, and it is 
necessary to use other bioconjugate and chemoselective techniques that target other solvent-




 Thus, bioconjugation techniques can be used to modify proteins. The proteins can be 
modified with specialized reagents to introduce affinity labels, catalytic functionalities and 
modifications useful in targeting applications.108 The AfFtn and Bfr capsids contain varying 
amounts of the 20 amino acids except for cysteine. Aspartic and glutamic acids, lysine, arginine, 
cysteine, histidine, and tyrosine, are frequently used for bioconjugation. The carboxyl groups of 
aspartate and glutamate can be activated by a carbodiimide reagent, such as 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC), or carbonyl diimidazole (CDI). The activated 
compounds can then be reacted with a desired nucleophilic reagent. Lysines and cysteines can be 
modified by alkylation and acylation reactions.109,105  
Secondly, the surfaces of ferritin capsids can be modified with organic and inorganic 
moieties through bioorthogonal conjugation. Bioorthogonal conjugation also uses genetic 
engineering to introduce non-native functional groups, unnatural amino acid, on different sections 
of the protein, unlike genetic fusion tags that are genetically restricted to the termini of the protein 
sequence.110,111 Recently, the surface of human ferritin was modified by genetic engineering to 
introduce the unnatural amino acid 4-azidophenylalanine which subsequently was utilized in click 
chemistry to immobilize alkynes and small targeting molecules onto the protein surface.112 Other 
reagents such as L-azidohomoalanine,111 p-acetophenylalanine (pAcF), and p-azidophenylalanine 
(pAzF) have been successfully used for biorthogonal modification of many proteins.113 Figure 1.7 
below illustrates the chemical modification of ferritin to display diverse functional molecules. 
 
Figure 1.7. Ferritin chemical modification. The amino acids on the surface could be modified 
via genetic engineering, chemical modification or by biorthogonal approaches to display 
contrasting agents, antibodies, peptides, and other functional groups. A chemical modification 




1.6. Project Goals 
1.6.1.Surface Engineering of Bfr and Exploration of Chemoenzymatic Modification of the 
Eexternal Surface 
The ability to overproduce mg to g quantities of several ferritins in different microbial 
expression systems has increased its applications in science.114-116,59 Many of the published 
studies in this area have focused on the interior surface of the cage with less attention focused on 
developing flexible strategies to modify the exterior surface, even though it is equally amenable to 
strategic modification. Furthermore, one of the advantages of ferritin-based drug delivery vehicles 
is its ease of endocytosis by cell surface receptors, but this process suffers from non-specific 
internalization.117,118 Hence, it is of interest to explore strategies to engineer the ferritin 
biomolecule for guided/targeted delivery and imaging applications. Additionally, the surface 
modification could generate materials with unique characteristics by a careful selection of 
reagents and ligating groups and expand the application of ferritins as building blocks for the 
fabrication of new protein-based polymers.119 
In this project, the Bfr nanoplatform will be engineered into a large enzyme substrate. First, 
the surface/ external tags will be evaluated for their abilities to convert the Bfr subunits into 
enzyme substrates. For example, the Qtag-Bfr constructs will be incubated with the TGase 
enzyme in the presence of a primary amine substrate. The covalent attachment of the primary 
amine will be analyzed for adducts by employing mass spectrometry, SDS-PAGE, fluorescence 
spectrometry (for amines with fluorophores), and SEC (and UV-vis absorption) utilizing the 
associated wavelength of the ligands. After that, the constructs will be characterized for 
quaternary structures via SEC and their abilities to be reconstituted with heme to form 24-mers 
similar to HisBfr. Also, the effects of the linker sequence on the 24-mer reconstitution will be 
evaluated, employing both SEC and TEM. Lastly, the tendency for these constructs to serve as 
potential  “on target” drug delivery vehicles will be investigated by encapsulating guest molecules 







1.6.2. Studies on the Encapsulation of HisGFP within WTBfr and AfFtn 
The use of Bfr and AfFtn ferritins in this project further extends the scope of ferritin 
bioengineering. For instance, the Bfr presents the additional heme cassette as a new strategy to 
mediate guest encapsulation. Work in the Honek laboratory has focused on bacterioferritin 
engineering via protein subunit (both exterior and interior) and cofactor modifications (both  and 
in silico). The heme cassette has been previously used to encapsulate hydrophobic molecules, 
dyes, and an intact green fluorescent protein, while subunit modification has led to the 
encapsulation of 2 and 5 nm gold nanoparticles, streptavidin, and even an upconversion 
nanoparticle.120-122  
The two ferritins will be chemically modified with NTA functionalities. For AfFtn, the 
AfFtnC54 mutant will be used for this application by using maleimide chemistry. The 
modification will be analyzed by mass spectrometry, and then the NTA-maleimide functionalized 
AfFtnC54 (AfFtnC54-NTA) will be used for encapsulating His-tagged enzymes. The effects of 
NTA modification on the 24-mer structure will be studied with SEC. The optimized conditions 
for forming the 24-mer AfFtnC54-NTA will then be used for encapsulating the enzyme. The main 
goal of enzyme encapsulation within AfFtn is to further probe the structural significance of the 
open triangular pore in AfFtn structure, how the pore shields substrates from the entrapped 
enzyme and the overall protection of the entrapped enzyme. 
On the other hand, Bfr will be engineered to encapsulate HisGFP using the heme cassette. 
The ability to reinsert the heme cofactor into the dimer interface and favor 24-mer formation will 
be used as an approach to reinsert heme analogs. The heme will be initially modified via NHS 
ester activation followed by a lysine-NTA modification to form the bisNTA-heme analog. The 
produced heme analog will be characterized and then reconstituted into WTBfr to produce 
bisNTA-heme-Bfr. The WTBfr interacts with HisGFP in the presence of Ni2+ under declustering 









1.6.3.Hydrophobic Engineering of Bfr 
Engineering of Bfr will be studied to extend the previous work on the hydrophobic 
engineering of the internal cavity of Bfr so that it can encapsulate hydrophobic guest molecules. 
The project will also evaluate the contribution of fatty acid length and the number of His-tagged 
Bfr subunits to wild type subunits to the hydrophobic engineering of bacterioferritin. The 
following experiments will be described: (i) The original C19-NTA will be encapsulated into Bfr 
capsules containing 50 % WTBfr and 50 % HisBfr, and a comparison of the sizes of the micelle-
encapsulated Bfr to the previous work will be made. (ii) The contribution of fatty acid chain 
length will be investigated with C14-NTA and C16-NTA. These short chains will be encapsulated 
into 100 % HisBfr and analyzed with SEC, +ESI-MS, and TEM. (iii) The extent of hydrophobic 
engineering will be evaluated with pyrene fluorescence and analytical ultracentrifugation.  
 
1.6.4. Bfr Pharmacophore Modeling  
Computational docking studies employing virtual compound libraries (over 19 million) to 
determine if this type of approach can identify molecules to replace the heme group in Bfr and 
hence to find small synthetic molecules that can control a protein’s quaternary structure. The 
ligands (compounds) identified from docking experiments were obtained from suppliers and 
















CHAPTER 2: EXPERIMENTAL DETAILS 
 
2. Materials 
All buffers were prepared with doubly distilled water (DDH2O) and filtered through 0.2 or 
0.45 µm disc filters (GTTP filters from Millipore) depending on the application. Other reagents 
were obtained as follows: Plasmids (Novogen, Mississauga, ON, Canada); Primers (Sigma-
Genosys, Oakville, ON, Canada); Custom gene synthesis (Genescript Inc); Enterokinase, light 
chain ( New England Biolabs, Whitby, ON, Canada); Recombinant Enterokinase (Addgene, 
Cambridge, MA, USA); Streptavidin, Fluorescein Isothiocyanate conjugate (Streptavidin FITC) 
(Sigma-Aldrich, Saint Louis, MO, USA); RNase Alert™ Lab kit (Thermo Fisher Scientific, 
Mississauga, ON, Canada); RNase S-tag peptide (APExBIO, Houston, TX, USA); Subtilisin A. 
(Sigma-Aldrich, Saint Louis, MO, USA); Hemin (Sigma-Aldrich, Saint Louis, MO, USA); Nε-(N-
(+)-Biotinyl-6-aminohexanoyl)-Nα,Nα-bis(carboxymethyl)-L-lysine tripotassium salt (Biotin-X-
NTA) (Biotium, Fremon, CA, USA); Microbial Transglutaminase (MTGase) (ZEDIRA GmbH, 
Darmstadt, Germany); Maleimide NTA (AAT Bioquest, supplied by Cedarlane, Burlinton, ON, 
Canada); Ni-NTA-Nanogold™ (Nanoprobes, Yaphank, NY, USA.); TEM grids (Formvar-Carbon 
400 mesh; Ted Pella, Redding, CA, USA); Molybdic acid ((NH4)6Mo7O24) (Sigma-Aldrich, Saint 
Louis, MO, USA.)  
Chromatographic column and resins: Sephacryl™ S-300 HR and S-200 HR (slurry) (GE 
Healthcare Bio-sciences, Pittsburg, PA, USA); HiTrap™ 1 mL IMAC HP and HiTrap™ 1 mL 
benzamidine FF (HS); Superose™ 6 10/300 GL (GE Healthcare Bio-sciences, Pittsburg, PA, 
USA); Sephadex™ G-10, fine (GE Healthcare Bio-sciences, Pittsburg, PA, USA); UNO™ Q1  
1.3 mL monolith ion exchange column  and Macro-Prep® High S resin (Bio-Rad Laboratories, 












This chapter describes the instruments and methods employed in this project. The 
experimental section begins with protein production, followed by the various approaches 
employed to modify the proteins and the techniques used to analyze these modified proteins. The 
experiments in this section focus on engineering two microbial ferritins: E. coli bacterioferritin 
(Bfr), and Archaeoglobus fulgidus ferritin (AfFtn) platforms on their inner (Bfr and AfFtn) and 
outer (Bfr) surfaces. The interior modification is useful for the encapsulation of novel guest 
molecules such as gold nanoparticles, lipid/surfactant molecules, intact proteins (such as Green 
Fluorescent Protein (GFP), glucohydrolase, and Streptavidin). Outer surface modification was 
achieved via the recombinant DNA modification of Bfr N-termini with peptide tags (Glutamine-
containing tags recognized as substrates for chemoenzymatic reaction with the enzyme microbial 
glutaminase or Sortase tags which are peptide sequences that can be utilized by Sortase enzymes 
for chemoenzymatic coupling with a co-substrate peptide or protein which has a sequence that the 
Sortase enzyme can react with).  
Streptavidin and GFP were utilized as proof-of-concept “guests” to showcase the ability of 
the Bfr cage to encapsulate more complex biological molecules. Different constructs of ferritins 
were designed to enable encapsulations of these guest molecules; Streptavidin encapsulation 
utilized the interaction between a nitrilotriacetic acid (NTA) and His-tag to capture biotinylated 
Streptavidin-FITC (SF). The protein “host” platforms were genetically engineered to contain a C-
terminal His-tag (HisBfr and HisAfFtn) fusion to interact with the biotin-NTA molecule in the 
presence of nickel (II) ions.  The encapsulation of GFP utilized a reverse polarity approach to 
exemplify how His-tagged “guest” proteins could be encapsulated within the Bfr cavity. The 
propionate groups of the Bfr heme cofactor were functionalized with Nα, Nα-bis(carboxymethyl)-
L-lysine and this modified heme reconstituted into wild-type Bfr (WTBfr) to interact with the 
His-tagged GFP during the encapsulation procedure. In contrast, AfFtn was designed to utilize an 
interior Cys-NTA moiety to interact with the HisGFP during the encapsulation procedure. The 
Cys-NTA was the result of the chemical modification of a cysteine residue (site-directed 
mutation; the sole cysteine residue in AfFtn) by the reagent N-(5-(3-maleimidopropylamido)-1-






Encapsulation of hydrophobic molecules within the Bfr cavity was explored by utilizing 
NTA-functionalized lipids: nonadecanoyl-NTA (C19-NTA), palmitoyl-NTA (C16-NTA), and 
myristoyl-NTA (C14-NTA) which also interacted with His-tagged Bfr via nickel (II) ion-
mediated affinity interactions. The lipids were encapsulated via cage-mediated micelle formation, 
wherein the surfactant molecules (or complex micelles) were made to interact with declustered 
His-tagged Bfr subunits followed by heme-mediated reclustering to the 24-mer capsule which 
constrained the hydrophobic surfactants to the Bfr interior to form a micelle or a hydrophobic 
aggregate. Conversely, a preformed micelle with known dimensions could also be encapsulated 
via the same NTA-Ni2+-His interaction.                                         
The encapsulation of inorganic complexes for applications in imaging and diagnostics was 
studied using 5 nm gold nanoparticles (AuNP). The AuNP particle has NTA functionalities 
exposed on the surface through a proprietary polymer (~ 1.8 nm long) which is attached to the 
outer surface of the AuNP. The HisBfr and HisAfFtn constructs interacted with the AuNP 
similarly to the micelle. All the encapsulated guest molecules within the ferritins were studied 
employing transmission electron microscopy (TEM), and size exclusion chromatography (SEC) 
was employed to monitor specific wavelengths associated with the guest and ferritin molecules. 
Fluorescent guest molecules were further analyzed utilizing fluorescence spectroscopy, and 
fluorescence quenching experiments were used to confirm the protection of the guest molecules 
within HisBfr from collision quenching agents such as iodide. Mass spectrometry was employed 
to obtain the relative masses of the guest and host materials in solution and to also confirm the 
presence of the guest molecule within the SEC-purified ferritins. 
The ability to remove and reinsert the native heme cofactor back into the Bfr dimer 
interface and eventually, due to reclustering, within the intact ferritin, allows for the heme moiety 
to act as a “cassette or module” to add additional complexity and capabilities to the 
bacterioferritin scaffold. The heme cofactor has been observed to play a significant role in the 
formation of an intact Bfr 24-mer.120 It has been reported to play a role in Fe3+ reduction. 102 The 
heme-mediated 24-mer formation was studied further by replacing the natural heme with 
commercial analogs and analyzing how they affect the formation of the Bfr quaternary structure. 
A protoporphyrin IX molecule and two others: Protoporphyrin IX dimethyl ester, Protoporphyrin 
IX Zn (II) were utilized in these experimental studies. Also, computational docking calculations 




that might be capable of binding within the heme pocket; the Maestro computational software 123 
was used for this purpose. The applications used to provide detailed binding information between 
the Bfr receptor and molecules in two commercial databases from Schrodinger. These were the 
CAP2011 and the Aldrich Market Direct® Phase Database. Molecules predicted to have very 
good binding affinities (and a few weak binders) were purchased and reconstituted into WTBfr to 
study if the compounds could also act in a similar fashion to the natural cofactor heme to stabilize 
the 24-mer quaternary structure (Chapter 4).   
Exterior surface modification of Bfr was achieved by extending the N-terminus with 
sequence tags which allowed Bfr to undergo enzymatic modifications on its surface to attach 
various compounds to its surface. One tag was also employed that would decorate the surface 
with S-peptide, a fragment of the RNase S protein, which upon reconstition with the RNase S 
protein, should reconstitute the protein and result in reactivation of the RNase enzymatic activity 
on the surface of the ferritin. The Qtags were used for transglutaminase-catalyzed reactions on the 
ferritin exterior surface. The Qtag1 and Qtag2 peptide sequences are double duty constructs since 
they are both reported to be MTGase substrates as well as capable of reconstituting RNase S 
activity when bound to the RNase S protein.106,124 Qtag3 and Qtag4 Bfr both have the MTGase 
substrate sequence reported by Lee and coworkers103 but with slightly different (Gly)n linker 
lengths (Figure 2). A sortTag-Bfr construct was also designed to enable Bfr to undergo sortase-
mediated modifications. Additionally, the construct containing an N-terminal deca-Histidine tag 
followed by an enterokinase proteolytic site and followed by the N-terminus of the Bfr (termed 
the HTEKBfr construct, figure 2c) was intended to aid in the preparation of a form of the wild-
type Bfr (termed HWTBfr) after subsequent protein expression followed by metal affinity 
chromatography and then enterokinase incubation to cleave the His-tag sequence from the N-
terminus of Bfr. This approach was taken to address initial challenges with the expression and 







Figure 2. The Bfr constructs designed for surface modification and Wild-type production. 
(a) The original HisBfr construct with C-terminal H6 tags were recombinantly modified with five 
different N-terminal surface tags into five new Bfr constructs, shown in the table. The red 
segment is the tag sequence and green is the linker sequence. (b) A representation of the 
constructs with both exterior and interior tags. The red shape represents the HisBfr subunit with 
H6 tags to the interior and yellow N-termini surface tags. (c) Shows the production of HWTBfr 
from the HTEKBfr construct having an enterokinase recognition sequence. 
 
 
Additionally, the thermostable ferritin from the archaea Archaeoglobus fulgidus, 
abbreviated as AfFtn, was explored in this work. The primary objective was to encapsulate a 
glycohydrolytic enzyme within the interior cavity of this capsule protein (~ 12 nm in diameter) 
and verify it it is protected against heat and explore its ability to hydrolyze a small substrate 
which could diffuse through the host’s large triangular openings but block larger substrates from 
being hydrolyzed. This work would be a proof-of-concept that the substrate profile of an enzyme 
could be controlled by the porosity of the nanoparticle cage surrounding it. The protein was 
characterized similarly to the steps used to characterize HisBfr due to the similarity in structure 




bacterioferritin). Streptavidin and AuNP were encapsulated within the interior of the AfFtn cage 
to understand how it might accommodate guest molecules. Previous work in the Honek laboratory 
has shown the protection of Bfr-encapsulated Streptavidin-Fluorescein Isothiocyanate (FITC) 
conjugate, abbreviated herein as Bfr-SF, from iodide fluorescence quenching. However, it is 
envisaged that a collisional quencher such as iodide should be able to quench the fluorescence of 
the guest entrapped within AfFtn due to the large triangular openings in the AfFtn host and the 
ability of iodide to freely diffuse through it.  
 
 
Figure 2.1. A representation of Archaeoglobus fulgidus ferritin (AfFtn) catalytic container.  
The guest molecules are encapsulated by employing an AfFtn cysteine 
modification(AfFtnC54) which is chemically modified to attach an NTA affinity tag. 
Alternatively, and not represented in this figure, streptavidin-FITC can be encapsulated by metal 
affinity interactions using the C-terminal His-tagged AfFtn. The encapsulated guest molecules 
will then be analyzed for their protection (GFP and Streptavidin-FITC) from quenching agents or 








2.1.1. Design and Expression of BFr Constructs  
The original DNA/protein sequences for wild-type bacterioferritin (WTBfr) and the C-
terminal His-tagged fusion version of bacterioferritin (HisBfr) were designed by Dr. Uthaiwan 
Suttisansanee, and Dr. Elizabeth Daub and the DNA and protein sequences for both of these 
constructs are shown in Table 1 and Appendix 8, respectively. Additional engineered versions of 
the Bfr protein were custom gene synthesized by Genscript (Piscataway, USA) and designed by 
Professor Honek. The constructs that were designed were: Qtag1-Bfr, Qtag2-Bfr, Qtag3-Bfr, 
Qtag4-Bfr, and Sorttag1-Bfr the tag sequences are in Figure 2, and the entire protein sequence is 
presented in Table 1.  WTBfr and HisBfr proteins were overproduced from ampicillin resistance -
containing pET-22b (+) plasmids, which contain a lac operon promoter, whereas the kanamycin 
resistance-containing pET-29b (+) plasmid was used for the Qtag1-Bfr construct. The pET-29b 
(+) plasmids with S-tag sequence (a subtilisin digest of RNase S protein) at the N-terminus and a 
C-terminal hexahistidine tag for purification was combined with the Bfr-pET-22b plasmid. The 
plasmids were then cut with both BglII and Xhol restriction enzymes, which resulted in ligation 
of the Bfr gene to the new vector that provided an S-tag at the N-terminus for surface 
modification(Appendix 8). The lac operon promoter allows for isopropylthio-β-galactoside 
(IPTG) induction during the production of E. coli QTag1-Bfr. QTag2-Bfr was designed similarly 
to QTag1-Bfr above; the only difference is in the sequence of the linker that ligates the S-tag to 
the surface of HisBfr (transformed into DH5α cells by Taylor Urquhart). These constructs are 
transglutaminase (TGase) substrates and contain the S-peptides for RNase S reassembly.125 The 
QTag3-Bfr and QTag4-Bfr constructs were designed based on a known TGase substrate.103 The 
latter construct used for surface modification was SortTag1, which allows for sortase-mediated 
enzymatic modification of the outer surface of Bfr.126  The genes were further isolated, employing 
a QIAprep Spin Miniprep Kit (QIAGEN, Toronto, ON, Canada) and transformed into competent 
E. coli BL21 cells via heat shock for protein expression. Similarly, three mutants of Qtag2-Bfr 
(Qtag2E86A, Qtag2K22A, Qtag2K22A-E86A) were designed to study the effects of changing 









Construct   Sequence  
WTBfr  M K G D T K V I  N Y L N K L L G N E L V A I  N Q Y F L H A R M F K N W G 
L K R L N D V E Y H E S I  D E M K H A D R Y I  E R I  L F L E G L P  N L Q D L 
G K L N I  G E D V E E M L R S D L A L E L D G A K N L R E A I  G Y A D S V 
H D Y V S R D M M I  E  I  L R D E E G H I  D W L E T E L D L I  Q K M G L Q N 
Y L Q A Q I  R E E G  
 
HisBfr  M K G D T K V I  N Y L N K L L G N E L V A I  N Q Y F L H A R M F K N W G 
L K R L N D V E Y H E S I  D E M K H A D R Y I  E R I  L F L E G L P  N L Q D L 
G K L N I  G E D V E E M L R S D L A L E L D G A K N L R E A I  G Y A D S V 
H D Y V S R D M M I  E  I  L R D E E G H I  D W L E T E L D L I  Q K M G L Q N 
Y L Q A Q I  R E E G L E H H H H H H  
 
Qtag1-Bfr  MKETAAAKFERQHMD  S P D L H  M K G D T K V I  N Y L N K L L G N E L V 
A I  N Q Y F L H A R M F K N W G L K R L N D V E Y H E S I  D E M K H A D 
R Y I  E R  I  L F L E G L P N L Q D L G K L N I  G E D V E E M L R S D L A L E 
L D G A K N L R E A I  G Y A D S V H D Y V S R D M M I  E I  L R D E E G H I  
D W L E T E L D L I  Q K M G L Q N Y L Q A Q I  R E E G L E H H H H H H  
 
Qtag2-Bfr  MKETAAAKFERQHMD S G G G G  M K G D T K V I  N Y L N K L L G N E L V 
A I  N Q Y F L H A R M F K N W G L K R L N D V E Y H E S I  D E M K H A D 
R Y I  E R I  L F L E G L P N L Q D L G K L N I  G E D V E E M L R S D L A L E 
L D G A K N L R E A I  G Y A D S V H D Y V S R D M M I  E I  L R D E E G H I  
D W L E T E L D L I  Q K M G L Q N Y L Q A Q I  R E E G L E H H H H H H  
 
Qtag3-Bfr  MERLQQPT G G G  M K G D T K V I  N Y L N K L L G N E L V A I  N Q Y F L 
H A R M F K N W G L K R L N D V E Y H E S I  D E M K H A D R Y I  E R I  L F 
L E G L P N L Q D L G K L N I  G E D V E E M L R S D L A L E L D G A K N L 
R E A I  G Y A D S V H D Y V S R D M M I  E  I  L R D E E G H I  D W L E T E L 
D L I  Q K M G L Q N Y L Q A Q I  R E E G L E H H H H H H  
 
Qtag4-Bfr  MERLQQPT G G G G  M K G D T K V I  N Y L N K L L G N E L V A I  N Q Y F 
L H A R M F K N W G L K R L N D V E Y H E S I  D E M K H A D R Y I  E R I  L 
F L E G L P N L Q D L G K  L N I  G E D V E E M L R S D L A L E L D G A K N 
L R E A I  G Y A D S V H D Y V S R D M M I  E  I  L R D E E G H I  D W L E T E 




MLVPR G G G G G  M K G D T K V I  N Y L N K L L G N E L V A I  N Q Y F L 
H A R M F K N W G L K R L N D V E Y H E S I  D E M K H A D R Y I  E R I  L F 
L E G L P N L Q D L G K L N I  G E D V E E M L R S D L A L E L D G A K N L 
R E A I  G Y A D S V H D Y V S R D M M I  E  I  L R D E E G H I  D W L E T E L 
D L I  Q K M G L Q N Y L Q A Q I  R E E G L E H H H H H H  
 
WTAfFtn  M A S I S E K M V E A L N R Q I N A E I Y S A Y L Y L S M A S Y F D S I G L K G F S N W M R V
Q W Q E E L M H A M K M F D F V S E R G G R V K L Y A V E E P P S E W D S P L A A F E H V Y
E H E V N V T K R I H E L V E M A M Q E K D F A T Y N F L Q W Y V A E Q V E E E A S A L D I V





Table 1. Protein sequences for the major constructs used in this project. The highlighted 
residues represent the Poly histidine fusion tags as well as mutations (AfFtnC54). The N-termini 
colored segments (red is the tag and green are the linkers) are for surface modification (Qtag and 
Sort tag) and enterokinase (EK) recognition sequence (HTEKBfr). The decahistidine (purple) 
segment in the HTEKBfr sequence was used for IMAC purification and the EK recognition 
sequence (orange) was used for His-tag removal. The corresponding DNA sequences for these 




HisAfFtn  M A S I S E K M V E A L N R Q I N A E I Y S A Y L Y L S M A S Y F D S I G L K G F S N W M R V Q
W Q E E L M H A M K M F D F V S E R G G R V K L Y A V E E P P S E W D S P L A A F E H V Y E
H E V N V T K R I H E L V E M A M Q E K D F A T Y N F L Q W Y V A E Q V E E E A S A L D I V E
K L R L I G E D K R A L L F L D K E L S L R Q F T P P A E E E K L E H H H H H H  
AfFtnC54  M A S I S E K M V E A L N R Q I N A E I Y S A Y L Y L S M A S Y F D S I G L K G F S N W M R V
Q W Q E E L C H A M K M F D F V S E R G G R V K L Y A V E E P P S E W D S P L A A F E H V Y
E H E V N V T K R I H E L V E M A M Q E K D F A T Y N F L Q W Y V A E Q V E E E A S A L D I V
E K L R L I G E D K R A L L F L D K E L S L R Q F T P P A E E E K  
HisGFP  M A S H H H H H H  M V S K G E E L F T  G V V P I  L V E L D G D V N G H K 
F S V S G E G E G D A T Y G K L T L K F I  C T  T G K L P V P W P T L V T T F 
T  Y G V Q C F S R Y P D H M K Q H D F F K S A M P E G Y V Q E R T I  F F K 
D D G N Y K T R A E V K F E G D T L V N R I  E L K G I  D F K E D G N I  L G 
H K L E Y N Y N S H N V Y I  M A D K Q K N G I  K V N F K I  R H N I  E D G S 
V Q L A D H Y Q Q N T P I  G D G P V L L P D N H Y L S T  Q S A L S K D P N 
E K R D H M V L L E F V T A A G I  T  H G M D E L Y K  
 
HTEKBfr  G H H H H H H H H H H S S G H I D D D D K H M K G D T K V I N Y L N K L L G N E L V A I N
Q Y F L H A R M F K N W G L K R L N D V E Y H E S I D E M K H A D R Y I E R I L F L E G L P N
L Q D L G K L N I G E D V E E M L R S D L A L E L D G A K N L R E A I G Y A D S V H D Y V S R
D M M I E I L R D E E G H I D W L E T E L D L I Q K M G L Q N Y L Q A Q I R E E G  
 
HisPfFtn  M L S E R M L K A L N D Q L N R E L Y S A Y L Y F A M A A Y F E D L G L E G F A N W M K A Q
A E E E I G H A L R F Y N Y I Y D R N G R V E L D E I P K P P K E W E S P L K A F E A A Y E H E
K F I S K S I Y E L A A L A E E E K D Y S T R A F L E W F I N E Q V E E E A S V K K I L D K L K F





Protein expression was achieved by inoculating a single bacterial colony from an Amp-agar 
plate (or a Kan-agar plate- 100 ug/mL Amp or 50 ug/mL Kan) into a 1.5 L Luria-Bertani media 
(LB- 15 g Bio-tryptone, 15 g NaCl, 7.5 g Yeast). Cultures were grown at 37 ˚C to 0.6 OD600, and 
protein expression was induced with 1 mM IPTG and incubated overnight with shakng at room 
temperature. The cells were harvested by centrifugation at 6371 g for 30 min in a Beckman JA10 
rotor. The harvested cells were resuspended in 50 mL lysis buffer (100 mM NaCl, 50 mM Tris- 
pH 8.0, 1 mM PMSF, 1 mM EDTA) and then homogenized at 17000 psi on an Avestin 
Emulsiflex-C5 (Mannheim, Germany) with cooling. Insoluble proteins and DNA were pelleted by 
centrifuging at 20,000 g for 40 min in a Beckman JA 25.5 rotor. 
 
2.1.2. Purification of His-tagged Proteins 
All H6-tagged variants (Table 1) were purified by heat shock at 70 °C for 10 minutes and 
IMAC chromatotraphy. The clarified protein solution to an equilibrated 1 mL Nickel HisTrap™ 
HP column (Binding buffer: 50 mM Tris-pH 8, 100 mM NaCl, 20 mM imidazole) attached to a 
BioLogic DuoFlow Chromatograph (BIO-RAD) instrument. The protein was loaded onto the 
column with binding buffer and washed with about 10X column volumes (CV) until the UV at 
260, 280 and 418 nm readings stabilized (and then the OD was zeroed). The bound protein was 
then eluted with buffer containing a higher concentration of imidazole (100 % of elution buffer: 
50 mM Tris-pH 8, 100 mM NaCl, 300 mM imidazole). The molecular weight of the subunits of 
proteins in the isolated chromatographic fractions was estimated employing a 15% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) protocol. Positive electrospray 
mass spectrometry (+ESI-MS) was further used to verify the protein monomeric mass. The 
purified proteins were then quantified using UV-vis absorbance (ε280 = 21430 cm
-1M-1 for Bfr, 
33920 cm-1M-1 for AfFtn), aliquoted into small storage tubes and then stored at -80 ˚C for further 








Figure 2.2. Schematic representation of the His-tagged protein overproduction and 
purification. The WTBfr production only differs at the chromatographic step, where ion 











2.1.3. Purification of WTBfr 
The WTBfr protein was expressed similarly to the other constructs. However, the 
purification process was different due to the lack of the C-terminal hexahistidine tag. The 
harvested cells, from 1.5 L of culture, were resuspended in 100 mL of lysis buffer (50 mM 
MOPS- pH 7.4, 5 mM MgSO4, 1 mM PMSF) and then frozen at -80 ˚C. The 50 mL thawed cells 
were incubated with DNase (50 µg) and RNase (50 µg) at room temperature for 30 min and lysed 
at 17000 psi. The lysate was centrifuged for 1 h at 20000 g, and the lysate was applied to a pre-
equilibrated BioRad UnoQ1 column (50 mM MOPS- pH 7.4, 5 mM MgSO4). The column was 
washed with the same buffer until the absorbance at 269, 280 and 418 nm decreased to 0 OD, 
bound proteins were then eluted with 100 % of 50 mM MOPS- pH 7.4, 1 M NaCl. The fractions 
were analyzed on a 15 % SDS-PAGE gel, and WTBfr-containing fractions were pooled, 
concentrated in 10 kDa  cutoff Amicon centrifugation tubes and buffer exchanged into 50 mM 
MOPS- pH 7.4, 0.5 M NaCl. The concentrate was loaded onto a Sephacryl® S-200 10/300 HR 
column to obtain pure WTBfr protein, verified by SDS-PAGE and MS. Figure 2.2.1 below shows 
the generalized purification protocol.  
In order to optimize the protein yield, the ion exchange step was substituted with 
ammonium sulfate precipitation summarized in Figure 2.2.1 below: 
 




2.1.4. Overproduction and Purification of Enterokinase (EKC122S) 
The ampicillin-resistant pET-15b-EK-C122S-His5 bacterial stab (obtained from Addgene, 
deposited by Skala and Coworkers127) was spread onto an LB-Amp agar plate and incubated at 37 
˚C overnight. A single colony was restreaked on to a new LB-Amp plate for another 37 ˚C 
overnight incubation. Another colony from the second plate was inoculated into a 5 mL LB-Amp 
broth for DNA extraction. EKC122S DNA was extracted with the GeneluteTM plasmid miniprep 
kit (Sigma-Aldrich) and transformed into competent BL21 cells via heat shock. EK protein was 
expressed and purified by Evan Shepherdson (Chem494 undergraduate student under my 
supervision) following the procedure reported by Skala et al.127 with few modifications.  
A 1 L solution of LB containing 100 µg/ml ampicillin was inoculated with an overnight 
culture to a starting OD of 0.05 and shaken (37 ˚C, 220 rpm/min) until the OD600 reached 1.0 
where it was induced with the addition of solid IPTG (0.5 mM final concentration). The cells 
were harvested after 3 h of induction in a Beckman JA10 rotor (15 min, 4000 g, 4 ˚C). The 
harvested pellet was suspended in 50 mM Tris- pH 7 based on its wet mass (3 mL buffer per 1 g 
of the pellet) and lysed at 17000 psi in an Avestin Emulsiflex-C5 (3 cycles, interrupted by 5 min 
of chilling on ice). The lysate was washed 3x with 15 mL of suspension buffer I (50 mM Tris-pH 
7, 1.5 M NaCl, 60 mM EDTA, 6 % Triton x 100), shaken for 30 min at room temperature and 
centrifuged at 18000 g. The pellet was washed with 30 mL of suspension buffer II (50 mM Tris-
pH 7, 20 mM EDTA) and the inclusion bodies (IB) were removed by centrifugation (18000 g, 20 
min, 23 oC). The residue was washed 2x, and 1 g of IB was dissolved in 20 mL of Solubilization 
buffer (7.5 M guanidine-HCl pH 9, 50 mM Tris, 100 mM BME), and stirred overnight at 23 ˚C. 
Undissolved particles were removed by centrifugation at 43000 g for 20 min at room temperature, 
and the pH of the supernatant was adjusted to pH 3.5 with 5 mM citrate buffer and dialyzed 
against 5 mM citrate buffer (12.4 kDa cut off) for 4 h. The white fluffy pellet was harvested by 
centrifugation (18000 g, 20 min, 23 oC) and resuspended in solubilization buffer (1:10 (w/v)). The 
EK in the clear solution was refolded in 2 L of refolding buffer (0.5 M arginine, 50 mM Tris-pH 
8.3, 20 mM CaCl2, 1 mM EDTA, 5 mM cysteine-HCl, 0.5 mM cystine) for 72 h at 23 
oC. The 
resulting solution was concentrated by employing 200 mL Amicon concentrators (10 kDa 
Millipore disc filters), and the concentrate was dialyzed overnight (at 23 oC) against the storage 
buffer supplemented with 3 mM NaN3. The EK protein was analyzed using SDS-PAGE and 




Elution buffer: 50 mM Tris-pH 7.5, 1 M NaCl) followed by an IMAC column (binding buffer: 20 
mM imidazole, 0.5 M NaCl, 50 mM Tris-pH 75, Elution buffer: 200 mM imidazole, 0.5 M NaCl, 
50 mM Tris-pH 7.5). The pooled fractions exhibited protein bands from the SDS-PAGE gel 
corresponding to EK of molecular weight of approximately 26 kDa. 
 
2.1.4.1. Recombinant EK His-Tag Removal 
 A reaction mixture containing 1 mg /mL HTEKBfr (in 50 mM NaCl, 2 mM CaCl2, 20 mM 
Tris- pH 8) and 300 nM pure EK was incubated at 37 ˚C for 15-24 h. The reaction was terminated 
by adding PMSF (to 1 mM final concentration) or exchanging the buffer for distilled water. 
Samples were then analyzed on both SDS-PAGE gels and mass spectrometry (+ ESI) for the 
cleaved substrate (no His-tagged protein). Removal of EK and the unreacted substrate was 
achieved by loading the mixture onto a 1 mL HiTrap™ Benzamidine FF column (in 500 mM 
NaCl, 50 mM Tris- pH 7.5) and eluting with 500 mM NaCl, 10 mM HCl- pH 2. The eluted 
fractions were neutralized by the addition of 1 M Tris-HCl- pH 9 (1 mL fraction to 200 µL 
buffer). The resulting fractions were concentrated and quantified for encapsulation studies. 
Alternatively, the cleaved protein could be separated by running the mixture through an IMAC 
column where the recombinant EK binds, and the cleaved protein flows through. 
 
2.1.5. Purification of Other Ferritins 
  Other members of the ferritin family were also explored in this project: 
Archaeoglobus fulgidis ferritin (AfFtn), the AfFtnC54 ferritin variant, and the Pyrococcus 
furiosus ferritin (PfFtn). These constructs were designed by Dr. Honek and commercially 
synthesized by Genscript, which included codon optimization. The plasmids AfFtn-pET-22b and 
PfFTn-pET-22b  that encode for the C-terminal His-tagged AfFtn and PfFtn respectively were 
transformed via heat shock into competent BL21 cells similarly to the other constructs described 
above (DNA sequence, Appendix 8). 
  An aliquot (5-10 mL) from a 100 mL (LB-Amp) overnight culture that was grown from a 
single colony was used to inoculate 500 mL of LB-Amp (40 µg/mL amp) to obtain a starting 
OD600 of about 0.05. The cultures were shaken at 37 ˚C to 0.4 OD600 where they were spiked with 
40 µg/mL Amp and shaken until 0.6 OD600, and induced with 1 mM IPTG. The cells were then 




cells were resuspended in buffer A [lysis buffer: 25 mM HEPES pH 7.5, 10 mM NaCl, 1 mM 
EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF)]. The resuspended cells were later lysed 
and purified similarly to the other His-tag constructs above. Buffers for the AfFtnC54 variant 
were supplemented with 2.5 mM DTT or 2.5 mM BME to prevent Cys oxidation to the disulfide. 
 
 
2.2. Bfr Surface Modification 
2.2.1. Transglutaminase (TGase)-Catalyzed Reactions  
The N-terminal modification (S-peptide) allows microbial TGase (MTGase) to 
enzymatically modify the surface of the protein with primary amines.128 Previous experiments on 
His-tagged bacterioferritin demonstrated that even though there are glutamines (Q) and lysines 
(K) on the surface of the protein, the glutamines are not accessible to MTGase enzyme hence 
there is a need for a peptide to be present that would provide the needed glutamine residue in the 
proper flanking amino acid sequences for MTGase catalyzed surface modifications.  
 
Figure 2.3. Schematic representation of Bfr (1Bfr)-MTGase Reaction. The top panel shows 
that surface Gln on HisBfr are not modified by TGase. The Bfr is recombinantly overproduced 
with surface tags (bottom panel) and becomes an MTGase substrate which is covalently modified 







A reaction mixture containing MTGase (1 equiv. 2.66 x 10-11 moles), QTag-Bfr (226 
equiv., 6 x10-9 moles), dansylcadaverine (DC) (451 equiv.,1.2 x 10-8 moles), and NaCl (38 equiv., 
1x10-9 moles) in 100 mM Tris-HCl-pH 8, was incubated at different temperatures (from 4 to 50 
˚C) for different times (ranging from 1 h to 24 h). The reaction mixture was then loaded onto a 
desalting column SephadexTM G10 (GE Healthcare) to exchange the buffer and also remove the 
excess enzyme and crosslinked products. The optimum reaction condition was chosen based on 
the fluorescence intensity of the protein band on an unstained SDS-PAGE gel. The gel was 
further stained with Coomassie brilliant blue dye to visualize for the molecular weight of 
covalently modified subunit and cross-linked products. 
The extent of crosslinking and band intensities were used to set optimum reaction 
conditions for the enzyme to be 10 ˚C for at least 2 h in a water bath. +ESI-MS was utilized to 
ascertain the overall mass of the DC-Qtag-Bfr protein adduct. The samples for mass spectrometry 
were run through an IMAC column to separate the modified His-tagged proteins from the excess 
enzyme. The fractions in the imidazole gradient were pooled, and buffer exchanged into DDH2O 
and then injected into the MS instrument (by adding 10 uL of protein to 90 uL of 1:1 MeOH: H2O 
with 0.1% formic acid mixture). Alternatively, reaction products were dried using a speed-vac or 
lyophilized and resuspended in DDH2O for MS analysis. 
 
2.2.2. Cyanogen Bromide Treatment 
 The dansylated proteins were further treated with cyanogen bromide (CNBr) to assess 
which glutamine was labeled with DC. A protein treated with CNBr will be cleaved into 
fragments at the C-terminal side of methionine residues.143 The choice of this reagent was based 
on an initial prediction from The ExPASy peptide cutter tool,129 which predicted 9 possible 
fragments from Qtag-Bfr. The CNBr was suspended in a 70 % formic acid (FA) solution to a final 
concentration of 50 mg/mL FA and was used to unfold and cleave the protein. The reaction 
mixture was incubated at room temperature overnight, and the excess reagents were evaporated in 
an SC10 speed-vac. The resulting protein powder was resuspended in DDH2O and buffer-
exchanged employing a Sephadex G10TM column (equilibrated with filtered DDH2O). The 






2.2.3. QTag-Bfr RNase Reconstitution 
The abilities of Qtag 1 and Qtag 2 to reconstitute RNase activities were explored in 
collaboration with Taylor Urquhart (Honek laboratory). First, the production the S-protein by 
subtilisin digest was undertaken, followed by chromatographic purification as reported by Genz et 
al. with slight modification.106 illustrated in Figure 2.4 below.  
 
 
Figure 2.4. Production of RNase S-protein as per the method reported by Genz et al.106 
 
 
2.2.3.1. RNase Reconstitution 
 RNase S protein, and therefore RNase activity, was fully reconstituted by incubating 
commercial S-peptide with the S-protein, prepared in the above protocol. Firstly, a commercial 
RNase S-tag peptide (KETAAAKFERQHMDS, from APExBIO, Houston, TX, USA) was 
incubated with the purified S-protein to test for reconstitution of RNase S activity on a 
commercial substrate. The reconstitution mixture contained 6 µM each of the S-protein and 
peptide in an RNase-free vial, from the kit, and the mixture was incubated on ice and then diluted 
with RNase-free water (kit) to a final concentration of 60 nM. The RNaseAlert™ substrate 




molecule on one end of the oligonucleotide and a quencher on the other end. The proximity of the 
quencher dampens fluorescence from the fluorophore until cleavage by an RNase. The RNA 
substrate is then cleaved, and the fluorophore and quencher are spatially separated in solution, 
which results in bright green fluorescence emission of the freed fluorophore (Figure 2.4.1). The 
RNaseAlert® substrate was prepared by resuspending it in 5 µL of reaction buffer (from the kit), 
and then 45 µL of the 60 nM reconstituted RNase S was added and quickly transferred into a 
black, opaque, half-area 96-well plate and placed in the plate reader. Top read fluorescence was 
recorded by setting the excitation and emission wavelengths at 490 nm and 520 nm respectively, 
with 515 nm emission cut-off. Also, the PMT was set to 6, and all measurements were recorded at 
37 oC. These conditions were used to prepare and record RNase samples from the Qtag-Bfr 
constructs (Qtag 1 and 2), with the Qtag-Bfr acting as the S-tag peptide. 
Secondly, the rate of hydrolysis was estimated by fitting the data to a modified first order 
reaction:  
𝐹 = 𝐹𝑚𝑎𝑥(𝑒−𝑘(𝑡+𝑇)) 
where F is the  maximum fluorescence (RFU), proportional to the hydrolyzed substrate, Fmax is 
the total amount of substrate, k is the rate constant, t is the elapsed time and T is the elapsed time 
between the first reading and the time it was displayed the screen. 
 
Figure 2.4.1. Schematic representation of the RNase assay. The commercial RNase substrate 
with a fluorescent probe and a quencher. Subsequent hydrolysis of the substrate increases the 




2.3. Heme Reconstitution 
  Heme was reconstituted into bacterioferritin following the procedure reported by 
Wong et al.101 A 0.01 M solution of hemin in a 0.1 M NaOH aqueous solution was diluted with 
0.2 M MES buffer-pH 6.5 to a final concentration of 1.5 mM of hemin. The resulting mixture was 
then centrifuged at 13250 g and the supernatant collected. The protein to be reconstituted was 
buffer-exchanged into a high salt buffer (1 M NaCl, 0.2 M MES-pH 6.5), mixed with 2 molar 
equivalent of hemin solution and heated at 80 ˚C for 15 min and then allowed to cool back to 
room temperature. The sample was then centrifuged at 13250 g to remove excess hemin, and 
further buffer-exchanged employing a 10 kDa spin column to remove excess and nonspecifically 
bound hemin. The nonspecifically bound hemin could also be removed via dialysis or Sephadex 
G25TM column chromatography (Figure 2.5). The product was analyzed employing UV-visible 
spectroscopy for the emergence of a Soret band at approximately 418 nm, which is an indication 
of oligomerization. Size exclusion was used to separate the 24-mers from dimers and monomers. 
The constructs that did not form 24-mers were mixed (50:50 WT: His) to decrease the steric 
interactions between C-terminal His-tags. The QTag2-Bfr variants (Qtag2E86A, Qtag2K22A, 
Qtag2K22A-E86A) were used to study (by Daniel Feng (Chem494), under my supervision) the 
structural effects of the Bfr-N-terminal sequence. These variants were purified on IMAC columns 
and analyzed on SEC for their size distributions and further reconstituted with heme to observe 
the formation of a possible 24-mer.  
 
 




2.3.1. Heme Analog Synthesis 
 Bis-N-hydroxysuccinimide-heme (Bis-NHS-heme) was synthesized (by Anton van der 
Ven; M.Sc. thesis) by the addition of hemin (200 mg, 0.307 mmol) and PS-carbodiimide resin 
(954 mg, 1.3 mmol/g, 4.0 equiv.) to anhydrous dimethylformamide (3.2 ml) with stirring at 23 °C 
for 10 minutes (Step1). N-Hydroxysuccinimide (NHS) (88 mg, 0.76 mmol, 2.5 equiv.) was added 
to this solution and stirred at 100 °C for an hour in a Biotage Initiator 8 microwave synthesizer 
(Biotage Inc., NC, USA) to produce mono- and bis-NHS-modified hemes. The dried NHS-Heme 
was further reacted with bis(carboxymethyl)-L-lysine (Lys-NTA) (10.3 mg; 0.127 mmol NHS-
Heme in 343 uL DMF, 10 mg; 0.381 mmol Lys-NTA in 1 mL of DMF)  in a microwave reactor 
for 1 h at 70 ˚C to produce bis- and mono-NTA-hemes (step 2). The product was analyzed by 
TLC and mass spectrometry. The product was dried in vacuo to remove DMF and resuspended in 
0.1 M NaOH supplemented with 50 % methanol and loaded into a C-18 samplet (3 grams of 
resin) and left to dry overnight. The sample holder was washed with 50-100 mL of 10 mM 
phosphate- pH 8 and eluted with a 0-100 % methanol gradient which separated mono- from bis- 
products. The bis-Lys-NTA-heme product was collected, dried and further resuspended in 
distilled water for a final cleanup using a P2 size exclusion column using distilled water as eluent. 









Figure 2.5.1 Synthesis of Heme-NTA. Step1 activation into the NHS ester (bis and mono NHS-
heme) followed by labeling with the Lys-NTA into bis and mono-NTA heme. 
 
 
2.3.2. His-tagged GFP Encapsulation 
The HisGFP BL21 stock was gifted to us by Dr. Jeanne Hardy (University of 
Massachusetts, Amherst) for encapsulation studies. The encapsulation of N-terminally His-tagged 
GFP into WTBr via a reverse polarity strategy was mediated by the interaction between the bis- 
NTA-heme cofactor of WTBfr and the polyhistidine tag of the His-tagged GFP guest. The 
overproduction of His-tagged GFP was similar to other His-tagged proteins with little 
modification; the plasmid was expressed in an E. coli BL21 cell line and induced with 1 mM 
IPTG at 37 °C. The induced media was shaken at 25 °C and harvested after 3 h to limit inclusion 
bodies. The purification procedure was identical to the His-tagged protein purification outlined 
above. Firstly, harvested cells were lysed at 17000 psi in Anvestin emulsiflex C25 and 
centrifuged at 20000 g to remove insoluble DNA. The clarified lysate was loaded onto a pre-
equilibrated 1 mL HiTrap™ IMAC column and washed with equilibration buffer (150 mM NaCl, 




then eluted with 100 % of elution buffer (150 mM NaCl, 300 mM imidazole, 50 mM Tris-HCl, 
pH 7.5). Finally, the pulled fractions were buffer exchanged into storage buffer (150 mM NaCl, 
50 mM Tris-HCl, pH 7.5). A few microliters (100 µL) of the protein was washed (in a spin 
column) with DDH2O for +ESI-MS to verify the mass of the pure protein. The verified protein 
was then aliquoted into 500 µL portions and stored at -80 °C for future experiments. 
Bis- NTA-heme was incorporated into wild type bacterioferritin by dissolving it in 0.2 M 
MES buffer and mixing with WTBfr in a ratio of 1:2 Bfr: Bis- NTA-heme (in 0.2 M MES-pH 6.5, 
1 M NaCl) ratio and heated at 80 °C for 10 min. The mixture was allowed to cool to room 
temperature and centrifuged at 13250 g and dialyzed (0.2 M MES-pH 6.5, 1 M NaCl; up to 24 
hours) to remove excess and non-specifically bound heme. The WTBfr-heme complex was then 
mixed with His-tagged GFP and Ni2+ in a 1:10:100 molar ratio respectively and incubated at 60 
°C for 90 min followed by a 30 min cooling period  at room temperature and then a size exclusion 
chromatographic step (Superose® 6 10/300 HR; buffer 25 mM HEPES-pH 7.4, 150 mM , NaCl, 
300 mM KCl) was employed. The absorbance of a protein fraction from this column having a 
molecular weight corresponding to an intact 24-mer bacterioferritin with 495 nm absorption was 
an indication of GFP encapsulation. The fractions were analyzed on a native-PAGE gel, and mass 
spectrometry and TEM experiments were conducted on the purified nanomaterial.  
 
2.3.3. Ellman’s Reagent (DTNB) Modification of HisGFP 
Guest protection was studied by comparing the accessibility of Cys residues in GFP to a 
bulky reagent such as DTNB. Free HisGFP was incubated with up to 250-fold molar excess 
DTNB for up to 3 h at room temperature with stirring. The reaction was centrifuged at 13250 g to 
remove precipitates and washed (with 150 mM NaCl,200 mM MES-pH 6.5) using a 100 kDa 
Amicon device to remove unreacted reagents. The HisGFP-TNB complex was analyzed using + 
ESI mass spectrometry and buffer-exchanged into 25 mM HEPES, 20 mM HEPES- pH 7.5 for 
UV absorbance measurement at 430 nm (ε430 nm =12205 mM
-1cm-1).130 Similarly, encapsulated 
HisGFP was incubated with DTNB and the results were compared. The results illustrate how the 







2.4. Gold (Au) Nanoparticle Encapsulation 
The capabilities of the cage proteins to encapsulate larger guest molecules was studied with 
a commercially available 5 nm gold nanoparticle (AuNP) (Ni-NTA-NanogoldTM, Nanoprobes, 
Yaphank, NY, USA). This guest molecule has an NTA functionality attached to the surface 
through a proprietary polymeric linker (Figure 2.6). The nanoparticle solution was initially 
characterized by UV-visible spectroscopy and was observed to absorb at 518 nm. Also, size 
distribution analysis employing DLS indicated that the Au particles had an 8 nm diameter on 
average, which could be due to the presence of the polymeric linker. A 24-molar equivalence of 
the guest proteins (1 cage) was mixed in a ratio of 60:40 His: WT protein mixture and buffer-
exchanged into the declustering buffer (8 M GdnHCl, 25 mM HEPES-, pH 7.6, 100 mM NaCl, 
for Bfr and 10 mM NaCl, 25 mM HEPES, pH 7.6 for AfFtn). The protein was incubated with 100 
molar equivalence of Ni2+ ions and 2 molar equivalence of heme (only for the Bfr ferritin host) 
for approximately 30 min, followed by the addition of 1 molar equivalence of the AuNP in 
solution. The mixture was allowed to incubate at 23 oC for at least 1 h before the removal of the 
declustering agent (by increasing NaCl concentration to 150 mM for AfFtn and dialyzing against 
25 mM HEPES, 150 mM NaCl, pH 7.6 for Bfr). The encapsulated proteins were applied to a 
Sephacryl® S-300 10/300 HR column, pre-equilibrated with 25 mM HEPES, 150 mM NaCl, pH 
7.6 and the fractions were monitored at four wavelengths: 280 nm, 260 nm, 418 nm (heme in 
Bfr), and 518 nm. The elution times were compared to prior runs of free AuNP and free protein. 
Fractions containing encapsulated AuNP (Au coeluted (518 nm) with 24-mer) were collected and 








Figure 2.6. The AuNP- Ni2+-HisAfFtn interaction. The AuNP, yellow sphere on the left, is 
stabilized by the interaction between the NTA functionalities on AuNP and two histidines from 
the polyhistidine tags of the subunits that coordinates Ni2+ (both HisBfr and HisAfFtn). The 
ferritin subunits are represented in red shape on the right. The Bfr cluster was generate with 
Maestro (Schrödinger LLC) 
 
 
2.4.1. Bfr-Targeted Guest Delivery 
The host-guest AuNP (5 nm)-protein complex (Qtag-Bfr-Au) was dansylated (DC-Qtag-
Bfr-Au) to illustrate that Bfr can be repurposed on both surfaces while a guest is within the 
protein shell. TGase-catalyzed reactions (Section 2.2.1) were used to modify the Qtags with DC 
using the procedure above (Section 2.5). The declustering buffer was then removed by dialyzing 
the mixture overnight against a reclustering buffer (150 mM NaCl and 25 mM MES-PH 7.4). 
Dansylation was carried out similarly to that described in Section 2.2.1. Moreover, the mixture 
was run on a Sephacryl® S-300 (10/300) size exclusion column using the reclustering buffer to 
separate the DC-Qtag2-Bfr-Au from the other oligomers in solution. The desired fractions were 
analyzed on a native-PAGE gel to observe a dansylated 24-mer protein band, while TEM was 





2.5. Lipid-NTA Encapsulation 
2.5.1. Synthesis of C19-NTA 
To investigate the hydrophobic engineering of the internal cavity of bacterioferritin, a 
strategy to load the interior cavity of Bfr with lipids was undertaken. The lipids were designed to 
have NTA functionalities attached to them so that any potential micelles or hydrophobic 
aggregates formed from them might likely interact with the hexahistidine tag of His-tagged Bfr, 
resulting in encapsulation of a large hydrophobic molecular ensemble. Nonadecanoyl-NTA was 
synthesized by Omaima Ben Krayem (M.Sc. University of Waterloo, 2017) using the procedure 
outlined by Mènard and coworkers which begins with carboxylic acid activation of the fatty acid, 
followed by modification with bis(carboxymethyl)lysine (Lys-NTA).118 The carboxy group of 
nanodecanoic acid was activated with 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide (EDC) to 
enable N-hydroxysuccinimide (NHS) ester formation. Nanodecanoic acid (1 equivalent, 29.3 g, 
98.2 mmol) and 1.5 equivalents of N-hydroxysuccinimide (16.9 g, 147.3 mmol) were dissolved in 
700 mL methylene chloride (CH2Cl2), followed by stirring at room temperature for 24 h. The 
resulting solution (containing Nonadecanoyl-NHS) was diluted with 700 mL of water. The 
organic phase was separated by washing the mixture with 3 x 250 mL of CH2Cl2, 250 mL of brine 
and dried over anhydrous Na2SO4. The methylene chloride was evaporated and the resulting solid 
was recrystallized with 700 mL EtOAc to obtain powdered nonadecanoyl-NHS (white powder). 
The powdered product (3.5 g, 9.1 mmol, one equivalent) was combined with one equivalent (2.4 
g, 9.17 mmol) of bis(carboxymethyl)lysine (Lys-NTA) and triethylamine (7 equivalents; 9 mL, 
64.2 mmol) and the mixture was dissolved in DMF (50 mL) at room temperature for 48 h with 
stirring. The mixture was evaporated under reduced pressure, and the residue was resuspended in 
150 mL H2O, which was then acidified with the addition of 1N HCl to precipitate the product. 
The product was filtered and dried under vacuum to obtain white powdered C19H54N2O7. A few 
mg of the final product was dissolved in DMSO and analyzed on a Bruker Avance 500 NMR 
spectrometer. Mass spectrometry analysis was performed using a linear ion trap quadrupole 
(LTQ) to identify the molecular mass of the product as well as the impurities that could be 
present. The MS sample was prepared by making a 1 mg/mL solution in water. The lipid was 




pH of 8.  The dissolved lipid (10 µL) was added to 90 µL of MS solvent (1:1:0.1, H2O: MeOH: 
FA) and injected into the ion source at a flow rate of 5 µL/min. 
  
2.5.2. Synthesis of C14-NTA  and C16-NTA 
A simplified version of the NTA functionalization strategy, similar to the heme-NTA 
synthesis, was employed by April Marple (Chem494 undergraduate student in the Honek 
laboratory). Commercially available NHS-ester activated fatty acids (myristic (C14) and palmitic 
(C16)) were directly reacted with bis(carboxymethyl)lysine (Lys-NTA). One equivalent (50 mg 
each, 0.141 mmole C14-NHS, 0.154 mmole C16-NHS) of the fatty acid-NHS ester was dissolved 
in 2 mL of anhydrous DMF and incubated with 1 equivalent of bis(carboxymethyl)lysine (Lys-
NTA) (39.6 mg) and 7 equivalents of Et3N (0.138 mL, 0.99 mmoles and 0.15 mL, 1.08 mmoles 
for C-14NHS and C16 NHS, respectively). The resulting mixture was then let to stir for 48 h at 23 
oC. Then the solution was evaporated in vacuo and the solid was redissolved in 4 mL of doubly 
distilled water and acidified with 1 N HCl until a white solid appeared. The solid was filtered 
under suction and further dried in a desiccator. The modified lipids/fatty acids (74 % and 79 % 
yield for C14-NTA and C16-NTA, respectively) were further analyzed employing thin layer 
chromatography (TLC) (stationary phase: silica, mobile phase: 100 % dichloromethane), mass 










Figure 2.7. Functionalized lipids for encapsulation. (a) Chemical structures of the three lipid-
NTA that were synthesized and (b) models of the extended length of the C19-NTA lipid when it 
interacts with the C-terminal H6-tag from the protein. Distance measurements were made using 
structures drawn in Spartan (Wavefunction, Inc). 
 
 
2.5.3. Lipid-NTA  Encapsulation 
The lipid-NTA was encapsulated utilizing two different approaches: Bfr-mediated 
encapsulation and lipid-mediated encapsulation. The Bfr-mediated encapsulation uses lipids at 
surfactant concentrations below the critical micelle concentration (CMC), whereas the fatty acid-
mediated encapsulation encapsulates a likely preformed micelle into the Bfr cage. DLS analysis 
was used to determine the aggregation concentration (2 mg/mL) of the synthesized surfactant 
before the encapsulation studies. Additional encapsulation studies with mixtures of 50:50 HisBfr: 
WTBfr were employed to study the effects of the multiple C-terminal tags on the Bfr-lipid 
complex and the resulting dimensions of the reclustered capsule protein. The Bfr-mediated 
encapsulation reaction contained, 1 equivalent His-tagged Bfr (2.04 x 10-8 moles, in declustering 




10-8 moles) and 2 equivalents of Ni2+ (4.08 x 10-8 moles). A ¼ CMC reaction was also set up to 
investigate lipid effects on Bfr cage dimensions. The lipid-mediated approach used a similar 
reaction setup with ND-NTA lipid at micelle concentration (1.85 x 10-6 moles). The mixtures 
were incubated at 5 °C for 90 min followed by overnight dialysis in a 12.4 kDa cutoff tubing 
(buffer: 50 mM HEPES-pH 7.4, 150 mM NaCl) to remove the excess GdnHCl, centrifuged to 
remove precipitate and loaded onto a Sephacryl® S-300 10/ 300 -HR column. The protein 
fractions eluting at a time corresponding to an intact capsule protein (24 subunits) were collected 
and analyzed using mass spectrometry, dynamic light scattering, and transmission electron 
microscopy.   
Alternatively, a mixture of 50 %: 50 % / HisBfr: WTBfr, or using shorter chain lipids can 
be used to overcome the internal space limitation (see Results and Discussion later in this thesis) 
since the lipids may not require all 24-mer H6-tags for encapsulation. Hence a reaction mixture 
containing equal parts of WTBfr and HisBfr was used as host while keeping all other reagents the 
same as the encapsulation at the 2 mg/mL lipid above for C19-NTA. In the case of C14 and C16, 
the amount of lipid that formed micelles within Bfr interior dimensions were encapsulated into 
100 % HisBfr cage due to their decreased chain length. 
 
 
2.6. Protein Encapsulation into AfFtn 
2.6.1. Streptavidin-FITC (SF) Encapsulation into AfFtn  
The ability of AfFtn to encapsulate intact proteins was demonstrated by attempts to 
encapsulate fluorescein-labeled streptavidin (SF). The streptavidin molecule has an 
isothiocyanate-functionalized fluorescein attached to ε and N-terminal amines in the streptavidin 
molecule as seen in Figure 2.8 below. The derivatization results in the formation of a thiourea 
bond between streptavidin and the FITC labeling reagent. The conjugation results in bright orange 
color with excitation and emission bands at 495 nm and 520 nm respectively. The encapsulation 
procedure begins with incubating the SF protein (1.85 x 10-9 moles) with Biotin-X nitrilotriacetic 
acid, tripotassium salt (Biotin-X NTA) (3.33 x 10-8 moles) for 30 min at 23 oC with 2.04 x 10-8 
moles of a 50:50 WTAfFtn: HisAfFtn mixture and a 4.0 x 10-8 moles Ni2+ were added followed by 
incubation at 50 °C for 90 min. The resultant mixture was allowed to cool to room temperature 




10/300HR column. The chromatographic peak corresponding to a molecular weight of the 24-mer 
structure with 495 nm absorbance (for SF) was collected and analyzed on a Native-PAGE gel, 
and UV-visible spectroscopy and TEM were employed to further explore the overall structure of 






  Figure 2.8. Schematic representation of streptavidin derivatization and encapsulation: 
The streptavidin-fluorescein conjugate (SF) was obtained from Sigma Aldrich and modified with 
biotin-X-NTA, which interacted with the streptavidin and also the hexahistidine from the capsule 
protein subunits (red dots).  
 
 
2.6.2. Glucohydrolase Encapsulation into AfFtn 
A catalytically functional nanoreactor was engineered from an AfFtnC54 variant through 
affinity mediated encapsulation (Figure 2.1). The C54 group was modified with Maleimido-C3-




then be expected to interact with a His-tagged guest enzyme (in the presence of Ni2+). A solution 
containing AfFtnC54 (1.2 x 10-8 moles in 20 mM NaCl, 25 mM HEPES-pH 7.4) was sparged 
with Argon gas and reduced with 50-100 molar excess TCEP (0.6-1.2 x 10
-6 moles) at room 
temperature for 30 min in order to reduce any inter-subunit disulfide bonds forming in solution. 
Maleimide-X-NTA (20x molar excess, 2.4 x 10-7 moles) was dissolved in the protein buffer and 
flushed with Argon gas and was added to the protein solution. The solution was then capped and 
allowed to react with the Cys groups of AfFtnC54 for about 60 min. The AfFtnC54-Maleimido-
X-NTA complex was analyzed utilizing mass spectrometry. The prepared protein was then 
investigated with (i) His-tagged GFP as a model protein of a His-tagged enzyme and (ii) a 
commercial recombinant alpha-glucosidase from Bacillus stearothermophilus (Megazyme, Inc.; 
Cedarlane, Inc as a local supplier). The above protocol for maleimide labeling was further 




2.7.1. Mass Spectrometry Analysis 
Accurate masses of purified proteins were verified employing a Thermo Scientific Q 
ExactiveTM Orbitrap instrument with an Electrospray Ionization (ESI) source. About 100 µL of 
the pooled fractions, identified by SDS-PAGE electrophoresis, was washed with DDH2O in a 
Nanosep® microcentrifuge spin column until all salts and buffers were removed and then 
suspended in DDH2O. The mass was acquired in positive ion mode by using a 1:1 MeOH: H2O 
with 0.1% formic acid mixture as a mobile solvent. The protein to be analyzed was then diluted 
with this solvent to a final concentration of about 1-10 pmol/uL and injected at a flow rate of 5 
uL/ min into the ESI ion source. The injected sample was heated and bombarded with ions of 
collisional energies between 40-60 eV, causing them to fragment into various daughter ions. The 
daughter ions (in mass/charge ratios, isotopically unresolved) were deconvoluted into their 
corresponding intact protein masses using either the Thermo Protein Deconvolution software: 
https://assets.thermofisher.com/TFS-Assets/CMD/manuals/Man-XCALI-97576-Protein-







2.7.2. Size Exclusion Chromatography (SEC) 
The Size Exclusion Chromatographic technique was used to determine and separate tertiary 
and quaternary structures in solutions of purified, heme reconstituted, and encapsulated proteins. 
Aliquots (0.25-1 mL; filtered and centrifuged) were loaded on to three different kinds of columns, 
Sephacryl™ S-300 10/300 HR, Sephacryl™ S-400 26/60 HR, Superose® 6 10/300 GL, depending 
on the time and the amount of sample available. The flow rates used were between 0.5-1.3 mL, 
and 1 mL fractions were collected. The BioLogic DuoFlowTM system used was equipped with a 
QuadTec UV-Vis detector which allowed for the simultaneous visualization of four wavelengths, 
making it very useful for detection of guest molecules with different absorption wavelengths. 
Calibration profiles were prepared by running BioRad Gel filtration standards (#1511109 
containing: 5 mg thyroglobulin- 670,000 Da, 5 mg g-globulin-158,000, 5 mg ovalbumin -44,000, 
2.5 mg myoglobin-17,000 Da, and 0.5 vitamin B12-1,350 Da) (Appendix 2) and used to estimate 
the elution times/ volumes of the samples injected, which then were used to estimate an 
approximation of the molecular weights of the various protein complexes. 
 
2.7.3. Dynamic Light Scattering (DLS) 
The size distribution of the particles in solution was analyzed by employing a Zetasizer 
Nano ZS model ZEN3500 (Malvern Instruments Ltd, Worcestershire, England) equipped with a 
He-Ne laser with 4.0 mW power at a 532 nm wavelength. The size measurement (DLS method) 
protocol was used. The fluctuations in scattered light at a specific angle were detected with an 
avalanche photodiode array (APDs) which was visualized in the form of intensity over a period of 
time. Water was used as dispersant with a refractive index of 1.33, and the temperature was set to 
20 o C. All samples were centrifuged and filtered before the measurement and were placed in a 45 
uL Hellma cuvette, with 0.3 mm path length and run in triplicates. Sizes were estimated from the 
Stokes-Einstein relationship (D = kBT/6πηRH), assuming that they all existed as spheres in 
solution and the dispersant viscosity (η) was set as the sample viscosity.  
 
2.7.4. Transmission Electron Microscopy (TEM) 
TEM analysis was performed on a CM10 Philips transmission electron microscope 




Department of Biology. The images were collected in bright field mode with 100 keV 
accelerating potential. 0.1 mg/mL samples were buffer-exchanged into DDH2O water to remove 
excess buffer and salt (when necessary). The samples were applied onto copper grids (Formvar-
Carbon 400 mesh; Ted Pella, Redding, CA, USA), placing the grid onto a 20 uL droplet of the 
sample. The grids were lifted up and dabbed with a piece of filter paper to remove the excess 
sample. The thin layer of the sample was then washed twice similarly to how the samples were 
applied and finally placed onto a droplet (20 uL) of 0.5-1 % Molybdic acid solution the excess 
dye solutions were dabbed with pieces of filter paper and put into Petri dishes and incubated at 
room temperature overnight before the TEM analysis. 
 
2.7.5. Fluorescence Measurements 
Fluorescence measurements were carried out on a Photon Technology International 
Fluorometer, A1010B Steady-State fluorescence system equipped with an LPS-220B lamp power 
supply, an SC-500 shutter control, MD-5020 motor driver, and 814 photomultiplier detector. 
Solutions of 500 µL were placed in a 1 mL micro fluorescence quartz cuvette and inserted into the 
sample holder and excited with the appropriate excitation wavelengths. The emission scans were 
collected at +15 nm from the excitation wavelength until it tailed off. A 1 nm slit width was used 
in most cases except for dilute samples where it was set to 2 nm.  
 
2.7.6. Ultraviolet (UV) Measurements 
All UV measurements were carried out on a SpectraMax 5 microplate reader. The sample 
solution and buffers were filtered with a 4.5 µm syringe filter to removed unwanted particles 
before placing in a 45 uL Hellma cuvette (0.3 mm pathlength).  On the other hand, optical density 
(OD 600) measurements were performed on the BioRad SmartSpec™ plus using 1.5 mL 
disposable polymethylmethacrylate cuvettes. 
 
2.7.7. Analytical Ultracentrifugation (AUC) 
The AUC samples were prepared in our laboratory, frozen, and transported, on ice, to the 
Biomolecular Interactions & Conformations Facility of Western University. Sedimentation 
velocity studies were carried out (by Lee-Ann Briere, facility manager) using a Beckman Optima 




centerpieces were used. Centrifugation was carried out at 20 °C, at 20 000 rpm or 30 000 rpm 
centrigugation speed depending on the sample. Forty-five absorbance measurements at either 280 
or 300 nm were collected at 10 minute intervals, in 0.002 cm radial steps.  Data were analyzed 
using the c(s) distribution model in Sedfit and normalized in GUSSI. The partial specific volumes 
(Vbar) were also calculated from the amino acid compositions, using the program SEDNTERP. 
SEDNTERP was also used to calculate buffer, densities, and viscosities seen in Appendix 9. 



























CHAPTER 3. RESULTS AND DISCUSSION FOR EXPERIMENTAL SECTION 
 
3. Brief Introduction 
This chapter combines both the results and the discussions of the experiments performed in 
this thesis( results from experiments in chapter 2). The chapter begins with the proteins used, 
discussing how the constructs were designed and transformed and the protein productions and 
purifications as well as the characterizations (sections 3.1.-3.1.5.). Subsequent sections 
(section3.2.-3.9.)focus on the biotemplating strategies and, where specific enzymes and reagents 
were utilized, will contain a brief description of the enzyme or the conjugation technique. 
   
3.1. Protein Production 
The recombinant proteins employed in this work were all designed and overproduced in the 
Honek laboratory as described in the Methods section (chapter 2). Several of the proteins were 
designed in our laboratories for particular functions (His-tagged; Cysteine mutation, etc.) and then 
commercially obtained through custom gene syntheses (Genscript, Inc.). The presence of C-
terminal hexahistidine tags was useful for immobilized metal affinity interaction (IMAC) 
purifications of all the HisBfr, HTEKBfr, HisAfFtn and HisPfFtn constructs. A BioRad DuoFlow 
instrument with a BioLogic QuadTec™ Detector was used for all chromatographic separations, 
allowing the detection of up to four wavelengths associated with the protein modification. These 
wavelengths were 280 nm, 418 nm, 490 nm, and 518 nm, which correspond to the spectroscopic 
properties of the proteins, heme, GFP, and 5 nm Au nanoparticle, respectively. 
 
3.1.1. Purification of His-tagged Protein 
The His-tag on the interior surface of Bfr and AfFtn constructs require buffer conditions 
that will decluster the subunits and cause the various quaternary structures to exist in equilibrium. 
The declustering process is necessary for the IMAC purification which is dependent on the 
exposure of the His-tags. For instance, AfFtn subunits associate into a 24-mer at salt 
concentrations of 50 mM (see DLS analysis, Figure 3.8.1) and greater so, 20 mM NaCl was used 
in both binding and elution buffers. Before the IMAC column purification, the lysate is heated to 
80 °C or 70 °C for 10 minutes to remove thermally labile host proteins and up to 100 °C for 




The general elution profile for the isolation of these His-tagged proteins employing an 
IMAC purification strategy includes a large flowthrough peak and a subsequent washing period, 
where the monitored UV absorbance is reduced back to the baseline, followed by the elution of 
the His-tagged protein as a sharp peak when an imidazole gradient is subsequently employed 
(Figure 3). The presence of a 418 nm peak in the Bfr fractions was indicative of the presence of 
the heme-group in Bfr (Figure 3a), unlike AfFtn and PfFtn which do not contain the heme 
cofactor (Figure 3b). A few microliters (20 µL) from several fractions such as the flowthrough, 
the wash, and the imidazole eluted regions were analyzed utilizing 15 % SDS PAGE for the 
detection of specific protein bands and the desired proteins were observed to be predominantly in 
the elution peak ( imidazole gradient peak) with sufficient purity for many subsequent studies. 
The presence of pure proteins in the imidazole gradient indicated that most of the proteins existed 
as monomers and dimers under the purification conditions, that exposed the C-terminal to Ni2+ 
His trap column. In instances where most or all of the proteins were in the flowthrough, such as 
the case of PfFtn, the binding and elution buffers were supplemented with 6 M GdnHCl to 
descluster the subunits. Unlike other proteins which completely unfold in 6 M GdnHCl and 
require subsequent refolding steps, Bfr dissociates in subunits which reassociate upon removal of 
the declustering agent. The fractions containing the pure protein of interest were pooled (usually 
all peak fractions in the imidazole gradient) and buffer exchanged into a storage buffer, and the 
dilute samples were concentrated, quantified and stored (in small aliquots) for further analysis. 
The average yield of all the ferritins was approximately 30 mg/L of cell growth, estimated 
from the Beer’s equation with an extinction coefficient of  21430 M-1cm-1 and 33920 M-1cm-1 for 
Bfr and AfFtn, respectively (extinction coefficients obtained from the amino acid sequence using 
the ProtParam tool; https://web.expasy.org/protparam/). The generalized elution profiles for heme 
and non-heme constructs are shown in Figure 3a, b, and c respectively. Electrospray ionization 
mass spectrometry was used to validate the estimated subunit mass obtained from SDS-PAGE 
electrophoresis; a 100 µL aliquot of each of the pure proteins was exchanged into DDH2O. The 
washed sample was mixed with 1H2O: 1MeOH/0.1 % FA   in a 10 :90 ratio (10 µL protein: 90 µL 
solvent) solution and ionized into daughter ions (source spectrum; mass to charge ratios, Figure 
3.1a) and deconvoluted to obtain the exact masses of the samples (Figure 3.1 b-e). The 1 amu 
mass deviation (M-1) in all samples could result from poor isotopic resolution of the quadrupole 




3.1d) depicts the loss of the N-terminal methionine and water from the HisGFP chromophore 
formation. The mass loss could result from the activity of the bacterial methionyl aminopeptidase 
(MetAP) in the expression system. The loss of an N-terminal methionine was observed for 




Figure 3. Generalized chromatograms of nickel his-trap affinity purifications. (a) Elution 
profile for heme-containing His-tagged proteins. (b) Elution profile for non-heme-containing His-
tagged proteins. (c) His-tagged GFP elution profile. The blue, red, and green curves represent 280 








Figure 3.1. Positive ion electrospray ionization mass spectrometry data. (a) the source 
spectrum of HisBfr; (b) Qtag1-Bfr deconvoluted spectrum (theoretical mass 21884.76 Da; 
observed mass 21883.62 Da); (c) HisBfr deconvoluted spectra (theoretical mass 19560.15 Da; 
observed mass 19559.17 Da); (d) HisGFP deconvoluted spectra (theoretical mass 28111.68 Da; 
observed mass 27959.38 Da); (e) HisAfFtn deconvoluted spectra (theoretical mass 21381.24 Da; 
observed mass 21247.18 Da). 
 
 
3.1.2. Purification and characterization of Pyrococcus Furiosus Ferritin (PfFtn) 
The third thermophilic ferritin studied in this project was the hyperthermophilic archaeon 
Pyrococcus furiosus ferritin (PfFtn). PfFtn has been reported to show increased Fe(II) oxidation at 




dimensions and mass to Bfr (but does not contain the heme cofactor) and AfFtn, but has the 
octahedral symmetry in Bfr unlike the open triangular pore of AfFtn (tetrahedral symmetry). 131 
The PfFtn construct used here has a C-terminal hexahistidine tag which is on the interior of the 
capsule which was used for IMAC purifications. Due to the similarity to the other His-tagged 
proteins used, the same purification protocol was initially used to produce pure HisPfFtn. 
However, no protein was observed in the 100 % imidazole gradient despite heating the samples at 
80 °C for 10 min before loading unto the column (Figure 3.1.2a). The flowthrough and the protein 
peaks from the imidazole gradient were collected and analyzed using 15 % SDS-PAGE, but 
HisPfFtn protein bands were not observed in the gradient peak; the protein was found in the 
flowthrough. Analysis of the SDS PAGE gel image (data not shown) indicated that the gradient 
peak, in Figure 3.1.2a, was due to the high concentration of imidazole (300 mM) in the elution 
buffer and did not contain protein. 
The elution of HisPfFtn in the flowthrough indicated that none of the HisPfFtn was bound 
to the IMAC column and perhaps the protein existed in its 24-mer form, with unexposed 
hexahistidine tags on the inside of the capsule. Hence the sample was reheated at 100 °C for 30 
minutes to attempt to purify the protein in a one-step heat treatment as reported previously for this 
protein by Tatur et al.131 However, the protein produced from this step showed conterminant 
bands on  SDS-PAGE gel, necessitating further purification. Hence, it was further purified by 
IMAC chromatography. The equilibration buffer was supplemented with 6 M GdnHCl (25 mM 
HEPES, 150 mM NaCl, 20 mM imidazole, 6 M GdnHCl-pH 7.5) and the same for the elution 
buffer (25 mM HEPES, 150 mM NaCl, 300 mM imidazole, 6 M GdnHCl-pH 7.5 ) to decluster 
the subunits and expose the C-terminal H6-tags. The elution profile presented in Figure 3.1.2 b 
shows that HisPfFtn eluted in the 100 % elution buffer and was verified by both 20% SDS-PAGE 
(not shown) and mass spectrometry (Figure 3.1.2c). The mass spectrometry ionization produced a 
single mass peak at 21373.232, which corresponds to the M-1 peak. Pure HisPfFtn was then 
dialyzed against 150 mM NaCl, 25 mM HEPES overnight and quantified using its UV-vis 
absorbance (ε280 nm= 31400 cm
-1 M-1). The amount of purified HisPfFtn was estimated to be 20 
mg/L of cell growth which is lower than the average 30 mg/mL yield obtained from the other 2 
ferritins. The decrease is due to the several steps involved in the isolation. Finally, the quaternary 
structure of the isolated protein was analyzed in solution by SEC and DLS analysis. Analysis of 




analysis of the DLS also yielded an average size distribution of 15±2 nm (Figure 3.1.2e), 




Figure 3.1.2. Purification and characterization of HisPfFtn. (a) The elution profile of HisPfFtn 
without 6 M GdnHCl (b) Elution in the presence of 6 GdnHCl (c) +ESI-MS data of the pure 
HisPfFtn (d) Size exclusion chromatography profile of pure HisPfFtn (d) DLS analysis of 







3.1.3. Production of Recombinant H5 Enterokinase and HWTBfr 
Previously WTBfr protein from E. coli was purified by heat treatment followed by three 
chromatographic steps: ion exchange chromatography followed by hydroxyapatite 
chromatography and lastly size exclusion chromatography (Anton van der Ven, MSc). Each of 
these steps resulted in protein loss and consequently, low yields of isolated protein. Hence there 
was the need to find an alternative approach for the WTBfr protein production. A new Bfr 
construct was recombinantly engineered with an N-terminal decahistidine (H10) tag and an 
enterokinase (EK) cleavage site. The H10 tag was used for IMAC purification which was 
subsequently removed via an EK cleavage reaction. The tag removal resulted in the isolation of 
WTBfr with an N-terminal histidine amino acid (HWTBfr).  
Enterokinase (Enteropeptidase) is a serine protease (in the duodenum) that converts 
trypsinogen to active trypsin. The trypsin catalyzes the hydrolysis of food proteins as well as 
activates digestive zymogens into their active enzymes. EK is composed of two chains, light and 
heavy chains, which are connected via a disulfide bond. The heavy chain with its transmembrane 
domain is responsible for anchoring the enzyme to the intestinal brush border while the light 
chain serves as its catalytic domain.132,133 The catalytic domain is capable of maintaining the 
enzyme’s catalytic activity with or without the covalently linked heavy chain. The catalytic 
domain recognizes the DDDDK-X or DDDDR-X sequence and cleaves C-terminal to K or R 134 
135. Figure 3.1.3 shows the catalytic domain of the EK light chain in bovine enteropeptidase 





Figure 3.1.3. A closeup view of the active site of bovine enteropeptidase light chain bound to 
a VDDDK ligand (PDB ID: 1EKB). The C-terminal lysine (Lys 306, ball and stick 
representation) from the peptide is covalently bound to His 57 and Ser 195 from the enzyme as 
reported by Lu et al. 136 (image prepared with Maestro) 
 
 
The HTEKBfr constructs were initially cleaved with a commercial EK enzyme (New 
England BioLabs, Inc.) which produced a yield of approximately 70 % of HWTBfr from 
HTEKBfr, but the EK enzyme was not efficient as it required a high concentration to obtain a few 
milligrams of cleaved HWTBfr. The typical cost of producing HWTBfr from HTEKBfr, with 
commercial EK, was high; the typical 25-30 mg of HTEKBfr (per L of growth) was estimated to 
require about 12800 units (27 vials; calculated total cost of ~ $ 4500) of EK.137 Hence, the 
protocol from Skala and co-workers was adapted. 127 This research group engineered a truncated 
(light chain) bovine EK (EK_C122S_His5) which similar to Figure 3.1.3, but contained a 
pentahistidine tag and required an in vitro folding procedure. The C-terminal polyhistidine tag 
facilitated enzyme purification as well as the removal of the enzyme after the His-tag cleavage 




enzyme is its ease of removal by IMAC chromatography, unlike the commercial source that 
requires a benzamidine column purification. The elution buffer for the benzamidine column is 
very acidic and, in some cases, resulted in protein precipitation.  Also, the C122S mutation 
present in this engineered EK eliminates the cysteine residues that form a disulfide bridge with 
the heavy chain and prevents inclusion bodies. Moreover, two mutations, P92R and E152D, in the 
sequence, do not impact the native EK structure. Finally, there is an N-terminal propeptide, 
MGPIDDDDK, which autoactivates the enzyme.127 
The amount of active enzyme produced, 1.5 mg/L, was similar to the reported yield of 2 
mg/L despite the slight variations in the protocols. (Appendix 1 for SDS page gels and 
chromatograms). EK cleavage reactions were carried out on HTEKBfr constructs using the pure 
EK_C122S_His5 enzyme under different buffer conditions to obtain an optimal set of conditions. 
Three buffer systems were employed; the buffer suggested for the commercial EK (50 mM NaCl, 
2 mM CaCl2, 20 mM Tris-HCl-pH 8.0), the buffer used by Skala et al. (50 mM NaCl, 50 mM 
Tris-pH 7.5) and a Bfr substrate buffer supplemented with CaCl2 (100 mM NaCl, 2 mM CaCl2, 50 
mM Tris-pH 8). The EK_C122S _His5 construct was expected to cleave similarly to the 
commercial light chain, but there were additional peaks detected in the +ESI data (Figure 3.1.2) 
which would appear to correspond to nonspecific cleavage at X+1 (18494 Da) and two others in 
the flexible regions of the tag (19702 Da and 19528 Da). The cleavage pattern observed confirms 
the reported promiscuous behavior of the EK enzyme,127,133,135,138 and necessitated a new protocol 
for WTBfr production as described in the next section. 
What was learned from these experiments despite the outcome are not limited to: (1) 
acquiring the technique of isolating an active ezyme, (2) mastered the technique of unfolding and 
carefully refolding  an enzyme to remove inclusion bodies and activating the ezyme, (3) how to 
adjust the chrotatographic condition,benzamidine chromatography, to preserve the intergrity of 
the purified proteins. Moreover, documenting the outcome contributes to the knowledge about 








Figure 3.1.2. +ESI MS results for enterokinase His-tag removal. The top panel shows the total 
conversion of HTEKBfr to HWTBfr using the commercial EK while the bottom shows a mixture 
of fragments from the expressed EK enzyme. The sequence indicates the possible cleaving sites. 
 
 
3.1.4. Removal of the EK Enzyme after Cleavage 
Since the expressed EK enzyme did not produce reasonable amounts of HWTBfr, the 
remaining stock of the HTEKBfr was cleaved with the commercial EK enzyme. After the 
cleavage reaction, the enzyme was removed by running a benzamidine column which removes 
serine proteases such as EK. The buffer contained 0.5 M NaCl and 0.05 M Tris-HCl- pH 7.5 
while the elution buffer contained 0.5 M NaCl and 10 mM HCl- pH 2. Due to the acidic nature of 
the elution buffer, the fraction tubes were supplemented with 200 µL (each) of 1M Tris-HCl -pH 
9 to neutralize and stabilize the eluent. Figure 3.1.3 below shows the elution profile from a 1 mL 
benzamidine column running at 1 mL/min. Most of the cleaved proteins were observed in the 100 
% elution buffer (Figure 3.1.3b, lane 5) with little unreacted HTEKBfr (Figure 3.1.3b, lane 4) 
which was not ionized on the +ESI since it showed the cleaved product in 100 % abundance 




The final step was to run the isolated HWTBfr fraction (from lane 5) on size exclusion 
chromatography and to obtain the quaternary structures in solution. The sample was exchanged 
into SEC buffer (150 mM NaCl, 50 mM HEPES-pH 7.5) and loaded onto a Sephacryl™ S-300 
10/300 HR column. The elution profile showed HWTBfr as dimeric. However, the presence of 
heme did not shift the protein to higher oligomers, unlike the other Bfr constructs. A significant 
shift toward the 24-mer form required extended heating at elevated temperature, as seen in Figure 
3.13c. The extended heating led to significant protein loss and may not serve as a useful host for 
the intended purposes. Therefore, no attempts were made to separate the reaction from the lab-
made EK cleavage. Even though the lab-made EK cleavage showed fragments that corresponded 
to WTBfr, its abundance was low relative to the HWTBfr and others (Figure 3.1.2. bottom panel) 
requiring more purification steps to produce very little WTBfr.   
Despite the unexpected results obtained here, it highlights the fact that the association of 
Bfr subunits beyond dimers is greatly affected by the N-terminal sequence and even the presence 
of a single bulky amino acid (like histidine) can altogether abolish 24-mer formation.  The 
previous WTBfr production from WTBfr plasmids (without any tags) was further optimized, in 







Figure 3.1.3. Enterokinase removal and characterization of HWTBfr. (a) The serine protease 
removal with 1 mL benzamidine FF column, flow rate 1 mL/min. (b) The SDS-PAGE (15 %) 
analysis of the fractions from (a). (c) Sephacryl™ S-300 10/300 HR column profile run on 
HWTBfr with and without heme at different temperatures. HWTBfr heme (red), HWTBfr + heme 
at 80 °C for 12 min (blue), HWTBfr + heme at 70 °C for 10 min (green), and HWTBfr + heme at 











3.1.5. Wild-type (WT) Bacterioferritin Purification 
The WTBfr from constructs were expressed in E. coli, and the cells were harvested and 
lysed similarly to the His-tagged constructs.  The crude supernatant from the cell lysate was 
heated for 10 min at 70 °C and allowed to cool to room temperature before centrifugation to 
remove insoluble and denatured protein from the lysate. The protein solution was applied to an 
ion exchange column, BioRad UnoQ1, in binding buffer and eluted with a 1 M NaCl gradient 
(Figure 3.1.4). SDS analysis on the fractions showed about 80 % of the protein in the salt gradient 
(Figure 3.4) with a few higher molecular band proteins, requiring further purification steps. The 
Sephacryl™ S-200 HR, 10/300 column was used for this purpose. The pooled fractions were 
concentrated down to 10 mL in the eluent buffer (50 mM MOPS, 1.5 M NaCl, pH7.5), the higher 
salt concentration aided DNA removal. Analysis of the gel image (Figure 3.1.4 b) showed 
significant loss of protein in the flowthrough, but exhibited higher 260 nm absorbance than 280 
nm absorbance, indicating high DNA contamination and hence these fractions were not collected. 
The 100 % gradient fractions showed higher molecular weight protein bands, which necessitated 
an additional purification step. The Sephacryl™ S-200 10/300 HR column (running at 0.5 mL per 
minute, in 500 mM NaCl, 50 mM MOPS-pH 7.5) was used to remove contaminants; the elution 
profile generated two well-resolved peaks that were analyzed on 15 % SDS-PAGE for WTBfr 
bands. The first peak, at retention time ~20-30 min, was WTBfr (Figure 3.1.4 c, gel), but the 
second peak at time 35-43 min did not show any WTBfr protein bands. The 260 nm absorbance in 
the fractions of peak 1 significantly decreased. However, the higher molecular weight bands 
persisted in lanes associated with the WTBfr peak, which were initially assigned to oligomeric 
forms of WTBfr (monomer, 18.5 kDa; dimer, 37 kDa; tetramer 74 kDa). There were no visible 
protein bands in peak 2. 
Positive ESI mass spectrometry was used to validate the mass on the WTBfr fractions, and 
the deconvoluted spectrum showed a WTBfr protein mass (Figure 3.1.5.) as the most ionizable 
species in solution. The abundance of monomeric WTBfr could imply that the protein solution is 
purely WTBfr, and the higher molecular weight bands resulted from subunit association. The 
association could have occurred upon cooling of the SDS samples before electrophoresis. The 
quaternary structures were analyzed by employing size exclusion chromatography. The WTBfr 




peak (RT, 40 min) corresponds to aggregates, and the broad peak is a distribution of WTBfr 
oligomers.  
Despite the reasonable amount of WTBfr protein (22 mg/L) obtained from the above 
protocol, there was a significant amount of protein loss in the flowthrough that resulted in low 
protein yield. This problem persisted after column regeneration. Hence an ammonium sulfate 
precipitation protocol (Figure 2.2.1) was utilized after the heat treatment and DNase I incubation 
steps. This protocol replaces the ion exchange chromatographic step, yet produced pure proteins 




Figure 3.1.4. Ion exchange and size exclusion chromatography. (a)The elution profile of 
loaded WT lysate shows two peaks, flowthrough (FT) and fraction peaks in the high salt gradient. 
(b) SDS-PAGE gel with Pure HisBfr (HBFr, 19.5 kDa) as a reference. (c) A Sephacryl™ S-200 







Figure 3.1.5. Mass spectrum of pure WTBfr. The observed mass was 18494.150 amu was 1 
amu less than the expected mass, 18495.03. The +17 ion (1088.9021 @ 1100 m/z) is the most 




Figure 3.1.6. Size exclusion chromatography of WTBfr after Uno Q1 and S-200 HR runs. 
The Sephacryl™ S-300 10/100 HR column was run at 0.5 mL/min with 150 mM NaCl, 50 mM 






3.2. Heme Encapsulation  
The Bfr heme cofactor has been reported to drive the formation of the 24-mer quaternary 
structure of this protein88 as well as to facilitate iron release from the ferroxidase site.102,100 The 
ability to remove and reinsert heme into the dimer interface makes the Bfr platform amenable to 
heme-mediated modifications without employing changes in the amino acid residues in the Bfr 
protein. The heme encapsulation is monitored via UV-Vis spectroscopy due to the heme group’s 
spectral changes upon binding to Bfr, and the resultant oligomerization can be visualized utilizing 
size exclusion chromatography (SEC) as well as transmission electron microscopy (TEM). Size 
exclusion chromatography was used to visualize the oligomeric forms (quaternary structures) of 
the protein in solution by loading purified protein samples onto high-resolution Sephacryl™ 
columns. The relative molecular masses of the proteins were estimated from calibrations curves 
(from the separate columns. Appendix 3). SEC was also used to isolate encapsulated Bfr from 
free Bfr monomers and dimers after host-guest interaction, based on their hydrodynamic radii or 
distinct host absorbance peaks. 
Unlike other heme-binding proteins which require the heme cofactor for proper folding 
(example, mitochondrial cytochrome c),139 Bfr properly folds in the absence of its heme cofactor, 
into apoBfr, leaving an empty heme-binding site. The recombinant Bfr proteins used in this work 
initially contained deficient levels of the native heme cofactor which could be ascribed to the 
overproduction of high levels of proteins within a short period with the inability of heme 
biosynthesis to provide the high levels of heme required for complete holoprotein formation. 
Hence most of the Bfr constructs were initially monomeric or dimeric in solution and required the 
addition of exogenous heme to form the intact 24-mers. Heme binding begins with a subunit 
dissociation step (declustering), followed by heme addition and a final reassociation (reclustering) 
step. The declustering agent used must sufficiently open up the heme-binding interface, hence 
temperatures ranging from 70 °C to 80 °C were used.  At the encapsulation temperature, the Bfr 
molecules were dissociated, but not denatured.101 Another route that was investigated was 
incubating at lower temperatures (35-60 °C) for extended times (1-2 h). However, incubating the 
Bfr and the heme at these lower temperatures for extended periods generated only dimers in 
solution (data not shown). The products of the binding interactions were visualized by employing 
UV-Vis spectroscopy or the appearance of a Soret band at approximately 415 nm in the 




Additionally, the reaction mixture was assessed using SEC for the nature of quaternary 
structures in the solution since dimers, trimers, and other intermediate forms of Bfr also produce 
Soret bands. The Soret band results from the axial ligation of methionine 52 to the heme 
molecule.100 Figure 3.2 illustrates the heme encapsulation process for WTBfr with the UV-vis 
scan (left panel) showing the emergence of a Soret band upon adding heme to apo WTBfr. A size 
exclusion profile of the encapsulated WTBfr generated a major 24-mer band (green and purple 
curves) from the heme reconstituted WTBfr, unlike the ensemble of oligomers in the apo WTBfr 




Figure 3.2. WTBfr heme encapsulation. The SEC column, Sephacryl™ S-300 10/300 HR, was 
run at 0.5 mL/min in a 150 mM NaCl, 50 mM HEPES, pH-7.5 buffer.  
 
3.2.5. Sedimentation Velocity Studies 
Even though WTBfr may not be required for most of the guest encapsulation studies 
(except His-tagged guest molecules), much effort was made to obtain significant quantities of 
WTBfr since it has been demonstrated to control the size of the Bfr capsule.120 The process of 
mixing  WTBfr and HisBfr constructs is useful for reducing the internal steric crowding 
associated with the multiple his-tags in the 100 % HisBfr capsule. Previous research by Anton 




encapsulated by using a mixture of 40 % WTBfr and 60 % HisBfr. Also, C19-NTA lipid 
encapsulation studies, described in section 3.6, requires a 50 %: 50 % mix of HisBfr and WTBfr 
to regulate the Bfr capsule dimensions. Hence at least 40 % of HisBfr in a capsule is sufficient to 
stabilize the guest via His-Ni2+-NTA interactions.  
Analytical Ultracentrifugation analysis was used to study the overall sedimentation 
patterns of  Bfr samples: (a) 100 % HisBfr + heme and (b) 50 % HisBfr + 50 % WTBfr + heme. 
The heme was used to lock the subunits into the 24-mer conformation. The primary aim of the 
AUC experiments was to characterize the two Bfr mixtures. The expected molecular weight of the 
100 % HisBfr based on the amino acid sequence is 469 kDa, whereas the 50 % HisBfr + 50 % 
WTBfr is 456.6 kDa assuming they exist as α12β12. Also, other oligomeric forms are expected 
since there is an equilibrium between subunits and the 24-mer in solution (even in the presence of 
heme).  
The sedimentation velocity plots (Figure 3.2.1) were obtained by fitting the velocity and 
the residuals scans Appendix 10) with the Sedfit and normalizing in Gussi. The sedimentation 
velocity analysis on samples 100 % HisBfr + heme, a) and 50 % HisBfr + 50 % WTBfr, b) 
produced slightly different sedimentation patterns shown in 3.2.1. However, the degree of 
symmetry (f/fo) similar for both samples with sample a) having a value of 1.2 and b) having a 
value of 1.17; hence, the mixing did not affect the roughly spherical arrangement of subunits. 
Overall, sample b (Figure 3.2.1. b) which is a mixture of WT and His Bfr showed fewer species 
than the 100% HisBfr sample, the predominant species having a molecular weight of 472.3 kDa 
whereas the mixed sample, b exhibited a molecular weight of 498.8 kDa, consistent with the 100 
% Histagged Bfr having the greater molecular weight. The data indicates that there could be 
mixing of subunits in the 50 % WTBfr + 50 % HisBfr subunits which led to lower molecular 






Figure 3.2.1. The distribution of species in solution. For: (a) 100 % HisBfr + heme showing 4 
populations of molecular weights: 68.3 kDa with 5.0 S (sedimentation coefficient), 208.1 kDa 
having 10.6 S ,  498.8 kDa with 18.9 S, and 1025.9 kDa with 30 .6 S. (b) 50 % HisBfr + 50 % 
WTBfr + heme has 3 populations: 102.6 kDa, 472.3 kDa , and 914.5 kDa MWs having 
sedimentation coefficients of 6.4 S, 17.7 S, and 27.6 S, respectively. Sedimentations were 
performed at 20 000 rpm.  
 
 
3.3. Transglutaminase (TGase)-catalyzed Surface modification 
Transglutaminase is an enzyme that catalyzes the posttranslational formation of a covalent 
isopeptide bond between a γ-carboxyl group of glutamines in a protein of interest (POI) and an 
incoming primary amine, ε-amino lysine of another protein, and deamination of glutamine (when 
the donor group is replaced by water).140 The reaction is illustrated in Figure 3.3. The covalent 
nature of the new bonds that are formed makes them resistant to proteolytic degradation, and they 
have exceptional mechanical properties. Hence TGases have become useful in food processing, 
and material sciences as well as health.141,142 These TGases have become popular in the food 
industry due to their abilities to form cross-linked products that improve the texture of foods such 
as wheat proteins, beef myosin, soy proteins, and whey proteins.141 For example, TGase has been 








Figure 3.3. Transglutaminase-catalyzed modification: The TGase enzyme forms an acyl 
complex which is modified with primary amines, water, and ε-amino groups from proteins to 




 The Bfr surface was modified with five different N-terminal tags to produce five new 
constructs for Bfr exterior modification. These constructs also contain C-terminal hexahistidine 
tags. The first four are Qtags in that they are transglutaminase substrates. Qtag1 and Qtag2 can 
also reconstitute RNase S activity if the RNase S-protein is added to these tags.  The Qtag1 tag is 
composed of the first 15 amino acids from the RNase S-peptide. The 15 amino acids were 
genetically linked to Bfr through a PDLH spacer from the pET-29b (+) vector used to express this 
construct, described in the experimental section (section 2.1.1). The Qtag-Bfr constructs become 
amenable to several forms of TGase mediated modification that could be introduced: intact 




amines). The data illustrates how a primary amine, dansylcadaverine could be modified on the Bfr 
exterior surface via a TGase mediated reaction (Figure 3.3.1). Also, the dansylated Qtag2-Bfr is 
capable of encapsulating a guest molecule (5 nm AuNP). Both exterior and interior modification 
demonstrates that Bfr could be used as a targeted guest delivery machinery. 
The Qtag-Bfr constructs were covalently modified using TGase with dansylcadaverine 
(DC), molecular weight (MW) 335.465 gmol-1, to generate fluorescent Qtag-Bfr products. The 
products were visualized on 15 % SDS-PAGE gels (unstained, Figure 3.3.1) and their intensities 
were measured using a PTI fluorimeter, using the excitation and emission wavelengths of 
dansylcadaverine which are 325 nm and 525 nm. Finally, electrospray ionization mass 
spectrometry (+ ESI-MS) was used to obtain the masses of the products (Figure 3.3.2). 
The SDS-PAGE gel image (Figure 3.3.1) showed higher molecular weight bands, which 
could result from cross-linked subunits. TGases have been reported to show strict specificity 
towards glutamines; the desired Gln has to be in the preferred sequence. However, TGase 
modification of ε-amino Lysines does not require the lysines to be in a specific sequence; in 
general, any accessible lysines could be crosslinked.128 The subunits of Bfr display six exposed 
lysines per subunit (Fig. 3.3.4a) that can potentially form crosslinked products with adjacent 
subunits. Moreover, the higher molecular weight labeled bands persisted after boiling the SDS 
sample, confirming that they are crosslinked lysine products since labeled Bfr dimers dissociate 
upon heating at temperatures above 70 °C. Bfr constructs without the Qtag (HisBfr) were not 
labeled by the MTGase despite the exposed lysines and glutamines (lanes 5 and 9, Figure 3.3.1). 
However, the presence of dimer bands in these lanes may suggest lysine cross-linking in HisBfr. 
The absence of DC-labeled bands in HisBfr validates the design of the Qtag constructs. Even 
though there are surface glutamines on the HisBfr (three exposed per subunit, Figure 3.3.4 b), 
they may not be in a prefered TGase recognition sequence. Analysis of product fluorescence 
spectra and +ESI- MS data confirms that Qtag1-Bfr and the other Qtag constructs are MTGase 
substrates (Figures 3.3.2 and 3.3.3). The labeled peak masses are only 1 or 2 amu off from the 
expected masses (M-1 and M-2 peaks) which could result from the loss of 1 or 2 protons during 







Figure 3.3.1. SDS-PAGE gel (15 %) showing the modification of Bfr-QTag1 substrate. The 
top panel is the fluorescent image of the unstained gel, indicating the presence of dansyl-labeled 
subunits as well as labeled cross-linked products. The lower panel shows the stained gel with a 
protein ladder (lane 0, units kDa). 
 
 
Figure 3.3.2. Emission spectra of dansylated QTag-Bfr constructs. Fluorescent measurements 
showing all DC labeled constructs except HisBfr are fluorescent (at the dansylcadaverine 
emission wavelength) when excited at 325 nm, excitation wavelength of dansylcadaverine. 






Figure 3.3.3. Positive ion ESI data for the MTGase catalyzed reactions. The table shows the 
masses of the unlabeled and labeled subunit and plots of abundance vs. mass for dansylated 
HisBfr (HisBfr-DC), Qtag1-Bfr(Qtag1-Bfr-DC), Qtag2-Bfr (Qtag2-Bfr-DC), Qtag3-Bfr (Qtag3-
Bfr-DC), and Qtag4-Bfr (Qtag4-Bfr-DC).
 
Figure 3.3.4. Exposed lysines and glutamines on a Bfr subunit. Panel a shows the surface 
lysines, in yellow, present on one of the Bfr subunits, whereas Panel b shows the exposed 
glutamines per subunit (also in yellow). Overall, there are nine lysines, six glutamines, and 19 





3.3.1. Cyanogen Bromide (CNBr) Reactions of Dansylated Qtag-Bfr 
The products of MTGase catalyzed reactions were treated with 50 mg/mL CNBr dissolved 
in 70 % formic acid. The formic acid solution is expected to unfold the protein to enable effective 
fragmentation of the protein. CNBr cleaves a protein by (i) The generation of a cyanosulfonium 
salt, via a nucleophilic attack on the cyanide group (of CNBr) by the sulfur atom of methionine. 
(ii) The cyanosulfonium intermediate is nucleophilically attacked by the methionyl carbonyl 
oxygen to produce methyl thiocyanate, byproduct, and an iminolactone. (iii) The thiocyanate is 
then hydrolyzed into C-terminal peptide and N-terminal peptide fragments (Figure 3.3.5).143 The 
number of fragments that can be generated from Qtag-Bfr was estimated with the PeptideCutter 
tool 144 to obtain the fragmentation pattern, which resulted in nine peptide fragments with even 
distribution of all the glutamines in the Bfr subunits and the tags (Figure 3.3.6.) 
 
Figure 3.3.5. Mechanism of CNBr fragmentation. Figure was drawn with ChemDraw based on 






Figure 3.3.6. Cyanogen bromide fragments of Qtag1-Bfr-DC. (a) +ESI-MS results showing 
the end of sequence mass as the most abundant peak and three fragments from the N-terminus. (b) 
The nine estimated fragments obtained from the ExPASy peptide cutter tool.  
 
 
3.3.2. Structural Effects of Bacterioferritin Surface Tags 
The introduced peptide surface tags (Qtags, for example) have successfully converted Bfr 
into a transglutaminase substrate as illustrated above. However, it is also important to be able to 
reconstitute the intact 24-mer in the presence of these tags. The intact 24-mer makes the platform 
more versatile, and it potentially could allow for 24 copies of a protein/enzyme/antibody to be 
built on the outer surface of a single Bfr capsule. Modified Qtag surface peptides could allow for 
a versatile strategy to provide targeting molecules to decorate such a capsule, such as EphB4 
targeting peptides which could target the Bfr to tumor cells expressing the EphB4 surface 
receptor.145 Also, the modified capsule will be capable of hosting a guest molecule(s) within the 
hollow interior. The presence of the heme cofactor plays a significant role in quaternary structure 
of the Bfr and decidedly in modified forms of Bfr. However, it was observed that the amount of 
endogenous heme present in Bfr after isolation from E. coli cells is not sufficient to convert all 
Bfr molecules into their 24-mer quaternary form. Hence it was necessary to supplement the Bfr 




with Bfr in a high salt buffer (1 M NaCl, 200 mM MES-pH 6.5) and incubated at 70 ° C for 30 
min or 80 °C for 10 min. This protocol was reported to by Wong et al. to be a satisfactory 
approach to removing and reinstalling the heme cofactor into Bfr 101. The high ionic strength 
ensured that the native structure is restored upon cooling to room temperature, thus making the 
declustering and reclustering processes reversible. The declustering temperature of 70 °C was 
used for these experiments since it was found that incubating Bfr at 80 °C for 10 min causes 
extensive precipitation of the surface tagged Bfr variants (Qtags and Sort tags) but was found not 
to be a concern for either the HisBfr or WTBfr proteins. To ensure that the subunits are well 
dissociated to expose the heme binding pockets, the incubation times were extended to 30 min at 
70 °C. Centrifugation (to remove excess heme) was performed at a medium speed 5018 g remove 
excess unreacted heme molecules. The nonspecifically bound heme molecules were further 
removed by dialysis or with desalting column. Figure 3.3.7 below shows the formation of the 24-
mer structure from Bfr subunits in the presence of heme and declustering agents. The approach 
was further used in all the Bfr encapsulation studies in this project. 
A UV scan is utilized to access the extent of encapsulation; free Bfr solutions exhibit the 
280 nm absorbance as well as a 418 nm absorbance peak indicative of the presence of heme 
associated with the protein capsule, depending on the expression and purification process.  Bfr 
bound with heme exhibits a blue shift of approximately 418 nm ( ε 418  = 1.09 x 10
5 M-1cm-1)101 
with minimal 280 nm absorbance from this cofactor, the absorbance ratio of 280 nm to 418 nm 
was calculated, and if it was greater than 0.7, then 24-mer structures were expected in solution. 
Since the 418 nm (Soret band) could correspond to any tertiary or quaternary Bfr intermediate 
conformation, size exclusion chromatography was used to identify the intact 24-mer structure. 
The 24-mer structure eluted at the retention times of horse spleen ferritin (also a 24-mer of similar 
size as Bfr) and other ferritins of similar size (see appendix 2 for calibration profiles). All the 
Qtag-Bfr constructs were analyzed for their ability to form intact 24-mers with heme, and the 
results were compared to HisBfr (Figure 3.3.7). 
Analysis of the data shows that apoHisBfr is mainly dimeric and monomeric. Heme 
addition shifts the equilibrium towards 24-mer production (red curve). In the case of Qtag1-Bfr, 
which was our initial Qtag construct, the apoQtag1-Bfr solution contained high mobility 
monomers which associated into dimers in the presence of heme. This observation prompted a 




would not interfere with the subunit association.  The Qtag peptide was expected to lie on the 
surface of the folded Bfr, but that was not the case. Reviewing a space filled model of the Bfr 
surface (Figure 3.3.8) the starting Met1 residue is adjacent to two bulky residues, Lys2 and Glu 
66, which might be expected to be fairly mobile in conformation and allow sufficient room for the 
incoming tag to be accommodated. In fact, molecular dynamics computations undertaken on 
solvated bacterioferritin (20 ns dynamics run) exhibited substantial conformational movement of 
the Lys2 and Glu66 residues; data not shown). However, even though the recombinant 
modification was successful, the purified Qtag1-Bfr only existed as dimers in the presence of the 
heme cofactor. The twenty amino acid residues of the tag could have a secondary structure which 
blocks the interface of the subunits, hindering the 24-mer formation. The lack of a 24-mer 
quaternary structure in solution led to the design of a new Qtag2-Bfr with a flexible linker (PDLH 
was changed to GGGG). The SGGGG linker was used in order to extend the tag sequence away 
from the subunit interface. 
Furthermore, the Qtag4-Bfr was redesigned based on the sequence of Qtag 3 (which was 
determined not to form a 24-mer).  The addition of one extra glycine to the linker in Qtag4-Bfr 
did result in the formation of the desired 24-mers structure. The combined results show that an 
optimal length of glycine spacer (containing at least four Gly residues) is required to permit 24-
mer formation. 
 Based on the above observations, the final sortTag1-Bfr construct was designed with a five 
glycine linker to facilitate the 24-mer conformation (Figure 3.3.7). This construct is expected to 
convert Bfr into an acceptor ligand that ligates to the acyl donor sequence transiently attached to 
the sortase enzyme. The process is simplified in Figure 3.3.8.5.  The Sort tag1-Bfr constructs 
were successfully expressed and characterized for quaternary structure composition and were 








Figure 3.3.7. Size exclusion profile of Bfr heme binding and 24-mer formation. Sephacryl TM 
S-300 HR (Hi Prep 26/60) column with a 1.3 mL/min flow rate was used to separate the various 
quaternary structures. The blue curves represent protein solutions without heme and the red 








Figure 3.3.8.  Space-filling model of bacterioferritin (PDB:1Bfr). Showing the N-terminal Met 







Figure 3.3.8.5. Sortase mediated condensation reaction. The sortTag1-Bfr having sequence 
MLVPRGGGGG serves as the precursor which, upon incubation with thrombin, provides the N-




3.4. N-Terminal Site-directed Mutations 
Two amino acid residues near the N-terminal methionine in Bfr were briefly investigated to 
attempt to understand further the factors that stabilize/destabilize the Bfr 24-mer quaternary 
structure. Two bulky residues that are close to the N-terminus were mutated via PCR based site-
directed mutagenesis to form three new Qtag2-Bfr constructs: Qtag2E86A, Qtag2K22A, and 
Qtag2E86A-K22 keeping the C-terminal His-tag for purification and future modifications. 
Similarly, the expression and purification produced sufficiently pure (without any conterminant 
bands on SDS gel) proteins with consistent yields of approximately 25 mg/L for Bfr (Appendix 
3). Heme binding was performed as described (at 70 °C) and 24-mer capsules were separated 
utilizing size exclusion chromatography as previously mentioned. The mutants were dimeric 
without the presence of exogenous heme (Figure 3.3.9 a). Analysis of the Qtag2-Bfr plot appears 
to indicate the presence of a 35:60 % monomer: dimer ratio under these conditions unlike Figure 
3.3.7 above, where the solution lacking heme was 100 % dimeric in the absence of the exogenous 
heme cofactor. However, it was expected that the addition of heme should shift the equilibrium to 
the 24-mers form, as seen for Qtag2-Bfr.  The heme binding results indicated dimer formation, as 
seen in Figure 3.3.9 b for both Qtag2K22A and Qtag2E86A-K22A mutants. Only the Qtag2E86A 
mutant showed a slight shift towards the formation of the 24-mer, suggesting that lysine 22 is 
useful for the electrostatic interactions between adjacent subunits and the resultant hydrophobic 
collapse of the subunits into a 24-mer cage. Also, the persistence of the dimer could indicate that 
the residues that are reported to stabilize the heme cofactor (Phe 26 and Met 5263a) are not 
affected by this surface modification.  Analysis of this data suggests that the mutants are very 
stable to purification but may not be suitable for manipulation that requires intact 24-mer 








Figure 3.3.9. Size exclusion profile (Sephacryl ™S-300 10/300 HR) of Qtag2 and its variants. 
(a) the no heme (apo) forms after purification with absorbance at 280 nm on the y-axis also and 













3.4.1. Encapsulation of AuNP into Qtag2-Bfr (Targeted Guest Delivery) 
The ability of Bfr to serve as a targeted cargo delivery system was investigated by 
encapsulating QTag2-Bfr with 5 nm gold nanoparticles (AuNP) and labeling the exterior surface 
with dansylcadaverine to yield the Qtag2-Bfr-DC nanoparticle, decorated with the dansyl 
fluorophore. This would be an approach to provide a proof-of-concept that a guest-loaded Bfr can 
be modified on its surface to attach molecules, which in future could be molecules such as 
antibodies, to help target these ferritins to cells or surfaces. The AuNP was encapsulated by 
clustering the Bfr subunits around the NTA-functionalized nanoparticle. The Bfr-C-terminal H6 
tags were coordinated by NTA in the presence of Ni2+ ions. A typical coordination complex is 
composed of a quadridentate NTA, and the two remaining valences on the Ni2+ are occupied by 
two histidine molecules from the H6 tags as seen in Figure 3.4a below. Moreover, hemin solution 
was added to the reaction to lock the Bfr subunits into their 24-mer structure. Since the Bfr 
solution is a mixture of monomers, dimers, and 24-mers, the buffer was supplemented with 8 M 
GdnHCl to decluster all the higher oligomers and expose the internal H6 tag to the NTA-guest. 
Hence the 8 M buffer system was used in all HisBfr-NTA mediated encapsulations. The 8 M 
GdnHCl did not affect any of the reaction components, and it was removed by dialysis after the 
encapsulation. Lastly, the encapsulated AuNP was separated from excess reagents (Bfr subunits, 
free AuNP) and other oligomers by size exclusion chromatography by monitoring the AuNP 518 
nm absorption.  Figure 3.4b below shows the encapsulated AuNP and free AuNP eluting at 43 
min and 47 min, respectively. Also, Bfr monomers and dimers were observed without any 518 nm 
absorption peaks. The shift in elution time corresponding to the retention of the 24-mer structure 
indicated that the AuNP was encapsulated within the Bfr interior cavity. The AuNP was 
successfully encapsulated despite its observed 8 nm size on DLS (data not shown). The extended 
size is due to the proprietary linker and the NTA (corona) on the surface of the 5 nm AuNP. The 
encapsulation was facilitated by the tendency of HisBfr to associate around the guest molecule. 
Hence it is not clear from this analysis the number of Bfr subunits which surround the AuNP, and 
further experiments are required to validate this. 
The Bfr-AuNP complex was further modified on its surface with transglutaminase-
catalyzed covalent attachment of dansylcadaverine (DC) molecules. First, the complex was 
incubated with the DC substrate in the presence of 5 mM NaCl and microbial transglutaminase. 




of Bfr with DC was verified by employing fluorescence spectroscopy and SDS-PAGE to detect 
that the Bfr subunits were labeled by the fluorophore (Figure 3.4 d). Transmission electron 
microscopic (TEM) analysis was used to visualize the encapsulated AuNP (Figure 3.4 c). 
Analysis of the TEM image indicates AuNP encapsulation with a few empty 24-mer shells and 
free AuNP aggregates. All the encapsulated products were 1-2 nm larger than the empty Bfr 24-
mer capsids. The results here show that Bfr could be repurposed for targeted cargo delivery where 
the cargo could be a drug or a magnetic resonance imaging (MRI) agent, and the exterior could be 




























Figure 3.4. External and internal surface modification of Qtag2-Bfr. Panel a shows a 
schematic diagram of the His-Ni2+-NTA interaction that stabilizes the AuNP. (b) SEC elution 
profile with the encapsulated AuNP (purple) corresponding to an intact 24-mer structure in size. 
(c) The TEM image of the pooled fractions corresponding to the 24-mer structure from SEC, 
indicating successful AuNP encapsulation (d) The SDS-PAGE gel illuminated to show the 
fluorescence of DC-labeled Qtag2-DC-AuNP, indicating that the AuNP-Bfr has been dansylated 




3.4.2. Bacterioferritin RNase S Reconstitution 
The second role of the Qtag1 and Qtag 2 Bfr construct is demonstrated by their tendencies 
to reconstitute RNase S activity. The Qtag1-Bfr contains the S-peptide of RNases S. The S-
peptide is obtained from the subtilisin digest of RNase A followed by separation of the RNase S-
peptide (residues 1-20) and S-protein (residues 21-124)146 from the unreacted RNase A as seen in 
Figure 3.5 below. The S-peptide is employed as a fusion tag for protein purification on resins 
having S-protein attached to them. Also, the reassociation of the S-peptide and S-protein produces 
a fully functional RNase S enzyme complex with dissociation of 5 x 10 -9 M or less ( in the 
presence of  5 x 10 -7 M  S-protein).146 Residues 1-15 have been reported to be necessary for the 
RNase S activity; hence, noncanonical peptide sequences can be used to reconstitute 




Figure 3.5. Representation of Qtag1-Bfr design. RNase A (2RNS) is cleaved into RNase S, 
which is purified to separate the S-peptide from the S-protein. The Qtag1-Bfr construct was 
designed with a plasmid coding for an S-tag peptide fused to the N-terminus of the HisBfr protein 
to produce Qtag1-Bfr (surface representation: HisBfr in gray and Qtag1 in yellow) which was 






 The Bfr surface was modified with the 1-15 oligopeptide (MKETAAAKFERQHMD), 
from the S-peptide (Figure 3.5). The commercial pET-29b vector, with S-tag, contained an 
SPDHL linker sequence between the Bfr N-terminal methionine sequence and the S-peptide. The 
plasmids were successfully transformed into E. coli BL21 cells and used to express the S-tag-Bfr. 
The sequencing results showed a Bfr with N-terminal S-tag and C-terminal H6 tag, as seen in 
Figure 2 b and Table 1. The construct was renamed Qtag1-Bfr due to its ability to be utilized as a 
transglutaminase substrate, making it a double duty construct. Attempts were made (in 
collaboration with Taylor Urquhart, Honek Lab) to reconstitute RNase S activity from Qtag-Bfr 
and S protein with the Qtag-Bfr acting as the S-peptide. The S-protein was purified by following 
the protocol from Genz et al.106  
The RNase assay was carried out with the RNase alert® lab test V2 kit. The RNaseAlert® 
proprietary substrate has a fluorescent label at one end and a quencher on the other end of a short 
oligonucleotide. The substrate has a low fluorescence in the absence of RNase due to the 
proximity of the quencher molecule, but this distance is increased upon RNase hydrolysis, which 
results in a bright green fluorescent signal upon excitation.  
The tendencies of QTag1-Bfr and Qtag2-Bfr to hydrolyze this substrate were studied by 
incubating these constructs with the purified S-protein to form an expected Bfr-RNase S complex 
which would likely have RNase activity. The Bfr-RNase S was then incubated with the substrate 
and the emission spectra of the cleaved substrate recorded. The chromatographic step successfully 
separated the S-protein from the reaction mixture, peak 2, Figure 3.5.1 b. However, the assay 
showed residual RNase S activity in the S-protein when it was incubated with the substrate 
without any S-tag peptide. The observed S-protein activity (Figure 3.5.2 a) indicated that there 
might be residual uncleaved RNase A in peak 2 (Figure 3.5.1 b), but it has a lower rate constant 
(estimated 0.033 min-1) than Qtag1-Bfr which was determined to be approximately ten-fold 
higher (approximately 0.33 min-1) as seen in Figure 3.5.2 b. Conversely, the Qtag2-24-mer + S-
protein sample showed low activity indicating that the Bfr surface (24-mer) may be affecting the 
assembly process and ultimately the hydrolysis of the substrate. Overall, the preliminary data 
suggest that the subunit Qtag1-Bfr can reconstitute RNase S activity, but the flexible linker region 
in Qtag2-Bfr may not be suitable for reconstitution of the RNase S activity. However, further 
studies would be warranted to explore the capability of reconstituting enzyme activity employing 





Figure 3.5.1. Purification and quantification of S-protein and S-tag peptide. (a) Absorption 
spectrum for the commercial S-tag peptide (KETAAAKFERQHMDS). (b) The elution profile 
from the Macro-Prep® High S 10/100 column showed two peaks; peak 1 corresponds to the 
RNase A while peak 2 corresponds to RNase S protein, and unresolved RNase A (faint band) as 
indicated in Figure c.  
 
 
Figure 3.5.2. Preliminary rate of hydrolysis. (a) The fluorescence intensities associated with the 
RNaseAlert® substrate using Qtag1-Bfr-S-protein (blue), Qtag2-Bfr-S-protein (orange), S-protein 
(yellow), and 24-mer Qtag2-Bfr-S-protein (gray). The S-protein was added to the substrate to 
check any background hydrolysis from the reaction components. Figures b and c show the 




 3.5. Encapsulation of His-tagged GFP (HisGFP) 
The HisGFP molecules were encapsulated via a reverse polarity approach wherein the 
cargo was His-tagged, and the host Bfr contained the NTA functionality. The reverse polarity 
approach shows that Bfr is very versatile and can be engineered to encapsulate a wide variety of 
His-tagged proteins and enzymes. The HisGFP variant used here is the enhanced GFP with a 
single S65T mutation. The Ser65 residue becomes dehydrated to form a vinyl side chain during 
the post-translational chromophore formation (as seen in Figure 3.6) and the resultant 




Figure 3.6. Formation of enhanced GFP chromophore. Figure was generated in ChemDraw. 
 
Preliminary HisGFP encapsulation into Bfr was undertaken by  Anton van der Ven (M.Sc.) 
and Sorina Choirean (undergraduate student) from the Honek laboratory. Firstly, the heme 
cofactor was activated by utilizing EDC/NHS to produce the bis-NHS ester of heme followed by 
reaction with Nα, Nα-bis(carboxymethyl)-L-lysine to produce the bis-NTA analog (Figure 3.6.1, 
insert), and it was reinserted into the dimer interface (at 80 °C for 10 min) to form the BisNTA-
heme-Bfr(BisNTA-Bfr) complex. The BisNTA-Bfr complex was further incubated (60 °C for 30 
min) in the presence of HisGFP molecules to produce a mixture of encapsulated and 
unencapsulated HisGFP. Secondly, the resultant mixture was separated on a Superose 6™ 10/300 
GL column, at 0.5 mL/ min using an eluent composed of 150 mM NaCl, 300 mM KCl, 50 mM 
Tris-pH 8. The increased ionic strength (addition 300 mM KCl) further assisted in locking the Bfr 




mixture of 24-mers and subunits in solution. The emergence of a 490 nm absorbance peak eluting 
at a fraction which also corresponds to the 24-mer capsule (as seen in Figure 3.6.1) was consistent 
with HisGFP (Sequence in Table 1) encapsulation since the free HisGFP eluted in the region 
associated with monomer and dimer sized proteins. Also, the presence of the GFP chromophore 
absorbance showed that the heat treatment at 60 °C mediated HisGFP encapsulation without 
affecting its stability. Even though both the spectroscopic and nonspectroscopic analysis indicated 
there could be some level of encapsulation, it was not clear whether the pooled fractions 
contained 100 % encapsulated HisGFP or a mixture of empty and encapsulated Bfr capsules. 
Hence transmission electron microscopy was used to visualize the fractions. The encapsulation of 
the HisGFP did not swell the WTBfr capsule (no increase in hydrodynamic radius) and the likely 
complex was eluted at the same retention time as the free 24-mer WTBfr.  
Also, the addition of increasing amounts of HisGFP in a series of encapsulation 
experiments did not enhance the 490 nm absorbance associated with the 24-mer Bfr during SEC 
chromatography but did produce increasing amounts of HisGFP eluting at the monomer/dimer 
position. The appearance of excess HisGFP was likely due to the inability to encapsulate more 
than one HisGFP molecule within the WTBfr 24-mer.  To show the relative sizes of the host and 
guest proteins, the crystal structure of a GFP (PDB:1C4F) was visualized and its dimensions 
determined (4.5 nm long and 3.5 nm wide; Figure 3.6.2). These dimensions would indicate that 
the size of GFP should be within the interior capabilities of the Bfr (1Bfr) cavity, but the presence 
of the His-tags and loop regions may increase the overall space the HisGFP occupies. The 
structure and dynamic nature of HisGFP may prevent the loading of two HisGFP molecules into 
the Bfr (also having Heme-NTA groups that take up some space). Control studies that were also 
undertaken by using unmodified heme did not exhibit any HisGFP encapsulation (Appendix 14). 
The results herein provide evidence that a modified heme cofactor can be used to encapsulate 







Figure 3.6.1. Size exclusion profiles of HisGFP encapsulation. This figure shows the elution 
profiles (on Superose 6™ 10/300 GL) of the starting material (WTBfr-noHeme) and its holo 
form, BisNTA-Bfr as well as the encapsulated product. The insert, top right, is the structure of 
BisNTA-heme molecule. The two bottom figures show that WTBfr has a limit to the number of 
HisGFP (490 nm) that can be encapsulated.  
 
Figure 3.6.2. Dimensions of host and guest proteins. A and B show the length and breadth of 
enhanced GFP (PDB:1C4F), respectively. C shows the interior and exterior dimensions to Bfr 
(PDB:1Bfr) to illustrate that the GFP molecule can fit into the Bfr cavity. The dimensions were 




3.5.1. Characterization of the Encapsulated HisGFP 
The pooled fractions from SEC (bottom right, Figure 3.6.1) were analyzed by employing 
UV-visible spectroscopy, 20 % SDS-PAGE electrophoresis, TEM (Figure 3.6.4 c) and mass 
spectrometry. The UV-vis scan of the encapsulated HisGFP was compared to the free HisGFP. 
The spectrum showed a Soret band at 415 nm for the 24-mer bisNTA-heme-Bfr as well as a 490 
nm shoulder peak for the WTBfr-HisGFP (Figure 3.6.3a). The SDS-PAGE analysis (Figure 3.6.3 
b) was used to verify that there were indeed two different proteins in the pooled fractions, and the 
490 nm peak was not associated with the bisNTA-heme molecules. The gel image showed that 
there were two distinct proteins in the sample, which corresponds to HisGFP (approximately 27 
kDa) and WTBfr (approximately 18 kDa). The exact masses of these proteins were obtained from 
+ESI MS analysis on the encapsulated sample (Figure 3.6.3c). However, the +ESI data showed 
the intact mass of WTBfr subunit,18494.33 Da, and cleaved HisGFP at 27741.051 Da. The mass 
loss was estimated to be Ni2+-mediated His-tag cleavage of Ala-Ser-His from the N-terminal and 
addition of two K+ ions (fragment ii, Figure 3.6.3e) and further investigated with +ESI-MS 
analysis. Free HisGFP was incubated with Ni2+ and bisNTA-heme (all at encapsulation 
conditions) for 60 minutes. The resultant mixture was washed with water and analyzed for the 
intact HisGFP peak. Surprisingly, no intact HisGFP was observed (Figure 3.6.3d). The HisGFP 
appeared to be cleaved into several species; the most abundant peak was 26473.101 Da (fragment 
v, Figure 3.6.3e). These fragments were assigned to C-terminal cleavages labeled ii to vi in Figure 
3.6.3e, possible due to metal-mediated cleavage.  
Finally, transmission electron microscopy was used to compare the WTBfr to the HisGFP 
encapsulated WTBfr (Figure 3.6.4b and c). The WTBfr without any guest molecules showed stain 
penetration, through the shell, into the interior cavity (Figure 3.6.4b) whereas the encapsulated 
HisGFP excluded the stain from the WTBfr interior cavity (Figure 3.6.4c). Figure 3.6.4c showed 
that there are a few empty WTBfr capsules and about 60-80 % WTBfr capsules filled with the 
HisGFP molecules, which means that the SEC column could not resolve the two forms of Bfr. 









Figure 3.6.3. Analysis of encapsulated HisGFP. (a) the UV-Vis spectrum of the encapsulated 
HisGFP compared to the free HisGFP, both showed the characteristic 490 nm absorbance. (b) The 
SDS-PAGE image of the encapsulation showed that the pooled fractions contain both proteins. (c) 
Positive ESI-MS analysis for the encapsulated HisGFP with peaks corresponding to intact WTBfr 
and cleaved HisGFP. (d)  Mass spectrum of HisGFP under the encapsulation conditions in the 
presence of bis-NTA-heme but lacking the presence of Bfr. (e) The deduced fragmentation pattern 
for HisGFP.  The mass of purified HisGFP is 27960 Da, which resulted from fragment (i) and the 
loss of  H2O during chromophore formation. Additionally, C-terminal fragments (iii and vi ) were 









Figure 3.6.4. The TEM analysis of Encapsulated HisGFP. (a) The left image shows how the 
heme cofactors (in space fill) can be modified and used for encapsulation of HisGFP (green). (b) 
The TEM image of WTBfr (1Bfr), showing interior 0.5% molybdate stain penetration. (c) Image 
c indicated stain exclusion in the presence of GFP (1C4F) guest molecules. The protein structures 
were generated with Chimera 
 
 
3.5.2 Modification of HisGFP Cysteines 
In 1994, Inouye and co-workers reported that the addition of strong reducing agents such as 
Na2S204, FeSO4, 2,2'-azido-bis (3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), and many 
others (at 5 mM, 2 mM, 0.2 mM, respectively) when added to recombinant GFP could extinguish 
the GFP fluorescence within a few minutes. 149 It has also been reported that DTNB, 5,5- 
Dithiobis (2-nitrobenzoic acid), could react with and quench GFP fluorescence. HisGFP 
fluorescence quenching was attempted therefore with DTNB, 5,5- Dithiobis (2-nitrobenzoic acid), 




alkaline conditions) to form colored solutions containing the thionitrobenzoate anion and the 
thionitrobenzoate-protein adduct (protein-TNB) as seen in Figure 3.6.4.1. The reduced TNB2- 
absorbs at 412 nm (extinction coefficient of 14,1500 M-1 cm-1)150 and this coefficient is used to 
estimate the amount of free cysteines versus cystines in solution. The HisGFP construct used in 
this work contains two cysteines (C58 and C80), which remain reduced after purification. Hence 
incubating with DTNB could produce two protein-TNB adducts which could be analyzed by 
either absorption spectroscopy or fluorescence emission (monitoring the effect on GFP emission).  
 
 
Figure 3.6.4.1. The reaction of Ellman’s reagent (DTNB) with the cysteine sulfhydryl group 
of proteins. Figure generated with ChemDraw. 
 
Firstly, the DTNB was solubilized in water and analyzed employing mass spectrometry, in 
negative ionization mode, to obtain the mass of 395 Da that corresponds to the M-1 ion (Figure 
3.6.4.2a). A reaction was set up by incubating 0.4 µM of HisGFP with 1 mM of DTNB (both in 
50 mM Na2HPO4, pH 8.0) at room temperature for an hour in the absence of Bfr. A few 
microliters of the reaction solution was then washed with DDH2O and analyzed by +ESI-MS. 
Analysis of the +ESI -MS data in Figure 3.6.4.2c showed that the protein mass of HisGFP had 
increased by 396.842 Da, corresponding to HisGFP with both Cys residues modified by TNB.  
The fluorescence of the HisGFP was analyzed for GFP chromophore emission, as seen in 
Figure 3.6.4.3 (Excitation = 490 nm, Emission = 525 nm). HisGFP was then reacted with varying 
amounts of DTNB (1 mM, 2 mM and 3 mM DTNB; blue, red, green, and purple curves 
respectively in Figure 3.6.4.3a). The sample was incubated for 30 minutes at room temperature 




DTNB concentration. The optimal incubation time was estimated from a freshly prepared 0.4 um 
HisGFP and 1 mM DTNB mixture and incubated at room temperature for different time points 
(Figure3.6.4.3 b). Again, the fluorescence intensity of the GFP continued to decrease with 
increasing incubation times, but a significant decrease, 50 % decrease, was observed after 2 hours 
of incubation unlike the “few minutes” reported by Inouye et al.149 
Finally, a solution of 0.1 µM HisGFP (500 µL) and 0.1 µM encapsulated HisGFP (500 µL) 
were separately titrated with DTNB (100 µM and 200 µM). The free HisGFP showed a decrease 
in fluorescence intensity in response to increasing DTNB concentrations and increasing time, 
respectively. However, the encapsulated HisGFP did not show a decrease in intensity for the 100 
µM DTNB and a slight decrease for the 200 µM DTNB addition. The two solutions behaved 
differently due to the protection afforded by the protein capsule. The results suggest that the 
encapsulated HisGFP molecules are shielded from the negatively charged DTNB either due to the 
physical barrier afforded by the protein shell and its overall negative electrostatic potential. Yeng 
et al. have reported this charge-selective permeation previously for ferritins.151   These researchers 
utilized both human H-type ferritin and horse spleen ferritin to show that the permeation of 
nitroxide spin probes is largely controlled by the selective porosity of the ferritin shells. They also 
reported that other factors like temperature, incubation time, and concentration might have minor 
contributions on the permeation.151 However, the observed decrease in fluorescence intensity 
upon addition of 200 µM DTNB also suggests that in addition to the charge selectivity, the 
concentration gradient may also play a role in the diffusion of DTNB molecules to the interior. 
Calisti et al. made a similar observation in their work entitled: “Probing bulky ligand entry in 
engineered archaeal ferritins” where they observed DTNB modification of internal cysteines in 
fully caged (closed pore) Archaeoglobus fulgidus ferritin, using DTNB concentrations of 200 µM 
to 700 µM.130 
Overall, the reverse polarity approach to control encapsulation was successfully used to 
encapsulate HisGFP. Even though the +ESI-MS data of encapsulated HisGFP (Figure 3.6.3 c) 
showed the presence of N-terminall-cleaved HisGFP the cleavage did not affect the process of 
posttranslational chromophore formation in the HisGFP molecule or its binding via the His-tag 
that had one fewer His hence the encapsulated HisGFP fluoresced. The preliminary quenching 
experiments showed a level of chromophore protection by the WTBfr shell (up to a particular 




(varying concentrations of DTNB) could be collected as well as separate experiments could be set 






Figure 3.6.4.2. HisGFP-DTNB reaction. (a) -ESI-MS data of DTNB reagent (b) +ESI-MS 






Figure 3.6.4.3. DTNB-mediated HisGFP fluorescence quenching. (a) A solution of 0.4 µM 
free HisGFP titrated with varying concentrations of DTNB (and incubated for 30 min) (b) Free 
HisGFP (0.4 µM) incubated with DTNB (1 mM) at room temperature for different time points. (c) 
Free HisGFP (0.1 µM) separately incubated with 100 uM and 200 µM DTNB for 30 minutes at 
room temperature. (d) WTBfr-HisGFP (0.1 µM) separately incubated with 100 µM and 200 µM 
DTNB for 30 minutes at room temperature. All readings were in triplicate using excitation and 















3.6. Hydrophobic Engineering of Bfr 
The process of engineering a hydrophobic core within bacterioferritin capsule (Bfr with 
lipophilic interior surface) could be useful in transporting hydrophobic drugs and perhaps provide 
new insights into an entrapped hydrophobic environment that is locked within the dimensions of a 
cavity. Another advantage of hydrophobic engineering is the tendency of the composite (example, 
Bfr-hydrophobic polymer) to load more hydrophobic drugs and retain them better than their 
porous unmodified counterpart.152 However, the slice through the Bfr shell shows that it is 
hydrophilic on the interior surface, just like the exterior surface, as seen in Figure 3.6.5. So how 
could one engineer a hydrophobic interior given this water-filled interior? One way is to turn all 
the internal amino acids hydrophobic, which could destabilize the quaternary structure of the 
capsule. An alternative route, which has been employed on viral capsid (not proteins), is 
derivatizing the subunits with hydrophobic molecules and causing them to assemble to create the 
hydrophobic core.153,154 For example, Kwak et al. employed Cowpea Chlorotic Mottle Virus 
(CCMV) as a model system for loading virus nanocarriers where they used DNA amphiphiles. 
The DNA amphiphiles aggregated into micelles with a negatively charged DNA corona (that 
forms viral capsid) and hydrophobic core.154 Even though this approach is indicated as a general 
method and could be expanded to other assemblies, it is of limited value since it does not control 
the complete cavity, just the internal surface of the cavity. 
Here, we present a novel approach to hydrophobic engineering of capsule protein by 
making a micelle and trying to entrap this using our already developed His tag-NTA strategy. The 
Bfr capsule was previously engineered by Omaima Ben Krayem in the Honek laboratory to 
encapsulate lipid aggregates such as preformed micelles. Two types of lipids with NTA 
functionalities were employed to explore the possibility that a hydrophobic environment could be 
engineered into the cavity of an assembled capsule protein. The first lipid, synthesized in the 
Honek laboratory, was nonodecanoyl-NTA (C19-NTA) and the second one, obtained 
commercially, was 1, 2-dioleoyl-sn-glycero-3- [(N-(5-amino-1 carboxypentyl) iminodiaceticacid) 
succinyl] (DGS-NTA) (Figure 3.6.5.1).121 Hence the established NTA-Ni2+-H6 interaction was 
employed. The HisBfr construct contains C-terminal hexahistidine tags that are exposed to the 
interior cavity. The His-tag exposure allows HisBfr to interact with the NTA functionalities of the 







Figure 3.6.5. A static representation of the water-filled interior of Bfr. This image was 
generated by first preparing and optimizing the 1Bfr structure in the Maestro Prep Wizard, using 
default settings. The Desmond subprogram for aqueous solvation was then employed, which 
solvates and minimizes water molecules both within the protein cavity and also on the outside 







Figure 3.6.5.1. Structures of NTA-lipids used by Omaima Ben Krayem. The C19-NTA was 
synthesized in the Honek laboratory (by Omaima Ben Krayem) while the DSG-NTA was 
obtained from Avanti® Polar Lipids. 
 
 
The results from these encapsulations were analyzed employing size exclusion 
chromatography, mass spectrometry, and transmission electron microscopy, similar to the 
approaches used previously in the characterization of guest molecule incorporation. Analyses of 
the SEC, TEM, and mass spectrometry results for the C19-NTA lipid showed that the Bfr capsule 
contained lipid, but the capsule had a larger diameter than the native 24-mer. The C19-NTA 
encapsulation produced capsules that were approximately 21 nm in diameter, almost twice the 
size of Bfr while the DGS-NTA was closer to the “normal” diameter of Bfr, 14 nm wide (Figures 
3.7.1 a and 3.7.2a) (Omaima Ben Krayem). The ability to entrap lipid molecules in the form of 
micelles or aggregates within the dimensions of Bfr could be useful in potential applications in 
hydrophobic transport similar to liposomes, lipid emulsions and drug-polymer conjugates with 
added size homogeneity and enhanced permeability and retention (EPR) effect. Even though the 




eventually to be able to control the dimensions of Bfr for future practical applications in drug 
delivery.  
In order to determine the factors involved in controlling the final diameter of the Bfr-lipid 
complex, various experiments were conducted which included variation in the concentration of 
the lipids, their composition, and the amount of His-tagged: wild type Bfr subunits that were used. 
The proximity of the hydrophobic fatty acid chains could result in micelles or hydrophobic 
pockets within the interior of Bfr. This approach stems from previous encapsulations of DGS-
NTA at surfactant levels (below the Critical Micelle Concentration, CMC) (by Omaima Ben 
Krayem), due to its ability to form lipid bilayers in solution, and this guest resulted in 14 nm 
diameter Bfr capsules being formed. The 2 mg/ mL lipid, employed previously by the Honek 
group, was decreased to 1 mg/ mL and 0.5 mg/ mL for two separate encapsulations to observe 
concentration effects on the Bfr diameter. The resultant mixtures were analyzed on SEC and 
overlaid with the 2 mg/mL sample to compare their retention/elution times. Both of the 0.5 
mg/mL and 1 mg/mL samples eluted within the expected 24-mer Bfr retention time, unlike the 2 
mg/mL sample, which eluted in the void region. The data indicated that the 2 mg/ mL preparation 
was broader than a 24-mer Bfr, as seen in Figure 3.7.1 a. Positive ESI-MS further analyzed the 
composition of the SEC fractions. Analysis of the MS data (Figure 3.7.1 b) showed a mass for the 
HisBfr subunit as well as the HisBfr-Ni2+ - C19-NTA for both 0.5 mg/mL and 1 mg/mL samples 
(Appendix 4) indicating that there are HisBfr subunits with lipids attached to them and the 
micelles (or aggregates of lipids) and their location were confirmed by TEM experiments. The 
TEM image in Figure 3.7.2 c revealed that a fraction of Bfr interior excluded the molybdate stain 
unlike the 2 mg/ mL encapsulation (Figure 3.7.2 a) which filled the entire Bfr capsule and 
prevented interior molybdate staining. However, the dimensions of the Bfr capsules were about 
12 nm for both 0.5 mg/mL and 1 mg/mL (the 1 mg data is not shown). Thus, the subunit-mediated 
micelle encapsulation (encapsulation at surfactant concentration) may retain the architecture, but 
may not lead to as highly a hydrophobically dense Bfr capsule. 
Another approach to forming an internally hydrophobic Bfr without expanding the capsule 
diameter was investigated. The lipids were encapsulated at micellar/ aggregation concentration 
similar to the previous conditions, but the composition of the Bfr cluster was changed. The Bfr 
subunits that were employed in this additional approach were composed of a mixture of 50 % 




employing 100% His-tagged subunits. The assumption here was that the declustered Bfr subunits 
would pack around the preformed micelle into a 24-mer (or some oligomeric) cluster, but not all 
the 24 H6 tags would be required to stabilize the entrapped micelle, resulting in additional space 
being available in the cavity to accommodate the entrapped micelle. 
 Alternatively, shorter chain lipids might be encapsulated into the normal sized Bfr even if 
100 % HisBfr subunits were employed. These chains were expected to form smaller diameter 
micelles, which might be better accommodated within a normal sized Bfr interior without a 
significant increase in cage dimensions. Three experiments were therefore undertaken: (1) C19-
NTA with 50:50 mixed subunits (WTBfr: HisBfr); (2) C16-NTA employing 100 % HisBfr 
subunits; and (3) C14-NTA employing 100 % HisBfr subunits. All three reactions were 
undertaken with the steps in Figure 3.7. The MS data and SEC profiles (Appendix 5) were 
consistent with successful lipid encapsulation. The encapsulated samples were visualized using 
TEM with 1 % molybdate stain (Figure 3.7.3a-c). The size distribution of the Bfr-lipid complexes 
for the C19-NTA in the 50:50 subunit mixture (Bfr: HisBfr) was within the dimensions expected 
for “normal” Bfr capsules (10-13 nm, Figure 3.7.3a). The size analysis showed that the His-tags 
take up internal space, and not all 24 His-tagged subunits are required for successful lipid guest 
stabilization. Also, the C14-NTA and C16-NTA encapsulation experiments employing 100 % 
HisBfr subunits produced Bfr capsules without any significant increase in size. However, their 
sizes were slightly larger than the 50:50 mixture (WTBfr: HisBfr) capsules produced utilizing 
C19-NTA lipids which are in agreement with the presence of the 24 His-tags that are not 
compensated for by the shorter lipid chains (smaller diameter micelles for C14 and C16).  
Finally, based on the level of stain penetration/exclusion, it would appear that the C19-
NTA (employing the mixed subunit approach) produced the most hydrophobic (filled) 12 nm Bfr 
followed by C16-NTA and lastly the C-14 NTA. The results herein highlight the ability to control 
the exact hydrophobic character of the internal cavity of Bfr by employing a combination of the 









Figure 3.7. Generalized lipid-NTA encapsulation steps. The HisBfr capsule is dissociated to 
expose the His-tags (in purple) which then interact with the NTA moieties on the lipid in the 









Figure 3.7.1. Separation and characterization of C19-NTA  lipid encapsulations. (a) Size 
exclusion profile of the three lipids with 2 mg/mL (green) sample eluting in the void/aggregate 
region and the 1 mg/mL (red) and 0.5 mg/mL (blue) at the 24-mer retention time. (b) The mass 
spectrometry analysis on the fractions at the 24-mer region (Appendix 2) for the 1 mg/mL sample 
shows ions corresponding to C19-NTA, heme, and protein in the source spectrum (top) and the 
deconvoluted (bottom) spectrum providing the masses of the HisBfr subunit (1959 Da) and the 







Figure 3.7.2. Preliminary Bfr hydrophobic engineering. (a and b) TEM images for the 
encapsulation studies performed by Omaima Ben Krayem, using 2 mg/ mL C19-NTA and 0.95 
mg/ mL DGS-NTA respectively, in 100 % HisBfr (c) The TEM image of the encapsulation of 0.5 









Figure 3.7.3. Optimized Lipid NTA encapsulation. (a) The TEM image of the complexes 
formed by employing C19-NTA in a 50:50 mixture of His-tagged and WT Bfr (b) TEM image of 
the complexes formed by employing C16-NTA in 100 % HisBfr (c) TEM image of the complexes 
formed by employing C14-NTA in 100 % HisBfr. All of the TEM samples were stained with 0.5 





3.6.1. Determining the Critical Micellar Concentration (CMC) of C19-NTA 
To study the dynamic nature of the entrapped lipids as well as its tendency to trap useful 
cargo such as hydrophobic drug molecules, it is necessary to know the aggregation number and 
the CMC of the trapped micelles. Hence pyrene excimer excitation was used to obtain the CMC 
of free C19-NTA in the buffer (150 mM NaCl, 50 mM MOPS-pH 7.5) as described by Mènard et 
al.118   Firstly, the pyrene solution (OD600 0.04) was made in a buffer (150 mM NaCl,50 mM 
MOPS-pH 7.5) and used to make a 2 mM C19-NTA stock solution. The stock solution was then 
used to make ten serial dilutions (from 1.5 mM to 0.02 mM, Figure 3.7.4 a). The emission spectra 
were collected from 350-600 nm (1 nm slit width), with 336 nm excitation wavelength (1 nm slit 
width). The local environments of the pyrene molecules were estimated from the I1/I3 (intensities 
at 374 nm/ 386 nm) and IE/IM (excimer/ monomer) ratios as seen in the Figure 3.7.4 b below.  
These experiments were done in collaboration with Abdullah Bassalem, a graduate student in the 
laboratory of Professor Jean Duhamel (Chemistry Department). 
 An analysis of the steady decrease in the I1/I3 ratio indicated that the pyrene molecules 
were migrating from a more hydrophilic macroenvironment (buffer) to a hydrophobic 
microenvironment (inside micelles). Also, the 0.2 mM sample produced the most intense excimer 
peak, and beyond that concentration, the emission began to drop. The drop in intensity could 
present the critical micellar concentration (CMC). Increasing the lipid concentration beyond this 
point produced additional micelles in solution which could entrap monomeric pyrene molecules 
and decrease the pyrene dimer excimer fluorescence (since pyrene concentration is kept constant) 
as seen in Figure 3.7.4 a; the C19-NTA CMC was estimated to be 0.2 mM, equivalent to 0.11 
mg/mL.  
The estimated CMC from this experiment is 0.11mg/mL. Tthis value is 8.3-fold the 
reported value (0.012 mg/mL),118 the reported CMC was recorded in water unlike the MOPS 
buffer used here. Even though the experiments here were performed in buffer only, the results 
may be useful in explaining the nature of the hydrophobic environment within Bfr upon 
lipid/micelle encapsulation. There may be multiple pockets of micelles in the encapsulation 
mixture which were squeezed within the Bfr cavity upon subunit packing. Therefore, it is 
necessary to analyze the entrapped micelle further to obtain information about the size and how 







Figure 3.7.4. Pyrene emission spectra. The CMC of C19-NTA was determined by exciting 
pyrene solutions (fixed concentration, with 0.4 OD), containing varying concentrations of C19-
NTA, at 336 nm (a) and plotting the intensities at 374 nm/ 386 nm (I1/I3), in blue circles, or ratio 
of the excimer to monomer (IE/IM) in red circles to obtain the CMC (b). The CMC was obtained 
from the concentration at the maximum (IE/IM) or the concentration where I1/I3 begins to plateau.  
 
 
3.6.2. Sedimentation Velocity Analysis on Lipid-encapsulated Bfr 
Similar to the velocity analysis described in section 3.2.5, two lipid-encapsulated Bfr 
samples ( a. 100 % HisBfr + heme + C16-NTA, b. 50 % HisBfr + heme + C19-NTA) were 
analyzed.Unlike the results in Figure 3.2.1 which showed a lower symmetry for mixtures of Bfr 
subunits (1.2 for 100 % HisBfr and 1.17 for 50 % WTBfr + 50 % HisBfr ) the introduction of 
lipid guest molecule lowers the degree of symmetry to 1.67 and 1.44 for the lipid within 100 % 
HisBfr and 50 % WTBfr + 50 % HisBfr, respectively. Since the f/fo ratio is related to frictional 
coefficient this observation may indicate that the surface exposed to the solvent may be less 
globular than the empty Bfr capsules. Moreover, the observed molecular weights were mostly 
lower than the expected molecular weights of the complexes (a. 100 % HisBfr + heme + C16-
NTA, 509.4 kDa, b. 50 % HisBfr + heme + C19-NTA, 487 kDa) as seen in Figure 3.7.5. The 




of 4.4 S and 8.5 S with molecular weights 95 kDa and 253 kDa, respectively and two more 
species at 495 kDa (13.3 S) and 994.1 kDa (21.4 S). Conversely, the C19-NTA sample (Figure 
3.7.5. b) exhibited a major peak with 4.7 S and molecular weight of 83.9 kDa and a smaller 
population with average molecular weight of 589.5  kDa having sedimentation coefficient of 17.1 
S. While the  larger species could result from the entrapment of several micelles within the Bfr 
cluster as suggested by the pyrene experiments, the observed lower molecular weights could 
likely be due to incompletely formed Bfr capsules or micelles with few Bfr subunits around them 
such as a dimer interacting with formed micelles in solution. The results shown here warrant a 
further look into these samples to estimate the actual aggregation numbers of the surfactant 
molecules interacting with the Bfr subunits.   
 
 
Figure 3.7.5. Sedimentation velocity curves for lipid encapsulated into Bfr. (a) 100 % HisBfr 
+ heme + C16-NTA. (b) 50 % HisBfr + heme + C19-NTA. The various populations are labeled 
with their average molecular weights. Sample a and b were recorded at 20, 000 rpm and 30,000 






3.7. Characterization of Purified Archaeoglobus Fulgidus Ferritin (AfFtn) 
The AfFtn constructs investigated in this work are similar in dimension and subunit 
organization to Bfr, yet they contain four 4.5 nm triangular pores. Three constructs were designed 
and prepared by custom gene synthesis (Genscript Inc): (1) wild-type AfFtn (WTAfFtn) without 
any modification to the native sequence; (2) hexahistidine-tagged AfFtn which contained C-H6 
tags which are exposed on the interior cavity; and (3) a cysteine mutant (M54C) AfFtnC54  which 
was modified with the reagent maleimide-X-Nitrilotriacetic acid (Maleimide-X-NTA, X is a 
proprietary linker) and used for His-tagged protein encapsulations. The cysteine location was 
designed to position the cysteine on one of the helices and able to point towards the middle of the 
protein cavity (Figure 3.8). Subsequently, an independent report appeared that utilized the same 
mutation to study the effects of protein structure on DTNB chemical modification. 130 Both the 
WT and Cys mutant were purified by heat shock, 80 % ammonium sulfate precipitation, and size 
exclusion chromatography. However, the His-tagged construct was purified by heat shock and 
immobilized metal affinity chromatography (IMAC, discussed in section 3.1). The SEC step was 
used to remove DNA contamination from the ammonium sulfate precipitation step as the resulting 
solution showed a high 260/280 ratio, seen in Figure 3.8.1a. 
 
 
Figure 3.8. Cross-eye stereo image of the AfFtn (1S3Q) showing the position of Met54. The 
Met 54 (which is the Cys54 mutant position) in red shows that the residue is in the middle of the 
protein and points to the inside of the cavity. Overall there are 24 subunits with 24 M54C 
mutations, however only one MC54 mutation is selected in this example. Chimera was used to 







Figure 3.8.1. Characterization of WTAfFtn and AfFtnC54. (a) Comparison the absorbance 
spectrum of WTAfFtn from the ammonium sulfate step and subsequent SEC. (b) Size exclusion 
chromatogram for WTAfFtn from ammonium sulfate precipitation step, the 15 % gel (b, insert) 
used to identify AfFtn containing fractions. (c and d) The deconvoluted +ESI- MS spectra for 
WTAfFtn and AfFtnC54, respectively. The AfFtnC54 was also precipitated by 80 % ammonium 
sulfate and run on SEC to remove DNA contamination before acquiring the +ESI data in Figure 
3.8.1d  
 
The purified AfFtn constructs were analyzed for their quaternary structures in solution by 
loading them onto the Sephacryl™ S-300 10/300 column and eluting with varying salt 
concentrations. The apo-AfFtn is reported to exist as dimers at salt concentrations of 20 mM and 
below and as 24-mers at 150 mM and above.8 The salt-mediated association was tested initially 
on the HisAfFtn construct with buffers containing 50 mM, 150 mM, and 300 mM NaCl. Analysis 
of both the SEC and DLS experiments, in Figures 3.8.1 a and b, showed the HisAfFtn in 50 mM 
and 300 mM salt buffers eluted at a retention time corresponding to the size of a 24-mer structure 
(approximately 45 min) and the size distributions for 150 and 300 mM salt samples were found to 




Despite the slight shift in the dimensions of the 50 mM sample, the protein is still considered to 
exist as a 24-mer with a few dimers similar to the 300 mM sample in the SEC profile (Figure 
3.8.2 a). Additionally, the HisAfFtn was dialyzed into 20 mM NaCl buffer and analyzed on the 
SEC and was found to contain a few 24-mers (data not shown). Based on the above experiments, 
the declustering buffer for guest encapsulation was chosen to be 10 mM NaCl, 25 mM HEPES, 
pH 7.5 to ensure that all the subunits were somewhat dissociated to expose the C-terminal H6 tags. 
Even though the AfFtn is reported to be more stable, in 24-mer form, at very high salt 
concentrations, up to 600 mM,8 the optimal reclustering and SEC buffers contained 150 mM 
NaCl, 25 mM HEPES, pH 7.5. Using physiological amounts of salts is not only beneficial for 
AfFtn association, but it also prevents salting out of future guest molecules. 
Similarly, the WTAfFtn construct existed as a 24-mer in 150 mM NaCl (data not shown) as 
was expected for the M54C mutant (AfFtnC54), but it was dimeric at 150 mM NaCl. The salt-
mediated subunit association was affected by the mutation, as was observed by Calisti et al.130 
Calisti and coworkers successfully showed that the charge distribution at the opening of AfFtn 
pore screened DTNB from reacting with the reduced SH groups on AfFtnC54. Also, they reported 
that low concentrations of divalent cations like Ca2+ and Mg2+ (5-20 mM) more efficiently shift 
the oligomerization towards the 24-mer form than high NaCl concentrations. Hence the AfFtnC54 
in 150 mM NaCl was buffer-exchanged into a buffer containing Mg2+ (20 mM MgCl2, 25 mM 
HEPES-pH 7.5) and run on SEC with the same buffer. It was observed that the Mg2+ ions in the 
buffer were indeed capable of shifting the protein to form 100 % 24-mers in solution unlike NaCl, 
which resulted in the protein existing predominantly as a dimer (Figure 3.8.2 c, red curve). 
Further DLS analysis on both samples, in Figure 3.8.1 d, agreed with the SEC results, where the 
150 mM NaCl sample was polydispersed unlike the monodispersed 20 mM MgCl2 sample.  
Finally, the  AfFtnC was modified with an NTA analog into AfFtnC54-NTA and dialyzed 
with a buffer containing MgCl2 to form  the 24-mer, and the 24-mer AfFtnC54-NTA was studied 
by AUC. Analyis of the results show that the species in 20 mM MgCl2, 25 mM HEPES buffer-pH 
7.5 are mostly intact 24-mers as seen the Figure 3.8.2.1. The sedimentation pattern showed mostly 
one population of 471 kDa molecular weight at 17.7 and a minor peak of 932.5 at 27.9 S. The 







Figure 3.8.2. Effects of sodium chloride and magnesium chloride on AfFtn. (a) Elution profile 
of HisAfFtn at 50 mM NaCl (blue) and 300 mM NaCl (red). (b) The DLS analysis on HisBfr at 
50 mM NaCl (red), 150 mM NaCl (blue), and 300 mM NaCl (green). (c) SEC profile of 
AfFtnC54 in 150 mM NaCl (red) and 20 mM MgCl2 (blue). (d) DLS of samples in AfFtnC54 in 
150 mM NaCl (blue) and 20 mM MgCl2 (orange). 
 
Figure 3.8.2.1. Sedimentation velocity analysis on AfFtn-NTA. The figure here was obtained 




3.7.1. Archaeoglobus Ferritin Encapsulation Studies 
3.7.1.1. Encapsulation of a 5 nm Gold Nanoparticle (AuNP) 
Similar to the  Bfr, the AfFtn construct with C-terminal (interior) polyhistidine tags was 
used to encapsulate a model inorganic guest, a AuNP via the H6-Ni
2+-NTA interaction. This was 
to determine whether this unusual ferritin having multiple large pores in its structure would 
behave in a similar manner to Bfr in regards to encapsulation strategies. For example, it could be 
possible that the larger pores complicate the encapsulation process in some way. Most of the 
reaction conditions employed were the same as those utilized for the formation of the Bfr-AuNP 
host-guest complex, but the declustering of AfFtn subunits was mediated by low ionic strength. 
The declustering buffer used in these studies was 10 mM NaCl, 25 mM HEPES-pH 7.5. First, the 
AfFtn subunits were allowed to interact with the guest molecules at room temperature for 90 
minutes with slow stirring. The second step involved AuNP encapsulation/entrapment, where the 
AuNP was entrapped within the AfFtn cluster by increasing the ionic strength of the buffer (to 
150 mM NaCl, 7.5pH). The encapsulated AuNP was isolated from the reaction mixture by SEC. 
Again, the SEC profile showed the presence of the AfFtn having the size of a 24-mer structure 
with 518 nm absorbance, indicating that the AuNP was successfully encapsulated within the 
AfFtn cluster as seen in Figure 3.8.3a. The TEM images of free HisAfFtn (Figure 3.8.3b) were 
compared to the AuNP encapsulated HisAfFtn (Figure 3.8.3c). The AuNP were encapsulated 
within the AfFtn imaged without added contrasting agents as a very dark interior with low 
contrast soft material (protein shell) around it. The size distribution of the TEM images was 
estimated to be around 12 ± 1.8 nm using the ImageJ software.148 Analysis of these results is 
consistent with the conclusion that AfFtn can be successfully engineered to encapsulate large non-
native guest molecules within its interior cavity. These results should serve as important 
information to help guide more complex encapsulation studies, such as the entrapment of 
enzymes or micelles within the protein cavity. The additional large pores available in this type of 
ferritin might then be employed to selectively screen substrate specificity of enzymes that work 
on substrates of varying length, such as a glycohydrolytic enzyme.  Additionally, the dynamics of 
fatty acid transfer into and out of such porous ferritin might be of interest in the control of the 









 Figure 3.8.3. Encapsulation of AuNP within AfFtn. (a) Size exclusion profile showing that 
AuNP having NTA labels coelute with the 24-mer AfFtn. (b) The TEM image of HisAfFtn 
without any guest molecules. The molybdate stain percolates into the interior of the 24-mer 
cluster. (c) The presence of high electron density AuNP within AfFtn cluster without any 









3.7.2. Encapsulating His-tagged Guest Molecules into the Archaeoglobus Fulgidus Ferritin 
3.7.2.1. Cysteine Modification 
In order to introduce the NTA functionality onto the Cys54 residue in AfFtn (AfFtnC54), a 
bioconjugation approach was followed which used tris (carboxyethyl) phosphine (TCEP) as a 
reducing agent to reduce the Cys sulfhydryl groups in the event that during purification and/or 
storage, two subunits would come together and form a disulfide linkage. The sulfhydryl groups 
might be expected to be oxidized under the modification/ storage condition (pH 7.5) if trace 
amounts of oxygen were present. Hence the TCEP incubation step and inert conditions would be 
required to reduce the disulfide bonds, preparing the free thiol required for the modification. 
Upon reduction, the thiolate anion (nucleophile) would then be able to attack a maleimide 





Figure 3.8.4.  Representation of cysteine modification with N-ethylmaleimide. Figure 





























The AfFtnC54 protein (in 20 mM NaCl, 25 mM HEPES-pH 7.5) was incubated with TCEP 
(100 equiv. at room temperature, for 15-30 min.) and then N-ethyl maleimide (1 equiv. AfFtn: 
100 equiv. TCEP: 50 equiv. N-ethyl maleimide final ratios) was added to the incubation mixture. 
It was felt that if the protein partially or completely existed as the disulfide-linked dimer (no other 
cysteine are present in the sequence of the AfFtn), then the addition of TCEP would address this 
possibility and prepare the protein for subsequent reaction with the maleimide reagent. N-
Ethylmaleimide was used as a simple model maleimide since it is less expensive than the 
commercial maleimide-X-NTA that was to be employed to attach an NTA functionality to the 
protein. The resulting mixture was further incubated at different time points (at room temperature) 
to obtain the optimal reaction time. Samples were collected, buffer exchanged into DDH2O and 
analyzed by ESI mass spectrometry (at time points 1 h, 4 h and overnight, 19 h), and the results 
were compared in Figure 3.8.5. It was observed that most of the protein in solution remained 
unmodified (20154 Da) despite the length of incubation (Figure 3.8.5 a-c). This was initially 
unexpected and indicated that the ratio of the TCEP reagent to N-ethylmaleimide perhaps was 
important but also it seemed that TCEP might be neutralizing the maleimide due to the expected 
nucleophilicity of the phosphorus in the TCEP molecule. It was therefore decided that the reaction 
with N-ethylmaleimide should be attempted again, but without the TCEP reagent. Indeed, the 
omission of the TCEP incubation step led to 100 % formation of the expected N-ethyl maleimide-
AfFtn adduct with a mass of 20281.06 Da (Figure 3.8.5d). The observed mass was the M-1 peak. 
These conditions were then used for the NTA maleimide as an acceptor molecule. Figure 3.8.5 e 
shows the modification in the presence of TCEP, whereas Figure 3.8.5 f is without TCEP. While 
the TCEP-containing sample showed peaks corresponding to both modified and unmodified 
AfFtnC54 at 20570 Da and 20158 Da, respectively, the reaction without TCEP showed complete 
modification without any traces of the AfFtnC54 unmodified subunit. 
The reduction step with TCEP continues to be utilized for cysteine bioconjugation since it 
has been reported to not react with maleimide, to be odorless, and more effective than both 
dithiothreitol (DTT) and β-mercaptoethanol (BME). 155,156 A recent use of TCEP for ferritin 
modification was reported by Calisti et al.130 They reported successful modification of a cysteine 
mutant of Archaeoglobus fulgidus ferritin with maleimide NTA in the presence of 3 mM TCEP. 
However, the reduction step has been reported to produce maleimide-TCEP adducts that 




containing the maleimide has indeed been found to react with the maleimide moiety forming an 
adduct which has been identified (Figure 3.8.6) and is in fact as rapid as maleimide-Cysteine 
adduct formation.157 A recent IR characterization by Kantner et al. identified the adduct as the 
ylene (approximately 70 %).157 instead of the previously proposed ylide/ylene resonance forms. 
Unfortunately, the ylene is reported to be very stable and not susceptible to nucleophilic attack by 





Figure 3.8.5. Optimization of the AfFtnC54 maleimide modification. Initial modification 
using N-ethyl maleimide, TCEP, and AfFtnC54 in ratios 50 equiv.: 100 equiv.: 1 equiv., 
respectively. (a) incubation for 1 h (b) 4 h (c) overnight (d) modification without TCEP; 1 equiv. 
of AfFtn: 50 equiv. N-ethyl maleimide (e) replacing N-ethylmaleimide with maleimide NTA 
ratios: 1 equiv. AfFtn: 100 equiv. TCEP: 50 equiv. Maleimide NTA (f) incubation without TCEP: 






Figure 3.8.6. The reaction of TCEP on a maleimide. The formation of undesirable products 
(ylene and ylide) as demonstrated by Kantner and co-workers .157 Figure made with ChemDraw. 
 
 
The results herein agree with what was reported since the omission of TCEP led to 
increased maleimide modification both for N-ethylmaleimide and maleimide-X-NTA. However, 
the mass of ylene was not observed in the deconvoluted spectra (of Figure 3.8.5a-c and e) due to 
the mass range used for the spectral analysis that focussed more on the AfFtn subunit mass. The 
curved shape of individual AfFtnC54 subunits may not allow intersubunit disulfide bond 
formation. Hence the cysteines exist in the reduced form. Moreover, addition of  Ellman’s reagent 
(DTNB) to the protein solution resulted in a yellow solution that absorbed at 430 nm (data not 
shown). Finally, the optimal reaction condition was set to 1 equiv. AfFtn: 20 equiv. Maleimide-X- 



























3.7.2.2. Encapsulation of His-tagged Proteins 
Initially, HisGFP was used as a model to study the conditions for encapsulating His-tagged 
enzymes such as a glucohydrolase. Unlike the HisGFP encapsulation into Bfr, which was 
mediated by heme-NTA, the HisGFP was encapsulated by the mediation of the Cys-S-NTA 
functionality on the AfFtnC54 subunit as illustrated in Figure 3.8.7 below. The modified 
AfFtnC54-S-NTA was washed (in a spin column) three times with declustering buffer (10 mM 
NaCl, 25 mM HEPES -pH 7.5) to remove excess maleimide-X-NTA. The washed sample was 
then incubated with HisGFP (in the same buffer) in the presence of Ni2+ (1 equiv. AfFtnC54-
NTA, 2.43 x 10-9 moles: 1 equiv. HisGFP, 2.43 x 10-9 moles: 20 equiv. Ni2+, 4.86 x 10-8 moles). 
The reaction mixture was allowed to equilibrate at room temperature (approximately 23 °C) with 
slow stirring for 30 minutes. After equilibration, the mixture was divided into two vials and one 
was  incubated at room temperature and the other  at 50 °C (for 60 minutes each). The ionic 
strength of the resulting mixtures was increased by adding 250 mM NaCl and dialyzing against 
the reclustering buffer (150 mM NaCl, 25 mM HEPES-pH 7.5) overnight to allow the AfFtnC54 
subunits to associate in the presence of HisGFP. The final mixtures were run on a Sephacryl™ S-
300 HR column to isolate the encapsulated HisGFP. 
The encapsulation results indicated that there was an association between the HisGFP 
molecules and AfFtnC54. However, the AfFtnC54-Ni2+-HisGFP complex eluted at approximately 
55 min instead of the 45 min retention time associated with the 24-mer AfFtn for these particular 
conditions with this specific column (Figure 3.8.8). This suggested that the HisGFP associated 
with the AfFtn subunit upon incubation since it eluted earlier than the free HisGFP (65 minutes). 
Also, the incubation temperature does not affect the interaction between the AfFtnC54-NTA 
subunits and HisGFP as the red (room temperature), and green (60 °C) curves overlap, as shown 
in Figure 3.8.8. Also, buffer containing only 10 mM NaCl was able to sufficiently expose the 
NTA functionalities on individual subunits for interaction.  
Hence, the encapsulation protocol was optimized by (i) Pre incubating 1 equivalent 
AfFtnC54-NTA (in 10 mM NaCl, 25 mM HEPES, pH 7.5) with 50 equiv. Ni2+ at room 
temperature for 15 minutes. (ii) Mixed with 1 equiv. of HisGFP and allowed to equilibrate at 
room temperature for 30 minutes. (iii) Incubation at 60 °C for 30 minutes. (iv) Further incubation 
at room temperature for at least 4 (up to 12 h) with slow stirring. (v) Recluster via dialysis, buffer 




chromatography to separate encapsulated HisGFP from the remaining components. The results of 
this optimized protocol are presented in Figure 3.8.9. The SEC profile (Figure 3.8.9 a) showed a 
peak eluted before the 24-mer retention time (40 min) with HisGFP absorption (490 nm, red) and 
another at the 24-mer retention time of 45 min without the 490 nm peak. They are indicating that 
there was some population of encapsulated AfFtnC54-NTA that are physically larger than the 
intact empty 24-mer. Hence, TEM analysis (Figure 3.8.9 b) was used to verify that the fractions 
(at 40 min) were indeed encapsulated AfFtnC54-NTA-HisGFP and not aggregates of proteins. 
The TEM image showed mostly encapsulated AfFtn (filled without stain penetration) and a few 
unencapsulated (empty with stain penetration) capsules. All the capsules, filled and empty, had an 
average diameter of 14.43 nm.  
   The observations illustrate that reclustering AfFtnC54 in the presence of guest molecules 
in a buffer contained low divalent ions followed by increasing salt concentrations is an effective 
method for guest encapsulation for the chemically modified AfFtn. Future work will explore the 




Figure 3.8.7. Schematic representation of HisGFP (1C4F) encapsulation into AfFtnC54 
(1S3Q). The C54 mutations are illustrated in purple spheres. The protein crystal structures and the 







Figure 3.8.8. Encapsulation of HisGFP into AfFtnC54-NTA. The blue curve represents free 
HisGFP elution on the Sephacryl™ S-300 10/300 HR. The red and green curves represent HisGFP 
interacting with AfFtnC54-NTA subunits at room temperature (RT) and 50 °C, respectively. The 
shift in retention times from the free HisGFP indicates the formation of new AfFtnC54-NTA-Ni2+-







Figure 3.8.9. Optimized HisGFP encapsulation into AfFtnC54-NTA. (a) Sephacryl S™ 300 
10/100 HR profile (at 0.5 mL per minute). (b) The TEM image of pooled fractions (retention 
times 35-42 min). The sample was stained with 0.5% of molybdate stain. 
3.8. Encapsulation of Streptavidin within AfFtn  
The strategy and protocols for the encapsulation of another model protein, streptavidin, 
were similar to those employed for encapsulation of the nanoparticle AuNP in terms of the 
affinity interaction that permits the important guest-capsule protein subunit interaction to occur 
before reclustering is initiated. However, preliminary experiments (in our laboratory) have shown 
that the composition of the host Bfr could not be 100 % His-tagged to obtain a successful 
encapsulation for this protein. A mixture of 60 % His-tagged to 40 % Wild-type (WT) Bfr 
subunits were used to decrease the amount of internal space that is occupied by the twenty-four 
His-tags of the shell. The streptavidin that was utilized in this work possesses a fluorescein 
fluorophore attached to the protein. The fluorescein modification exhibits 495 and 520 nm 
absorbance and excitation maxima, respectively. 
Firstly, the streptavidin-fluorescein (SF) protein was made to quickly interact with biotin-
X-Nitriloacetic acid (biotin-X-NTA) to produce the streptavidin-biotin complex seen in Figure 
2.8. The complex has one of the strongest dissociation constants (4 x10-14 M)161 and is stable 
under harsh conditions such as extremes of pH and temperature, high concentrations of 
chaotropes, and organic solvents.162 The properties of the complex coupled with the robust ferritin 
structure allows the encapsulation to occur in either 8 M GdnHCl or at 50 °C for up to 90 min of 
incubation with neither significant denaturation nor precipitation. The 8 M GdnHCl declustering 
buffer or higher temperature was used to separate the ferritin subunits and expose the his-tags to 
the NTA functional groups on the biotin-streptavidin complex. The resulting mixture was 
separated on a size exclusion column, and the peak eluting at the 24-mer retention time with 
fluorescein absorbance was collected for further analysis.  
Secondly, the extent of guest protection by the Bfr shell was studied by comparing SF 
encapsulated into Bfr with Sf encapsulation with the AfFtn ferritin. Previous work in the Honek 
laboratory (by Anton van der Ven) showed that the fluorescein fluorophore attached to the 
streptavidin, when encapsulated within the Bfr capsule, through use of the compound biotin-X-
NTA, was protected against collisional quenchers such as iodine.120 Here, The SF molecule was 




Subunits (100 % HisAfFtn) were incubated with Ni2+ at room temperature, and SF was separately 
incubated with biotin-X-NTA at room temperature for 30 min. The two reactions were combined 
and allowed to further incubate (at RT) for 60 minutes and then the ionic strength of the solution 
was increased to 150 mM by the addition of NaCl. The resulting mixture was further incubated 
for 30 minutes and separated on a Sepahacryl™ S-300 10/300 HR column, as seen in Figure 3.8.9 
a. The elution profile was compared to the free HisAfFtn to monitor the appearance of a 495 nm 
peak at the 24-mer retention time (approximately 45 min). The chromatogram for the HisAfFtn-
SF (red and green curves) showed that the SF molecule was not encapsulated within the HisAfFtn 
cluster since the SF eluted at a later retention time (around 52 min), similar to where the free SF 
elutes. The results in Figure 3.8.9a indicated that the encapsulation was unsuccessful.  
Due to the several components in the reaction that could be varied, it was reasonable to 
reproduce the previous work by Anton van der Ven to ensure that all the components were active 
and the protocol appropriate. SF encapsulation into Bfr employed a mixture of HisBfr and WTBfr 
at 60 % and 40 % respectively, to ensure that there were sufficient His-tags for NTA interaction 
while reducing interior steric interaction. 
Also, encapsulation was mediated by heating at 40-60 °C to ensure sufficient subunit 
dissociation without any significant streptavidin-fluorescence. The SEC profile, in Figure 3.8.9 b, 
showed SF coeluted with Bfr-24-mer and the pooled fractions were analyzed further with UV-vis 
where a shoulder peak was observed for encapsulated SF at 495 nm (data not shown). 
Experiments were undertaken to encapsulate SF employing 100 % HisAfFtn subunits with 
heating. The subunit association was mediated by low salt (10 mM NaCl), and the SF 
encapsulation was mediated by both low salt and heating either at 40 °C or 60 °C. However, no 
encapsulation was observed as no 495 nm peak was observed at 45 minutes in Figure 3.8.9c. 
Perhaps the use of HisAfFtn for SF encapsulation must be performed with a mixture of wild-type 
and His-tagged AfFtn subunits just as was found of being successful in employing Bfr. Hence, the 
WTAftn construct was engineered and purified (described in section 3.7).  Finally, a 60:40 % 
mixture of His-tagged AfFtn to wild type Aftn subunits was used for SF encapsulation, the 
results, Figure 3.9 d, however, were not as expected. The SF guest did not coelute with the AfFtn 
host molecule,but SF freely existed in the solution (eluting at approximately 53 min). The 





The encapsulation of SF into AfFtn may require different encapsulation conditions which 
may or may not require subunit mixing. Alternatively, the MgCl2 buffer could be used for 
reclustering and shifting the equilibrium to the 24-mer complex. 
 
 
Figure 3.9. Encapsulation of Streptavidin-fluorescein (SF) into AfFtn. (a) The initial 
encapsulation trials with 100 % HisAfFtn at room temperature. The red line corresponds to the 
280 nm absorbance of the HisAfFtn-SF complex, whereas the green is for the same mixture but 
specifically monitors the 495 nm associated with SF. The blue is the free AfFtn protein (at 280 
nm) without SF guest molecules. (b) Reproducing SF encapsulation in Bfr. The encapsulation was 
tried at 40 °C (blue curve) and 60 °C (red). (c) Encapsulation of SF into HisAfFtn at 40 °C (blue 













CHAPTER 4: BFR PHARMACOPHORE MODELING 
 
4. Current Objective 
Current research on Bfr bioencapsulation in the Honek laboratory has focused on driving 
24-mer formation via the dimer intermediate. The 24-mer Bfr is then used to encapsulate native 
proteins (such as streptavidin and His-tagged GFP), a 5 nm gold nanoparticle, nitrilotriacetic acid 
(NTA) functionalized-lipids, and NTA-labeled dyes. These modifications are all mediated by the 
heme 24-mer association (Figure 4). The heme cassette has also been employed in a reverse 
polarity guest encapsulation, where it was modified with NTA and reinserted into apoBfr. This 
modification allowed the heme to target polyhistidine-tagged proteins into the Bfr cavity 
specifically. The heme cofactor is not just a structural component, but a means to engineer the Bfr 
platform. Finding alternative molecules with different properties that are capable of binding into 
the heme site will be useful in future applications of the Bfr nanoplatforms. For instance, a 





Figure 4. Heme-mediated 24-mer formation in Bfr. The different colors represent the 





   
The primary objective of this section of the thesis research was to computationally identify 
novel molecules that could equally fit the heme binding site and drive 24-mer capsule formation. 
More specifically it was of interest to explore whether drug docking software, used extensively in 
medicinal chemistry to identify enzyme inhibitors, for example, could be utilized to identify non-
heme molecules that could control the quaternary structure of the Bfr capsule.  
Molecular modeling (MM) simulations can be used to screen small molecule databases and 
eventually narrow the possible molecules that could be experimentally tested on the protein in the 
laboratory. MM could also provide more information about the energetics of the binding between 
a possible analog and the heme binding site in the Bfr 24-mer. Insight into the important features 
required for a ligand to bind to this the site could be obtained from the identification of non-heme 
ligands. Furthermore, the identified ligand could then be synthetically modified to enhance its 
aqueous solubility (if it were too water-insoluble to be practically useful). Another advantage of 
this approach would be the amount of time and money that would be saved here compared to the 
traditional trial and error methods of experimentally screening small molecules.  
 
4.1. Computing for Bfr Cofactors 
4.2. Software 
 In 1990, Richard A. Friesner and William Andrew Goddard III founded the Schrödinger 
Incorporation. The software company focuses on developing simulation software for scientific 
research. The software packages are developed specifically for biotechnology, materials science, 
and pharmaceutical research. The Schrödinger computation package contains several software 
applications such as Prime, Glide, LigPrep, Jaguar, Strike, and many more.  
Maestro 11 (and its recent update) is a versatile molecular modeling environment from the 
Schrödinger cooperation, which is not just a graphical user interface, but the portal to all 
Schrödinger's computational technology. The Maestro 11 interface is designed to assist the user in 
preparing, organizing, and analyzing data. Maestro supports several file formats (example. SD, 
PDB, Maestro). Also, the builder tool could be used to construct any other molecular model 
preferred by the user. Tasks can also be automated and customized via scripting. Another exciting 
feature of the software is the 3D visualization of objects in the workspace. Figure 4.1 shows the 







Figure 4.1. The Maestro 11 interface. This figure outlines the various computational features of 
the Maestro 11 software. The GUI is not different from recent updates, Maestro 12. This image 














4.3. Maestro 11 Applications 
The Maestro Molecular Modelling interface contains several applications located in the 
Task Tool. This section includes a detailed description of the primary applications used in this 
work. These applications are; The Protein Preparation (Prep) Wizard, Phase, Glide Docking, 
Prime, Ligand preparation, and Induced fit docking applications. 
 
4.3.1. The Protein Preparation Wizard 
This application allows the user to directly import Protein Data Base (PDB) structures from 
the RSCB site 164 or import a previously saved structure. A PDB structure may not be suitable for 
MM calculations due to the limited resolutions of X-ray crystal structures. The limited resolution 
results in part of the residues in connecting loops (flexible regions, high B factors) of the protein 
to be missing from the crystal structure in some PDB structural data files. Therefore, there is the 
need to bring the structure from its raw state to a more useful state for MM simulation.  
The Protein Preparation wizard performs this task in three stages. The first stage involves 
importing the structure, followed by the performance of basic tasks of fixing the structure in the 
three main tabs. The first tab is the Import tab, followed by the Review and Modify tab and the 
Refine tab. The Import tab allows the user to include structures into the entry list.  It also contains 
several sub-tabs that can be used to perform functions such as: align to reference structures, 
assign bond orders, Add /remove hydrogens, cap termini, create zero bond orders to metal ions, 
convert selenomethionine to methionine, fill in missing side chains, and fill in missing loops. 
After the structure has undergone preprocessing, it can be reviewed and modified. The solvent 
molecules used in crystallization can be removed. Also, parts of the subunits from multimeric 
proteins can be deleted if they are not be involved in the modeling and the remaining structure can 








Figure 4.2. Preparation and optimization of the 1Bfr crystal structure. The Figure is a screen 
capture of  1Bfr imported into the workspace and the protein Preparation wizard highlighting a 
few of the options employed. 
 
4.3.2. Phase Screen 
The Phase Screen application is another computational program available from the Maestro 
program. The Phase screen application is a virtual screening process that is useful for the 
generation of a pharmacophore, which is subsequently utilized in database screening. Similar to 
other virtual screening applications, the Phase screen protocol can rapidly screen millions of 
molecules from a database and rank them based on their abilities to recognize molecular features 
of the active site and dock (as illustrated in Figure 4.3). These molecular features are termed a 
pharmacophore or a pharmacophoric pattern. Hence a pharmacophore is an abstract description of 
molecular features (both steric and electronic) that a particular molecule or a receptor must have 
for it to be recognized by a docked ligand. The general concept of a pharmacophore is that 




groups in three-dimensional space. The chemical groups include hydrogen bond donors and 
acceptors, negative charges, and aromatic groups.165,166  
 
 




A typical pharmacophore generated from the Phase program illustrates a spatial 
arrangement of the relevant chemical features that are required for binding. The spatial 
arrangement may be generated via ligand-based information or fragment-based information, or a 
mixture of both. The ligand-based approach generates a hypothetical pharmacophore from the 
structures of a known ligand and receptor, whereas the fragment-based strategy uses only a 
receptor molecule and its interaction with numerous small molecule probes which generate a 
pharmacophore based on this “mapping” approach. Alternative ligands could be generated with 
this approach in cases where there is limited receptor information but sufficient ligand 
information.167 
The fragment-based (protein-based), on the other hand, generates a pharmacophore using 




a pattern of the relevant, interactive sites in the receptor molecule. The 3D arrangement may or 
may not be very similar to the spatial organization from the ligand-based approach. A library of 
ligands is virtually screened against these features to identify new ligands that could bind to the 
receptor molecule. The active ligands obtained from the virtual screening are ranked with the 
PhaseHypScore (PhaseScore) in the Schrodinger software. The score orders millions of molecules 
based on their performance in virtual screening as well as the quality of the ligand alignment. 168  
 
4.3.3. Glide Docking 
The Glide high throughput docking screening program is used to screen several molecules 
for their biological activity.169 Glide tends to identify active molecules from a smaller database of 
molecules identified as possible ligands based on the initial Phase screening process. Glide docks 
ligands to an active site and estimates their binding affinities. Additionally, the conformations of 
the docked ligands (ligand Poses) and the positions of correctly docked ligands can be obtained 
and visualized.170 Virtual screening may be performed with standard precision (Glide SP) or in 
extra precision (Glide XP). The Glide SP docking employs functions which reduce the number of 
conformers and torsional refinements used in the docking process, making it less expensive, 
whereas Glide XP performs an extensive torsional and conformational sampling to eliminate false 
positives that are obtained from the SP docking. The docking process usually begins with a fast 
Glide SP docking, and the top ligands are further docked with Glide XP to obtain a docking score 
in terms of the Gibbs free energy. A typical XP score (equation 1) is made up of the principal 
terms that favor binding (equation 2) and those that hinder binding (equation 3).171 
 
𝑋𝑃 𝐺𝑙𝑖𝑑𝑒𝑆𝑐𝑜𝑟𝑒 = 𝐸𝑐𝑜𝑢𝑙 + 𝐸𝑣𝑑𝑊  + 𝐸𝑏𝑖𝑛𝑑  + 𝐸𝑝𝑒𝑛𝑎𝑙𝑡𝑦    (1) 
𝐸𝑏𝑖𝑛𝑑 = 𝐸ℎ𝑦𝑑𝑒𝑛𝑐𝑙𝑜𝑠𝑢𝑟𝑒 + 𝐸ℎ𝑏𝑛𝑛𝑚𝑜𝑡𝑖𝑓
+ 𝐸ℎ𝑏𝑐𝑐𝑚𝑜𝑡𝑖𝑓
+ 𝐸𝑃𝐼 + 𝐸ℎ𝑏𝑝𝑎𝑖𝑟 + 𝐸𝑝ℎ𝑜𝑏𝑖𝑐𝑝𝑎𝑖𝑟   (2) 
𝐸𝑝𝑒𝑛𝑎𝑙𝑡𝑦 =  𝐸 𝑑𝑒𝑠𝑜𝑙𝑣 + 𝐸𝑙𝑖𝑔𝑎𝑛𝑑_𝑠𝑡𝑟𝑎𝑖𝑛  (3) 
 
The Ecoul, and EvdW terms describe the coulombic and the van der Waals energies, 
respectively. The hydrophobic enclosure  (𝐸ℎ𝑦𝑑𝑒𝑛𝑐𝑙𝑜𝑠𝑢𝑟𝑒) and the hydrophobic pair  (𝐸𝑝ℎ𝑜𝑏𝑖𝑐𝑝𝑎𝑖𝑟 ) 
functions describe the interaction between the hydrophobic section(s) of a molecule that come 
into proximity to the receptor cavity as the ligands bind to the receptor. The displacement of the 




entropy of the system. The increased entropy favors the binding process. The Protein-hydrogen-
Bonding interactions are described by the functions containing the hb terms (𝐸ℎ𝑏𝑛𝑛𝑚𝑜𝑡𝑖𝑓
+
𝐸ℎ𝑏𝑐𝑐𝑚𝑜𝑡𝑖𝑓
+ 𝐸ℎ𝑏𝑝𝑎𝑖𝑟  ) where the nn and the cc terms refer to the neutral-neutral motifs and the 
charge-charge motifs, respectively. The transfer of hydrophobic molecules from the bulk solution 
upon ligand binding could favor binding energy since there will be more hydrogen bonding 
between the water molecules that have been displaced from ligand and receptor surfaces into the 
bulk solution. The overall ionization state (𝐸𝑃𝐼) of the molecules can also enhance binding. 
Conversely, the desolvation energy (𝐸 𝑑𝑒𝑠𝑜𝑙𝑣 ) function describes the decrease in free energy. The 
inability of the bound ligand to freely rotate in solution (𝐸𝑙𝑖𝑔𝑎𝑛𝑑_𝑠𝑡𝑟𝑎𝑖𝑛) leads to a significant 
decrease in entropy and leads to less favorable binding.171 
 
4.3.4. Ligand Preparation (LigPrep) 
Similar to protein structures obtained from the PDB which have to be refined in order to be 
utilized in a docking simulation, ligand structures from databases or vendors may require initial 
preparations and optimizations as well. In the Maestro software this is termed the LigPrep 
program. The LigPrep application converts 2D structures to low energy 3D structures. Also, 
LigPrep expands the input structure by the generation of various ionization states, tautomers, 
stereochemistry, and ring conformations which may be present for a potential ligand. 
The application is briefly described using the color-coded (steps) in Figure 4.4. First, the 
ligand structures can be imported into the LigPrep panel by either browsing for the structure files 
in the top panel (red) of the application or by using existing structures in the entry list (or project 
table). Next, a criterion (orange) can be used to filter out unwanted ligands such as molecular 
weights or functional groups. The third step (teal) involves setting the ionization state, which 
generates all the possible ionization states for each ligand on file. Also, metal binding states can 
be added when docking to the active site that contains a metal (metalloproteins). Fourthly, the 
ligand can be desalted to remove unwanted water molecules and counterions from the crystal 
structure. Additionally, the last but one step (green) generates keto-enol tautomerization, sulfur 
and nitrogen tautomers, histidine, and DNA base tautomers. Also, chirality information can be 
retained or generated from the new 3D structures of the ligands. Here a limit can be set on the 




format (purple) SD or Maestro can be chosen from the output tab and the number of processors to 
be used for the computation can be chosen from the job settings icon (right of the job name). The 
prepared ligands, now in 3D with correct ionizations, can then be added to the project table and 
used for induced fit docking.172  
    
Figure 4.4. The LigPrep application menu screen. A screen capture from Maestro 11, LigPrep 
application. 
 
4.3.4. Induced Fit Docking (IFD) 
The rigid receptor docking (such as Glide) models the docking between a receptor that does 
not undergo significant changes upon ligand binding and the ligand itself. The modeling is 
performed by scaling the van der Waal’s radii of the ligand binding site and freezing or deleting 
highly flexible receptor side chains to prevent close contacts173 But, the process of deleting side 




hence produce false positives. The benefit of this approach is that a rapid throughput of ligands is 
the result which in practical terms allows for rapid screening of large ligand databases, providing 
a list of molecules from the original database which could potentially bind to the receptor. 
To overcome this, and many other, limitations, the soft docking model was described by 
Jiang and Kim in 1991, which accommodated small changes in protein conformation. In their 
work entitled “Soft docking”: matching molecular surface cubes,” the authors modeled minor 
conformational changes by developing a “cube representation” of molecular surface and volume. 
This process, described by Jiang and Kim, used a fixed receptor molecule but used a “soft” 
scoring function to evaluate the interactions. Some of the interactions are charge-charge 
interaction, hydrogen bonding, van der Waals interaction, and the size and shape of surfaces 
(Figure 4.5 a).174  The soft scoring functions are derived from the molecular mechanic's force field 
to allow for small overlaps between the ligand and the receptor that are used to estimate small 
plasticity in the receptor molecule within a short computation time. However, ligands with 
multiple functionalities and diverse sizes may not perform well under soft docking.175 
Alternatively, ensemble/ multiple docking (Figure 4.5 b) can be used to account for 
receptor flexibility. In ensemble docking, multiple conformations of the receptor molecule are 
used to simulate large-scale conformational states. The ensemble docking approach was 
employed by Kua et al. to study the specificity of acetylcholinesterase with acetylcholine. The 
computed k(cat) and K(M) values were in general agreement with the experimental values. 176 
Despite the success of this method, it suffers from the lack of evaluating wide-range receptor 
conformations. Also, since the receptor conformations are generated before docking and are not 
allowed to vary during the docking process, it does not correctly account for any ligand-induced 
conformational change.177 Hence, the Indiced Fit Docking protocol can be applied to overcome 
these limitations.  
Unlike Glide docking, which employs a rigid receptor to estimate the binding energies 
quickly, the induced fit docking application attempts to accurately predict the change in receptor 
conformation and its associated energy/ modes upon ligand binding within a reasonable time 
frame. The Induced Fit Docking protocol combines both Glide and Prime applications to account 
both ligand and receptor flexibilities (Figure 4.5c). The receptor is allowed to have some 
flexibility by decreasing the van der Waals (vdW) radii, and an increased Coulomb-vdW cutoff 




combines components of the Glide and Prime178 applications to estimate the energies of the 
docked active ligand quickly.  
The Glide application is used to generate the various binding modes for the ligands and 
receptors while the Prime application178 samples the flexibility in the receptor. As mentioned, 
Glide docking is performed on the 3D ligands from LigPrep to generate diverse Ligand poses. 
The Ligand poses are then accommodated into the binding site by performing Prime structural 
prediction which reorients receptor sidechains and trims highly flexible chains to make room for 
the ligand and the resultant pose for the residues, and the ligand is minimized to obtain the low 
energy receptor conformations for each ligand. This step is the main difference between the IFD 
and the Glide docking. In Glide docking there is a single receptor conformation in which all 
ligands have to dock. The minimized receptors (for each ligand) is used to separately redock their 




Figure 4.5. A representation of docking models. (a) the “soft” docking model with the rigid 
receptor and a flexible ligand. Also, the first figure (a) can represent rigid receptor docking in the 
Glide docking strategy. (b) ensemble docking having multiple rigid receptor conformations and 
flexible ligand. (c) the Induced Fit Docking approach, having both flexible receptor and ligand 




4.4. Force Field 
The Optimized Potential for Liquid Simulation All-atom (OPLS-AA) force field was 
developed by Jorgensen and Coworkers.180 The OPLS mathematical functions are used to 
describe the atomic and molecular interactions in larger systems (protein and polymers). The 
torsional and nonbonded parameters of the force field were originally obtained from an ab initio 
molecular orbital calculation at the 6-31G* level. Initial parameterization involved 34 pure 
organic solvents (including: alkanes, alkenes, alcohols, ethers, amides, acetals, sulfides, 
disulfides, thiols, aldehydes, and ketones). These solvents were used to mimic the amino acids 
since peptide residues have organic functional groups. Rotational energy profiles from the ab 
initio calculation were then fitted to obtain the torsional parameters.  Bond charge correction 
factors were also applied to all charge distributions (lone pair and sigma hole-charge) in aqueous 
solutions to obtain a high level of accuracy.  On the other hand, bond stretching and bending 
motions were adopted from the AMBER (Assisted Model Building with Energy Refinement) 181 
force fields. The overall OPLS function is similar to other potential functions, AMBER, and 
CHARMM (Chemistry at HARvard Macromolecular Mechanics)182 force fields.  
Hence, the first OPLS force field was a combined AMBER/OPLS180 which was later 
updated to OPSL-AA. The OPLS-AA (all-atom)183 force field. Subsequently, The OPLS-AA 
force field was improved into newer versions for diverse applications; (i) OPLS-AA/L(or OPLS-
2001), reparametrized OPLS-AA for peptides and proteins.184 (ii) OPLS_2005, an improvement 
of OPLS-AA/L to provide a larger coverage for organic functional groups.185 (iii) OPLS2, to 
predict absolute solvation energies for diverse small molecules.186 (iv) OPLS3187 and the more 
recent the OPLS-UA (united atom) proposed by Patsahan et al.188 to model curcumin molecule in 
water, methanol, and dimethyl sulfoxide solvents. The OPLS updates cover a broad range of 
molecules, decrease computation time, and sufficiently reproduce experimental data. The Maestro 
11 software uses the new generation OPLS3 force field. This newer version is capable of fitting 






Figure 4.6. The evolution of the OPLS force field. Through the AMBER/OPLS to the recent 
OPLS-UA. All of the updates stem from the OPLS-AA, the largest sphere (orange). The Figure 














This section describes how the various types of pharmacophores are generated for the Bfr 
cage protein (PDB ID; 1Bfr) and how the screening process is undertaken. The computational 
workflow is as follows. A hypothetical pharmacophore was produced with the Phase program for 
virtual screening. Glide docking was performed for the ligands obtained from the Phase 
screening. Finally, IFD (not in the initial workflow) was to obtain the computed binding energies 
between the ligand and the receptor molecule, and they were used to categorize the identified 
ligands (ligand molecules) into strong binders and weak binders. The Figure 4.7 below shows the 
various steps leading to the hypothesis. 
 







4.5.1. Protein Preparation 
The E. coli bacterioferritin crystal structure (PDB: 1BFR) reported by Daurant and 
Coworkers 84 was imported with the Maestro protein preparation wizard tool. The native 24-mer 
structure was imported by checking the biological unit box. (Figure 4.8) The imported structure 
was loaded into the workspace, colored by PDB conversions to show areas that required attention 
(very high B factor regions with missing side-chain atoms and metal atoms). Bond orders were 
also assigned, but zero-order bonds were created to the heme Fe2+ ion. All water molecules that 
were within 5 angstroms from hetero groups were deleted. Steric clashes were removed with a 
brief relaxation in the OPLS3 force field with the Impact refinement module. Finally, hydrogens 
were added to all of the atoms in the system. The hydrogen network was optimized, and the 









Figure 4.8. Optimizing the 1Bfr crystal structure for modeling. The Maestro Prep wizard on 
the right was used to import the 1Bfr biological unit and prepared with the options selected in the 














4.5.2. Subunit and Ligand Extraction 
The Review and Modify tab (in the protein Prep wizard) was used to strip down the 1Bfr 
structure to two adjacent subunits (G and H) and their shared heme cofactor. The Fe atom 
associated with the heme ligand was also removed (to remove the bias towards the Fe2+-
methionine sulfur interaction), and the Mn2+ ions at the ferroxidase site were deleted to prevent 
active site blockage.  The co-crystallized ligand (protoporphyrin IX) was extracted from the 
minimized subunit and labeled as Ligand, and the remaining subunit was labeled Bfr receptor. 
The ligand extraction was performed by selecting the molecules of interest and right-clicking and 
selecting Extract. The extracted structures then appeared as separate entries, and they were 
labeled as “heme ligand” (protoporphyrin IX) and “Bfr receptor” (only subunit, no heme). The 
process of subunit extraction is illustrated in Figure 4.9 below. 
 
Figure 4.9. Bfr subunit and ligand extraction. In step 1, the optimized structure was loaded, 
and 22 chains were deleted leaving only chains G and H. The 2 chains were the labeled Bfr and 
the heavy atoms (Mn2+ and Fe2+) removed in step 2. Finally, the protoporphyrin ix molecule was 









4.6. Hypothesis Generation 
 The Schrodinger Phase program 168 was used to generate a 3D mold (Hypothesis) of the 
interactive sites on the receptor. The atoms from the protein residues forming the binding cavity 
were treated as a set of atomic spheres with sizes determined by their van der Waals radius. 
Excluded volumes were added to the hypothesis to allow small overlaps between the ligand and 
the receptor, creating a kind of induced-fit effect. The excluded volume spheres for the receptor 
atom were positioned within a 5 Å shell around the ligand surface while ignoring all receptor 
atoms whose surfaces were within 2 Å or closer to the docked ligand surface. This restraint 
creates a loose excluded volume that forces the matched ligand to stay in the binding site most of 
the time. Two different hypotheses were generated, the first from the Ligand-based (using both 
the receptor cavity and heme ligand) and the Fragment-based which employed 667 fragment 
molecules to create the interactive sites in the receptor cavity (no ligand involved).  
 
4.6.1. Ligand-based Hypothesis Generation 
The Bfr dimer with a heme cofactor at the interface was imported into Maestro. The Phase 
application was selected from the task tab, and the “generate a hypothesis from a receptor and an 
active ligand” option was selected. The ligand was defined by clicking on an atom in the heme 
ligand in the workspace and the parameters described above were set as well as the maximum 
number of interactive sites. The generated pharmacophore was listed as “hypothesis” in the entry 
list and also appeared in the workspace. The seven interactive sites and their corresponding 
interaction energies were labeled in the hypothesis (Figure 4.9.1a) 
 
4.6.2. Fragment-based Hypothesis Generation 
The second hypothesis (Hypothesis1: Epharmacophore-Receptor cavity) was obtained by 
selecting Phase from the task menu and subsequently selecting: Develop a hypothesis; Receptor 
cavity in the workspace. This approach employs small fragment molecules (Figure 4.9.1d) to map 
out the various interactions in the active site. Before that, the active site region was defined by 
picking residues (Figure 4.9.1 c), which are expected to interact with the active ligands. The 
centroid of the cavity was set to x = -2.25, y = -27.83, z= 29.17, to ensure that the fragment 








Figure 4.9.1. Generating Bfr pharmacophore. (a) Shows the dimer (receptor) subunit with its 
reference heme ligand (green) for the Ligand-based hypothesis (b) The receptor without a 
reference ligand showing the centroid where the fragments must dock. (c) A table of all the 
residues in the highlighted region of panel b. (d) examples of the 667 fragment molecules used to 




4.7. eMolecule Screening 
The Phase screen is a rapid but less refined strategy to virtually screen millions of 
molecules from a database or imported ligands to obtain matches (hits) for the generated 
hypothesis. The Molecules are sorted by the number of interactive sites, volume score, and their 
overall effective interactions. The databases used in this work were the CAP2011 and the Aldrich 
Market Direct®. The CAP2011 contains about 2.3 million (up to 4.8 million including all 
conformers) ligand molecules with average molecular weight not higher than 650 Da. Similarly, 
the Aldrich Market Direct® contains 7.3 million (up to 19.1 million conformers) ligand molecules 
with molecular weights between 250 to 500 Da.  
Both of the databases were separately screened with two different hypotheses (ligand-based 
and from fragment-based). Each of the hypotheses contained seven interactive sites, and one of 
the conditions of the hypothesis screening was that a screened molecule must match at least four 
out of the seven interactive sites of the pharmacophore before it can be classified as a hit. The job 
was divided between 7 processors which took up to 2 weeks to successfully screen the entire 
CAP2011 database and up to one month for the Aldrich Market Direct® database. The top 500 
hits were retained for each screen (fragment-based and ligand-based) and incorporated into the 
Entry list as well as the project table. The entry list showed a specific hypothesis with its 















The Phase screen hits were docked into the Bfr receptor molecule using the ligand 
docking protocols in Maestro. Figure 5 outlines the various steps in the docking process. 
 
Figure 5. Docking funnel. Summarizes the process involved in the docking process. The 
Docking funnel was designed in Microsoft PowerPoint. 
 Glide SP and XP dockings were performed on the hits to obtain a set of molecules which 
optimized their fit into the Bfr receptor site. The 500 phase ligands were selected for a quick 
Standard Precision glide (Glide SP) docking, followed by an Extra Precision glide. A receptor 
grid was generated using the procedure outlined in the Schrödinger Academy Maestro 11 
Tutorials entitled, “Structure-based Virtual Screening using Glide.” 189 The receptor grid was 
made by loading the ligand (protoporphyrin IX) and receptor molecule (Bfr dimer-nonheme) into 
the workspace and specifying which molecules should be treated as ligand and receptor in the 
Glide application. This process creates green and purple boxes around the ligand and receptor, 
respectively (Figure 5.1). The receptor box defines the outermost regions that a docked molecule 




the docked molecule (where it must be positioned to pass the initial docking stages. The X, Y and 
Z coordinates of the ligand box were adjusted to 10 Å, 8 Å and 6 Å respectively, to ensure that 
the size is not dependent on the size of the docked ligand, but well positioned in the center of the 
grid. The van der Waal (vdW )  radii of the receptor were scaled by a factor of 0.8 to partially 
account for suboptimal fits that could be associated with minor receptor movements. Also, highly 
flexible receptor sidechains were frozen in this process to allow many ligands to dock within a 
reasonable time. A constraint was set on the receptor to enable free rotation of rotatable groups 
such as serines and tyrosines. Several ligand conformations were docked into a fixed receptor 
conformation. However, only one conformation was retained after the post-docking minimization 
step. The same receptor was used to dock all the molecules from the two pharmacophore 
hypotheses. Each molecule was docked within 10.8 seconds in Glide SP.  The SP docked ligands 
were further used for Glide XP (same receptor conformation) which took about 6.8 minutes per 
ligand on 7 processors. The output files were added to the project table and the Entry list in order 
of decreasing glide scores. The ligand poses were visualized in the workspace by loading the 
ligands into the workspace with a fixed receptor molecule. 
 
Figure 5.1 The Bfr grid. The green area defines the centroid of the docked ligand while the 
purple dox defines the region where a ligand must occupy to pass the initial docking stage. Screen 




4.9. Induced Fit Docking (IFD) 
The Induced FIT docking was run selecting the top 15 tight binders, 3 moderate binders, 
and 2 weak binders from Glide XP, using the Market select database (Schrodinger, LLC). The 20 
ligands were prepared employing LigPrep to generate each ligand’s corresponding low energy 3D 
structure; overall 128 structures were obtained and used for IFD using the flow chart outlined by 




Figure 5.2. The induced fit docking protocol. A flow chart showing how both Glide and Prime 








5. RESULTS AND DISCUSSION 
 
5.1. Protein Preparation and Optimization 
The starting point of any computational calculation is to obtain an optimized structure that 
is suitable for the application since the simulated result is dependent on the initial structure. The 
ability to fill in missing parts of the structure is important for protein X-ray crystal structures 
(which focuses more on heavy atoms than smaller ones). Several protein crystal structures have 
missing atoms in flexible regions that tend to fragment the structure, making it difficult to work 
with computationally. However, the Protein Preparation wizard has proven to be an indispensable 
tool for this task. The entire Bfr structure and its environment were modified with this tool. The 
Bfr subunit was extracted from the native 24-mer as well as unwanted solvent molecules were 
removed from the crystal structure. The structure was successfully optimized and minimized with 
the Protein Preparation Wizard. The extracted ligand and receptor were further used in modeling 
processes outlined above. The Figures below show the structure of 1Bfr going from an intact 24-
mer to a dimer (heme-bound) and the ligand. These applications show how powerful the OPLS3 
force field sufficiently covers large molecules (over 31 thousand atoms in Bfr) without any errors 
or software issues, as seen in Figure 4.9. 
 
5.1.1. Ligand Preparation 
Similarly, the 2D ligand structures obtained from the Glide rigid receptor docking were 
successfully optimized to generate the correct ionization states, tautomeric states, and the 
corresponding low energy structures were used for IFD-based docking. Each ligand generated a 
maximum of 32 ligand conformers/isomers, but not all ligands had multiple conformers and 
isomers. A total of 128 ligands (3D) were generated from the 20 original Glide ligands (2D). 
 
5.2. Ligand-based Pharmacophore Modeling (Phase Screen) 
The ligand-based pharmacophore approach generated a possible spatial arrangement of the 
most energetically favorable sites necessary for ligand recognition. The arrangement was based 
on the structures of the ligand and the receptor and their interaction. Even though this approach of 
pharmacophore modeling is thought of as biased (as an already known ligand is used as the 




binding properties. The generated pharmacophore had 7 interactive sites (Figure 5.3). Four of 
them are from the aromatic groups associated with the 4 pyrrole rings (R13-R16) with equal 
theoretical binding energies (-2.84 kcal/mol each). Two hydrophobic interactions related to the 
ethylene groups on R14 and R16  (-0.6 kcal/mol and -0.43 kcal/ mol, respectively). Lastly, an 
ionic interaction (N12, -0.36 kcal/mol) associated with one of the propionate groups that is 
observed to interact with Lysine 53 in the receptor (Figure 5.5b). The analysis of these results 
showed that the 4 aromatic groups appear to be the most important interacting groups, followed 
by the two hydrophobic groups and the single negative charge interaction.  
The 5 top-scoring hits obtained from the Phase screen were structurally similar to 
protoporphyrin IX but had different substituents at sites H7 and H8. The top 4 hits obtained 
(Figure 5.3.1) validate the generated hypothesis since the virtual screen was able to find 
molecules that were structurally similar to the reference ligand. Overall, Phase screen is a rapid 
approach that limits the number of molecules to work with, but there is the need for an extensive 








Figure 5.3. The Bfr Pharmacophore (Ligand-based). The teal spheres show the excluded 
volumes, indicating that a ligand could experience steric clashes (from receptor molecules) within 
those regions. The Orange color represents aromatic groups, red for ionic groups and green for 






Figure 5.3.1. Phase Screen hits. (a) An overlay of the top 4 hits from Phase Screen with the 
heme ligand on the left. (b) Other interesting hits obtained and their respective structures. All 





5.3. Fragment-based Pharmacophore Modeling (Phase) 
The fragment-based approach employed 667 small molecules which eventually resulted in 
the identification of seven small fragments (Figure 4.9.1. c) of importance to map out the defined 
binding site (Figure 4.9.1 b), which resulted in 7 essential interactions (Figure 5.3.2). Three out of 
seven were aromatic regions (R 19, R 21, R 22), two hydrophobic sites (H 13, H14) and two 
Donor sites. All the sites allow interaction within 2 Å distance. The fragment-based approach 
ranks by distances. The top 4 Phase screen molecules had a score of about 1.7 (Figure 5.3.3), 
which is similar to the scores obtained for the non-protoporphyrin molecules from the ligand-




Figure 5.3.2. Fragment-based hypothesis. The fragment-based ePharmacophore showing 7 
sites: 3 aromatics (orange), 2 donor sites (light), and 2 hydrophobic sites (green).  This image 







Figure 5.3.3. An overlay of the top 4 fragment-based ligand molecules. Image was exported 
from the Maestro 11 application. 
 
 
5.4. Glide XP Docking 
Glide docking results obtained from the top 500 fragment-based hits were similar to the 
ligand-based results, regarding the score and the pose viewer interactions between the receptor 
molecules and the docked ligand. Met52 was observed to contribute unfavorably to the interaction 
energies in most cases. Phe26 was quite favorable in both ligand and fragment-based results 
despite its size it was involved in either pi-pi or pi-cation interactions with most of the ligands. 
This shows that not all bulky amino acids at the active sites are sterically hindering, this 
observation agrees with the work reported by Nam and coworkers where they reported Trp 26 at 
the heme binding site of RsBFr (bacterioferritin from Rhodobacter sphaeroides) to be an essential 
residue for stabilizing the heme molecule.63a The most favorable residue at the binding site is Asn 






Glide SP and XP docking applications were used as a more precise approach to sort the 
Phase screen ligands. The docking is used to eliminate false ligands which may have successfully 
passed the initial Phase screen process. The ligands were individually docked to the Bfr receptor 
grid in rigid receptor approach within a reasonable amount of time. The docking process begins 
by generating several conformers of the Phase screen ligand and roughly scoring them to obtain 
promising ligand poses (initial docking stage). The promising ligand poses are further refined in 
torsional space in the field of the receptor molecule with a distance-dependent dielectric model to 
a fewer number of poses which are finally minimized with full ligand flexibility (Post Docking 
minimization, PDM).190 The 0.8 vdW scaling factor was used to soften the active site potential 
and compensate for some receptor flexibility, as well as to generate a diverse ensemble of poses. 
A constraint was set in the grid to allow rotation of Ser and Tyr to mimic aqueous conditions. 
Also, the docking process generated tautomeric forms of the neutral ligand molecules using the 
Epik (Empirical pKa prediction) application.191 Highly flexible side chains with poor interactions 
were frozen to minimize computation time. 
 
5.5. Glide Ligand Poses 
 A ligand pose shows how the ligand interacts with the receptor molecules in 3D. Several 
ligands were docked into the receptor, and the top pose (from Glide XP using the CAP2011) is 
seen in Figure 5.5a. A typical pose shows how favorable or unfavorable a ligand-receptor 
interaction is. The residues with favorable interactions are colored blue, whereas unfavorable 
interactions are red. This is very useful in that the preferred ligand structure could be fine-tuned to 
reduce steric clashes with the Bfr receptor molecule. Met52 was observed as unfavorable for all 
the non-protoporphyrin IX ligands (Figure 5.3.4, molecules 1, 6-10). The unfavorability may arise 
from the sterics associated with the side chains. A previous study in the Honek laboratory 
reported  the formation of a 24-mer in Bfr constructs with Met52 mutation (bFTM52L ).122 Even 
though it been reported that the heme-Met52 ligation is essential for Bfr oligomerization, 101 the 
presence of intersubunit salt bridges, hydrophobic interactions, and other tertiary interactions 
could stabilize the Bfr 24-mer similar to other non-heme ferritins. Lysine 53 was also observed as 
another unfavorable residue in most cases even when it interacted with the propionate groups in 
the protoporphyrin-like ligands. This supports the low interaction energy obtained from the 




between the receptor and the ligand molecule may not be very critical to binding affinity and may 
also explain why ligand 1 (Figure 5.3.4. a) is the best ligand despite the lack of that particular 
interaction.  
The protoporphyrin-like ligands were expected to be the top ligands since they are 
structurally similar to the reference ligand. This was obvious in the Phase screen results as the top 
5 molecules were all identical to that structure (average 2.5 kcal/mol PhaseScore). However, the 
docking results indicate that resemblance to the reference ligand does not always correspond to a 
true ligand. Phase screen molecule 5 (Figure 5.3.1. b, the first molecule on the left) was 
eliminated from the Glide docking due to lack of rotatable groups (zero rotatable groups), this 
results in high ligand strain penalty ( 𝐸𝑙𝑖𝑔𝑎𝑛𝑑_𝑠𝑡𝑟𝑎𝑖𝑛, eq (3)) on the overall Glide score. Overall the 
top 9 molecules did not have many unfavorable interactions (red dashed lines) and they have 
comparable binding affinities with no Epik state penalties (table 2). Epik state penalties for the 
various tautomer states of a particular ligand is applied to the Glide score. Ligand 10 had a 
different docking score from the Glide score due to its 0.0106 penalty. 
The Glide model score is useful for ranking conformers of the same molecule since it 
accounts for the effects of the orientation of a particular conformer in the forcefield in terms of its 
















Figure 5.3.4. Glide ligand poses (from the ligand-based screen). (a) The most active ligand 
pose oriented in the receptor. The receptor backbone in thin tubes; the side-chains are in sticks 
while the ligand is in the skeletal model. (b) Ligand interaction diagram for the ligand and 
receptor. (c) Screenshot of the reaction legend. (d) Glide ligand poses of the top 10 higher affinity 

















Figure 5.3.5. Glide Ligand interaction diagrams. Shows 2D representation of the interaction 
between the docked ligand (from ligand-based) and Bfr receptor. All images were exported from 















Figure 5.3.6. Top 10 Glide ligand-based structures. The structure which was originally ranked 
432 from Phase screen emerged as the most active ligand in Glide. 
 
 
5.5.1. Glide Ligand Poses from Fragment-based Screen 
Similar to the ligand-based molecules, the fragment-based molecules were ranked on the 
Phase Score, and the top 500 were used in Glide docking to obtain the highest and lowest affinity 
binding molecules. The results are summarized in Figures 5.3.7. and 5.3.8. and the table 3 below. 
The ligands obtained here are not structurally similar to the native heme molecule but have 
similar planarities to heme. The lack of reference ligand produced an active site mold without any 
similarity to the ligand-based pharmacophore. Hence, this can account for the structural 
differences between the structures from the two approaches.  
An advantage of this approach is that it diversifies the number of ligand molecules which 
may not resemble heme, but have other functional groups capable of binding to the Bfr receptor 





Analysis of the Phase Screen results indicate that the molecules were high affinity ligands 
since most of the top 500 molecules scored above 1.5 (the top 10 are shown in table 3, column 8). 
However, most of the Phase molecules were reranked during the Glide docking process as seen in 
column 8 of Table 3 and apart from the protoporphyrin-like molecules from the ligand-based 
screen which had almost all the 7 sites matched (Table 2, column 8) the number of matched 
interaction sites in both approaches were similar (mostly 3-5 sites). To compute the theoretical 
binding energies of the top 500 ligand-based structures, they were docked into the same Bfr 
receptor in Figure 5.1. Moreover, the results are shown in Table 3, as well as the ligand poses in 
Figure 5.3.7. and Figure 5.3.85. Again, the docking scores were very high and comparable to the 










Figure 5.3.7. Glide ligand poses (from the fragment-based screen). (a) Shows the most active 
ligand pose oriented in the receptor. The receptor was represented in a thin tube while the ligand 
is in a skeletal model. (b) Ligand interaction diagram for the ligand and receptor. (c) Screenshot of 
the reaction legend. (d) the ligand poses of the top 10 active ligands. All images were exported 















Figure 5.3.8. Ligand interaction diagrams for top fragment-based ligands. 






Table 3. Docking results (fragment-based). shows how the Phase screen molecules perform in 








5.6. Induced Fit Docking 
In order to account for the Bfr receptor flexibility, the IFD docking strategy described 
earlier was employed. The molecules from the Aldrich Market Direct® database were used 
since it contained virtually all the molecules in the CAP2011 database as well as those in the 
current database and information was present that would allow for purchasing of various 
molecules from commercial suppliers. Hence, the database was screened against the two 
hypotheses as described for the CAP2011 database to obtain ligand-based and fragment-
based molecules/ligands. The two sets of ligands were separately docked into the same Bfr 
rigid receptor to obtain their Glide scores. 
The top 15, middle 3, and bottom 2 structures from each set of data were prepared by 
employing the LigPrep program and further used in IFD docking, employing the same 
receptor, but this time using Prime and Glide together to obtain a more flexible Bfr receptor 
as illustrated in the flowchart (Figure 5.2). The IFD score was then used to rank the ligands 
into tight binders, moderate binders, and weak binders. Figures 5.4.and 5.4.1 below show the 









Figure 5.4. IFD rank of the top 13 molecules obtained from the Ligand-based screen. The 
ranks are in red, followed by the Glide XP score in kcal/mol also, the IFD score in kcal/mol. The 









Figure 5.4.1. IFD rank of the top 14 molecules obtained from the Fragment-based screen. 
The ranks are in red, followed by the Glide XP score in kcal/mol and IFD also score in kcal/mol. 





5.7. Reconstitution of the Docked Molecules into WTBfr 
The results from IFD docking, using the Market select® database, were combined (both 
fragment-based and ligand-based) and compared to select a mixture of final ligands to purchase 
from suppliers. The selection contained most active ligands, moderately active ligands, and least 
active ligands. Overall, 11 ligands were studied: 4 protoporphyrin analogs (Protoporphyrin IX Fe 
(II) (heme or FePP), Protoporphyrin IX Zn (II) (ZnPP) Protoporphyrin IX molecule (PP), and 
Protoporphyrin IX dimethyl ester (DMEPP)) seen Figure 5.5 and 7 others from the 2 screens 
(Table 4) The selection of ligands with different binding energies will be used to study how the 
IFD score correlates to experimental results. 
 
 
Figure 5.5. The structures of heme analogs used for the initial encapsulation trials. All of the 











Table 4. Structures of ligand molecules to be used for future encapsulation. FB and LB 
represent fragment-based and ligand-based, respectively. These molecules were purchased from 





Preliminary reconstitution experiments were set up with the four protoporphyrin analogs by 
combining 1 molar equivalent of WTBfr with 2 molar equivalents of the ligands at 80 ⸰C for 10 
minutes each and allowing the mixtures to cool down to room temperature. The mixtures were 
then buffer-exchanged into 150 mM NaCl, 50 mM MOPS or HEPES-pH 7.5 and filtered through 
a 0.45 um nylon syringe filter. 
Dynamic Light Scattering (DLS) analysis was used to analyze the sample for quarternary 
structures in the solution after reconstitution. The preliminary data are shown below, Figure 5.6, 
indicates that all the analogs shift the equilibrium (Figure 4) towards a 24-mer with an average 
size of 16 ± 2 nm. 
Finally, calibration curves (of size to mole equivalents of heme analogs) will be used to 
determine the minimum mole equivalent of heme required to form a 24-mer. This knowledge will 
then be used to study the possible binding of the remaining seven compounds and study their 
effects on their ability to reconstitute the 24-mer quaternary structure of Bfr. If observed, a 
correlation with the experimental ranking of each compound in the group with the computed 










Figure 5.6. Preliminary DLS analysis on ligand reconstitution. WTBfr: Wild-type Bfr, FePP: 
hemin, ZnPP: protoporphyrin IX Zn (II), PP: protoporphyrin IX, DMEPP: protoporphyrin IX 
dimethyl ester  
 
5.8. Summary and Future Directions for Bfr Pharcophore Modeling 
This project has demonstrated the application of computational methods to a complex 
system, Bfr. Significant progress has been made regarding initial protein preparation and 
minimization. Also, a combination of Phase and Glide applications has been used to identify 
novel compounds that might bind to the Bfr-heme binding pocket. SP docking is sufficient in 
identifying “actives” for Bfr binding sites since it computes similar binding energies as the XP 
method, but in a fraction of the time. However, XP becomes essential when dealing with ligands 
with different conformations. Moreover, the rapid Phase screen results obtained validate the 
initial hypothesis, but a higher Phase score does not guarantee tighter binding, docking is required 
to obtain the binding energies, and FID has proven to be useful for estimating the binding 





SUMMARY AND FUTURE DIRECTIONS 
 
6.1. Encapsulation of Inorganic Nanoparticles 
The work in this thesis has explored how two microbial ferritins nanoplatforms, 
Archaeoglobus fulgidus ferritin (AfFtn) and E. coli Bacterioferritin (Bfr), can be engineered to 
make them more versatile. Expanding the versatilities of these nanoplatforms could repurpose 
them for nonnative applications such as drug delivery vehicles,4b,38 hydrogen gas production 
(energy),5-6new materials with diverse functionalities,2 water purification,40 and many more.  
Firstly, the Bfr nanoplatform was engineered both experimentally and computationally 
(Chapter 4). Previous investigations in the Honek laboratory and the research outlined herein 
involved the redesigning of the Bfr gene to encode for internal (C-terminal) polyhistidine tags 
which were used for entrapping NTA functionalized guest molecules like NTA-functionalized 5 
nm gold nanoparticles (AuNP) (Figure 6). The AuNP contained about 4000 atoms of Au coated 
with a proprietary linker to which the NTA is attached. The AuNP was used as a proof of concept 
for encapsulating inorganic materials for applications in imaging. For example, gadolinium-based 
contrast agents can be functionalized with NTA groups and internalized into Bfr via the His-Ni2+ - 
NTA interaction. Encapsulated contrast agents can be utilized in Magnetic Resonance Imaging 
(MRI). 192  
 In line with this, encapsulation of NTA-functionalized upconversion nanoparticles into 
HisBfr is under study in collaboration with Yang Hu (graduate student, Honek (Chemistry) and 
Lu (Physics) laboratories). The NaGdF4: Yb, Er (20%, 2%) upconversion nanoparticles were 
synthesized in oleic acid/ 1-octadecene (3:7) by a combined synthesis (at 150 °C) and nucleation 
process (at 300 °C). The synthesized nanoparticles with an oleic acid corona have 5.6 nm 
diameter, within the dimensions of the internal cavity of Bfr. Encapsulation is mediated by 
stripping the hydrophobic corona with 0.1 M HCl and reacting the bare nanoparticles with high-
affinity N-(phosphonomethyl)iminodiacetic acid. Lastly, the nanoparticles, with phosphate corona 
are then modified with NTA functional groups to form NaGdF4: YbEr-NTA for encapsulation 








Figure 6. Inorganic nanoparticle encapsulation.  
 
 
6.1. Hydrophobic Engineering 
Additionally, a health-related application was explored by the hydrophobic engineering of 
Bfr. Manipulation of Bfr to encapsulate hydrophobic guest molecules such as hydrophobic drugs 
was investigated in a proof-of-concept by using the His-tagged Bfr (HisBfr) construct to 
encapsulate aggregates (micelles) of NTA functionalized lipid molecules. Encapsulating variable 
chain lengths of these lipids into either homopolymeric Bfr (100 % HisBfr) or heteropolymeric 
Bfr (50% HisBfr: 50 % WTBfr) allowed for control over both the capsule dimensions and the 
extent of hydrophobicity of Bfr. The hydrophobic cavity may find applications in transporting 
hydrophobic drugs such as curcumin. Curcumin is a polyphenolic compound derived from the 
turmeric spice. This compound has anti-inflammatory and anti-oxidant as well as an antitumor 
agent 193. Luckily, it can be administered at a very high dose, up to 12 g per day,194 yet suffers 
from bioavailability at this dose as a result of its limited intestinal solubility.188,193-194 Most of the 
research on curcumin has focused on breaking this physiological barrier and reaping the 
medicinal benefits of curcumin. For example, Berginc et al. reported the addition of piperine, a 
curcumin metabolism inhibitor, into curcumin-containing formulations to inhibit curcumin 




mucous lining, which could be overcome by compromising (reversibly) the mucus integrity to 
minimize non-specific binding of curcumin.193 
 Hence, “hydrophobic” Bfr could overcome this limitation by serving as a medium to 
solubilize the curcumin molecule and transport it to the target. The ability of Bfr to encapsulate 
hydrophobic drugs within the hydrophobically engineered cavity was previously modeled with 
pyrene molecules by Omaima Ben Krayem (Honek laboratory). The HisBfr containing C19-NTA 
micelles internalized the pyrene molecules successfully. The process was monitored by pyrene 
emission, and it was found that the pyrene molecules within HisBfr-C19-NTA were shielded from 
the solution by the HisBfr-micelle cluster. Maturation of pyrene emission was observed upon 
declustering the HisBfr subunits with increasing concentrations of GdnHCl (up to 8 M).121 
Regularly sized C19-NTA- Bfr capsules obtained from this work (with a mixture of 
WTBfr and HisBfr) could enhance its EPR effects, and warrants a further look into solubilizing 
the pyrene molecules within these regularly sized capsules. The knowledge gained from pyrene 
solubilization could be transferred to other hydrophobic drugs not limited to: curcumin (Figure 
6.1), carmustine,195 bevacizumab (Avastin™),195 and haloperidol196 (Figure 6.2). Furthermore, 
AUC and pyrene fluorescence will be used to determine the aggregation numbers of the lipid 
molecules within the Bfr capsules. 
 

























Figure 6.2. Structures of several hydrophobic drugs. 
 
6.2. Surface Modification  
Moreover, one of the most challenging issues in drug delivery is that of targeting the drug 
to a specific receptor. 29 This can be achieved by modifying the formulation with cell-targeting 
moieties which specifically target cells expressing surface antigens particular to an infection or a 
disease.4b,36a,197, For example, the surface of human apoferritin nanocages were modified with an 
RGD recognition sequence (Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys) which was successfully 
used to deliver doxorubicin to U87MG subcutaneous tumor models. The drug-loaded apoferritin 
was reported to have very high efficacy (up to 73 wt %) and less cardiotoxicity than free 
doxorubicin.197 
Additionally, the surface modification can be useful in multi-target drug (MTD) design. 
This design principle is becoming popular in drug discovery as a result of varied causative factors 
in diseases such as cancer, Alzheimer’s (AD), and Parkinson’s (PD) diseases.198 The traditional 
“on-target” drugs specifically target a receptor on the diseased cell to prevent unwanted side 
effects. However, it not sufficient to treat the “current incurable diseases” (listed above). 199 200 
Hence, the emergence of the single drug molecule, multi-target drug, capable of achieving 
therapeutic effects in complex diseases.199,200,198 A single Bfr capsule could be engineered to 
display variable tags/ peptide sequences/ antibodies that could recognize different receptor 
molecules in these diseases.3,201 This way, it increases the probability of binding to at least one 























 Here, the Bfr nanoplatform has been engineered with multiple N-terminal surface tags 
that enable Bfr to undergo transglutaminase-catalyzed reactions (QTag-Bfr), Sortase mediated 
modification (Sort tag-Bfr) and also the tendency to reconstitute RNase activity (Qtag1-Bfr and 
Qtag2-Bfr). The Qtag2-Bfr has been used to demonstrate the ability of Bfr to be used in target 
cargo delivery vehicles similar to apoferritin above. The model cargo used was AuNP in the 
interior of Qtag2-Bfr while the Qtag on the surface was covalently modified with 
dansylcadaverine (DC). The success with DC, as primary amine, could be extended to incorporate 
diverse biological molecules such as antibodies and intact proteins. Incorporation of intact 
proteins could be beneficial for developing binary complexes of biomolecules.2 
Lastly, the amino acid residues, such as exposed lysines on Bfr, can be modified via NHS 
activation to introduce diverse molecules. Current work in the Honek laboratory (by Fatima 
Merza, graduate student) involves the building of 3D ferritin frameworks (networks) through 
ferritin-polyethylene glycol (PEG)-biotin-avidin networks. The four biotin sites on avidin engage 
biotinylated ferritins in a 3D network, as seen in Figure 6.3 below. Also, the other exposed amino 
acid functional groups in the network, on ferritin surfaces, could possibly be chemoselectively 








6.3. Encapsulation of His-tagged Guest Molecules into Bfr  
The reverse polarity encapsulation strategy discussed in a previous chapter investigated 
the process of encapsulating His-tagged guest molecules into the Bfr cavity. In reverse polarity, 
the heme cassette is used as the biotemplating tool due to the ability to chemically modify it and 
reinsert it into the Bfr dimer interface. The modified bisheme-NTA interacts with the His-tags of 
the guest molecule (in the presence of Ni2+) to internalize the guest into the Bfr cavity (Figure 
6.4). This approach of modifying Bfr extends the host encapsulation capabilities to include His-
tagged enzymes and proteins as most enzymes are now genetically engineered with polyhistidine 
tags for their ease of purification. Hence to use Bfr as an enzyme container, it is necessary to use 
this reverse polarity to accommodate the enzymes.  
His-tagged enhanced GFP (HisGFP) was used as a model His-tagged protein for this 
study. Successful encapsulation was monitored by HisGFP absorbance (at 490 nm). Also, the 
extent of HisGFP fluorophore protection was briefly studied with DTNB, and the results showed 
that the Bfr shell protects the HisGFP molecules from DTNB modification. However, a detailed 
titration with varying DTNB concentrations should be performed to obtain the exact 








Figure 6.4. The reverse polarity encapsulation of HisGFP into BisNTA-heme-Bfr.  
 
 
6.4. Characterization and Modification of Archaeoglobus Fulgidus Ferritin (AfFtn) 
This work explored the ferritin from the hyperthermophilic organism Archaeglobus 
fulgidus to study how the presence of the AfFtn triangular pores will affect the chemistry of 
encapsulated guest molecules compared to bacterioferritin. The AfFtn was successfully 
engineered into three different constructs (WTBfr, HisAfFtn, and AfFtnC54) for various 
encapsulation applications. Similar to Bfr, the protein yields were about 30 mg/L, and all the 
subunit masses were validated by +ESI-MS. 
The NTA-functionalized gold nanoparticle (5 nm in diameter) was encapsulated 
successfully into HisAfFtn. The encapsulation was mediated by decreasing the salt concentration 
to 10 mM to allow subunit dissociation and increasing the salt concentration to 150 mM to cause 
subunit association and guest entrapment. However, the AfFtnC54 construct did not associate in 




His-tagged glucohydrolase (and other His-tagged guests) since the AfFtn capsule is a non-heme 
containing ferritin. 
Again, HisGFP was used as a model for encapsulating a His-tagged protein since it is easy 
to monitor its encapsulation as well as there is an existing knowledge on it from the Bfr 
experiments. The AfFtnC54 was modified via maleimide chemistry to introduce NTA 
functionality to the C54 residue (toward the interior of the cavity, Figure 6.5a). The resultant 
AfFtnC-54-NTA was then utilized to entrap HisGFP in a 20 mM MgCl2, 25 mM HEPES-pH 7.5 
buffer. The results from this encapsulation showed that HisGFP was encapsulated under these 
conditions and will be applied to the encapsulation of a glucohydrolase enzyme to study the 
effects of the cage porosity on substrate specificity. 
In the future, the thermostable His-tagged glucohydrolase, alpha-D-glucoside 
glucohydrolase, from Megazyme (through Cederlane, Burlington, ON) will be encapsulated into 
AfFtnC54-NTA. The encapsulation will be similar to the HisGFP above, mediated by low salt 
and MgCl2. After the encapsulation, the entrapped alpha glucohydrolase will be examined for its 
ability to hydrolyze various oligomers of the sugar substrate. Some of the sugars will include 
maltose, p-nitrophenyl ɑ-ɒ-galactopyranoside, and maltotetraose up to maltooctaose. The masses 
of the substrates (sugars) will be determined by electrospray ionization mass spectrometry before 
incubation with the encapsulated enzyme and post-incubation to determine the structure of the 
hydrolyzed products. Also, some of the sugars have fluorescent labels which can be used to 
monitor the hydrolysis. 
Of interest is how the triangular pore of AfFtn is capable of screening the substrate 
molecules from the entrapped enzyme (as seen in Figure 6.5b). This platform may have 
applications in stabilizing the entrapped enzymes under high temperature as well. Thermostability 
can be studied by NMR spectroscopy where the changes in chemical shifts can be used to study 
the denaturation of the enzyme. It might be possible that the entrapped glucohydrolase, when 
heated, will be protected against heat denaturation and have similar NMR chemical shifts to the 
intact enzyme. 
Overall, significant progress has been made towards AfFtn and Bfr biotemplating. Both 
capsules may have similar chemistries in terms of guest encapsulation and protection. More 




insights to the scaffold since it was recently reported,8 and there is limited knowledge about the 





Figure 6.5. The AfFtn catalytic container. (a) Illustrates the modification of AfFtnC54 to AfFtn 
C54-NTA for HisGFP and His-alpha glucosidase encapsulation. (b) This figure is a representation 
of our hypothesis; the encapsulated enzyme may or may not be able to hydrolyze the substrates, 
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TABLE OF CONTEXT-GLOSSARY 
 





Amu: Atomic mass unit 
Au: Absorbance units 
AUC: Analytical Ultracentrifugation 
Bfr: Bacterioferritin 
Biotin-XNTA: Biotin nitrilotriacetic acid 
BfMF: Bullfrog middle chain ferritin 
C14-NTA: Myristol-Nitrilotriacetic acid 
C16-NTA: Palmitoyl-Nitrilotriacetic acid 
C19-NTA: Nanodecanoyl-Nitrilotriacetic acid 
CCMV: Cowpea chlorotic mottle virus 
CtFtn: Chlorobium tepidum ferritin  
CMC: Critical Micelle Concentration 
Cys: Cysteine 
DLS: Dynamic light scattering 
DGS-NTA: 1, 2-dioleoyl-sn-glycero-3- [(N-(5-amino-1 carboxypentyl) iminodiaceticacid)             
succinyl] 
DMF: Dimethylformamide 
DMSO: Dimethyl Sulfoxide 
Dps: DNA-binding proteins from starved cells 
EDC: N-(3-dimethylaminopropyl-N’-ethyl)-carbodiimide 
EPR: Enhanced permeability and retention 





FRET: Förster resonance energy transfer 
FITC: Fluorescein isothiocyanate 
Ftn: Ferritin  




Glide SP: Glide Standard Precision 
Glide XP: Glide Extra Precision 
GdnHCl: Guanidine HCl 
His: Histidine 
His6-tag: Hexahistidine affinity tag 
HisGFP: His-tagged enhanced GFP  
HoSF: Horse spleen ferritin 
HPV: Human Papillomavirus 
HRP: Horseradish peroxidase 
Hsp: Heat-shock protein 
HuHF: Human heavy chain ferritin 
HuLF: Human light chain ferritin 
Ile: Isoleucine 
IFD: Induced Fit Docking 
IMAC: immobilized metal affinity chromatography 
kDa: kiloDalton 
keV: kiloelectron volt 
Leu: Leucine 
LigPrep: Ligand Preparation 
Lys: Lysine 
Lys-NTA: Nα, Nα-Bis(carboxymethyl)-L-lysine 
MRI: Magnetic Resonance Imaging 
Met: Methionine 





MTD: Multi target drug 
mM: millimolar 
MW: Molecular Weight 
NBA: N-Butylamine 
Native PAGE: Native polyacrylamide gel electrophoresis 
nM: nanomolar 
nm: nanometer 
NCL: Native chemical ligation 
NHS: N-Hydroxysuccinimide 
NP: Nanoparticle 
NTA: Nitrilotriacetic acid 
PEG: Polyethylene glycol 
Phe: Phenylalanine 
Psi: Pounds per square inch 
Pro: Proline 
Prep Wizard: Preparation Wizard 
PfFtn: Pyrococcus furiosus ferritin 
QD: Quantum dots 
QTag: Glutamine tag 
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC: Size exclusion chromatography 
Ser: Serine 































Appendix 2.SEC calibration profiles, using Sephacryl™ 300 10/300 HR and Sephacryl™ 
300 26/60HR. calibration plots was prepared by running BioRad Gel filtration standards 
(#1511109 containing: 5 mg thyroglobulin- 670,000 Da, 5 mg g-globulin-158,000, 5 mg 


















Appendix 5. SEC profiles of C14-NTA and C16-NTA encapsulated into 100 % HisBfr. The 











Appendix 6. Mass Spectrometry results for synthesized NTA-fatty acids. (a) Myristoyl-NTA 
showing the expected 471 Da peak. Accurate mass data m/z: calculated for C24H43N2O7: 
471.3075; Found: 471.3076. (b) Palmitoyl-NTA with the expected peak at 499 Da. Accurate mass 























Appendix 7. NMR Results. (a) 1H-NMR of synthesized C14-NTA characterized as follows: (500 
MHz, DMSO) δ 7.67 (t, 1H, J= 5.35 Hz), 3.49-3.39 (m, 5H), 2.95 (dd, 2H, J = 6.4 Hz, J = 12.25 
Hz), 1.99 (t, 2H, J = 7.45), 1.56 (q, 2H, J = 7.15), 1.43 (m, 4H), 1.24 – 1.21 (m, 22H), 0.83 (t, 3H, 




(b) 1H-NMR of C16-NTA results were (500 MHz, DMSO) δ 7.66 (t, 1H, J = 5.45), 3.47 (m, 5H), 
2.95 (dd, 2H, J = 6.4, J = 12.05), 1.99 (t, 2H, J = 7.45), 1.58 (q, 2H, J = 7.7), 1.43 (m, 4H), 1.33 
(t, 6H, J = 7.9), 1.24 – 1.21 (m, 20H), 0.83 (t, 3H, J = 7.1).As well as  
 
(c) 13C-NMR for C14-NTA results were (125 MHz, DMSO) δ 174.0 (s), 173.2 (s), 172.2 (s), 64.3 
(d), 53.3 (t), 38.3 (t), 35.5 (t), 31.4 (t), 29.3 (t), 29.1 – 28.7 (t), 25.4 (t), 23.2 (t), 22.2 (t), 14.0 (q). 
and  
(d) 13C-NMR for C16-NTA characterized as: (125 MHz, DMSO) δ 174.4 (s), 173.7 (s), 172.5 (s), 
64.7 (d), 53.7 (t), 38.6 (t), 35.8 (t), 31.7 (t), 29.4 - 29.1 (t), 25.7 (t), 23.5 (t), 22.5 (t), 14.4 (q). The 
solvent peak (not integrated) appears at 2.5 ppm for the 1H-NMR and at 39-40 ppm for the 13C-































































































































































































































Sample 1 Monomer MW 
(Da) 
Expected 24-







100% HisBfr + heme 19,560 469,440 0.735 1.0083 1.0474 
      
Sample 2      
50% HisBfr, 50% wt Bfr 
+ heme 
19,560 (His)  
18,495 (wt) 
443,880-469,440 0.736 1.0083 1.0474 
      
Sample 3      
100% HisBfr + heme + 
AuNP + Ni2+ 
19,560 1,257,440 0.735 1.0083 1.0474 
      
Sample 4      




509,440 0.735 1.0083 1.0474 
      
Sample 5      
50% HisBfr, 50% wt Bfr 
+ C19-NTA 
19,560 (His)  
18,495 (wt) 
~43,360 (C19) 
487,240-512,800 0.736 1.0083 1.0474 
      
Sample 6      
100% AfFtnC-NTA 20,288 486,912 0.735 1.0019 1.0300 
      
 
 
Appendix 9. Initial parameters for AUC. The estimated with molecular weights calculated 
from amino acid sequences Partial specific volumes (vbar) were also calculated from their amino 
acid compositions, using the program SEDNTERP. SEDNTERP was also used to calculate buffer 






Appendix 10. Sedimentation velocity(top) and residuals curve (bottom). (a) 100 % HisBfr + 
heme (b) 50 % HisBfr + 50 % WTBfr + heme. All measurement were recorded at 20 000 rpm in a 
1.2cm pathlength centerpiece cuvette at 280 nm wavelength.The sedimentation curves were 












Appendix 11. Sedimentation velocity(top) and residuals curve (bottom). (a) 100 % HisBfr + 
heme (b) 50 % HisBfr + 50 % WTBfr + heme. Sample a and b measurement were recorded at 20 




Appendix 12. Sedimentation velocity(top) and residuals curve (bottom) for AfFtnC54-NTA. 
AfFtnC54-NTA was dialyzed in 20 mM MgCl2, 25 mM HEPES-pH 7.5. The sample was 













Peak 3 Peak 4 
MW (kDa) 68.3 208.1 498.8 1025.9 











Peak 3  
MW (kDa) 102.6 472.3 914.5  












Peak 3 Peak 4 
MW (kDa) 138.4 546.4 1686.1* 3906.8** 
s20,w  (S) 7.6 18.9 40.1* 70.3** 
f/fo 1.25 
RMSD 0.0086 
 *this broad ‘peak’ encompasses values of s = 25-50S, so 
the MW is an average of the population 






100% His Bfr 





Peak 3 Peak 4 
MW (kDa) 95.0 253.0 495.0 994.1 
s20,w  (S) 4.4 8.5 13.3 21.1 
f/fo 1.67 
RMSD 0.0070 
     
Sample 5 
50% HisBfr, 







MW (kDa) 83.9* 589.5   
s20,w  (S) 4.7* 17.1   
f/fo 1.44   
RMSD 0.0037   
 *I am unable to resolve this peak into multiple species, 









MW (kDa) 471.1 932.9   
s20,w  (S) 17.7 27.9   
f/fo 1.21   
RMSD 0.0065   
     
     
 







Appendix 14. Encapsulation of HisGFP into WTBfr using unmodified heme cofactor. The 
SEC column (Superose 6 ™ 10/300 GL) run shows empty WTBfr-heme capsules at ~ 38 min and 
free HisGFP at ~ 45 min 
 
 
